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Summary
Haemopoietic cells are dependent on the appropriate cytokine for their growth and 
survival. Upon cytokine withdrawal, haemopoietic cells cease to proliferate and undergo 
apoptosis. Treatment of responsive cells (BaF/3, FD - 6  and MC9) with a number of 
cytokines, results in the activation of classU PI3K, which has been implicated in the 
proliferation and survival of many cell types. One downstream effector of PI3K, thought 
to be involved in growth and survival, is the serine/threonine kinase, PKB. Therefore, 
we investigated the role of PKB in the cytokine-mediated growth and survival of 
haemopoietic cells.
Treatment of responsive cells with IL-3, IL-4, GM-CSF, SCF and insulin resulted in the 
rapid phosphorylation and activation of PKB, which was inhibited by treatment with the 
PI3K inhibitor LY294002. However, the cytokine-mediated activation of PKB did not 
correlate with the growth and survival of haemopoietic cells in all cases. Nor was the 
activation of PKB sufficient to induce the hyper-phosphorylation of the pro-apoptotic 
Bcl-2 family member Bad in all cases. These results suggest that PKB activation alone 
is not sufficient to provide a survival and proliferative signal to these cells.
The major effect of PI3K inhibition by LY294002 observed in these cells was a 
reduction in the cytokine-mediated proliferation. LY294002 treatment did not result in a 
significant increase in apoptosis. To determine whether PKB is involved in this PI3K- 
mediated proliferation, the constitutively active PKB variant gagPKB was inducibly 
expressed in BaF/3 cells with the dominant negative PI3K, Ap85. Expression of Ap85 
alone resulted in a substantial reduction in IL-3-stimulated cell growth and the co­
expression of gagPKB in these cells did not reverse this inhibition. Therefore, other or 
additional pathways must be required for the mitogenic response of IL-3 that is mediated 
through PI3K.
In order to investigate in more detail the role of PKB in IL-3-mediated cell survival, 
PKB variants were expressed under the control of the tetracycline-regulated expression 
(tet off) promotor. The effects of the putative dominant negatives, cxPKB and kdPKB; 
wtPKB; and the constitutively active gagPKB on IL-3-mediated growth and survival 
were investigated. gagPKB expression did not increase the survival of these cells either 
in the presence or absence of IL-3. Interestingly kdPKB expression increased the 
phosphorylation of endogenous PKB, therefore, generating doubt about its effectiveness 
as a dominant negative. cxPKB expression did not significantly decrease the survival of 




I would like to take this opportunity to thank the many people who have given me 
unending support and encouragement throughout the last few years. Firstly I must thank 
my supervisor, Dr Melanie Welham for her direction and expertise and for her ability to 
see the positive side of a negative result. I would also like to thank the other members of 
the Welham Group, both past and present. I am indebted to Drs Bridget# 1, and 
Heather# 1, Helen and Karen, who were about when I arrived and taught me most of the 
things I needed to know to get this far. I am also indebted to the newer members of the 
group Drs Christine and Bridget#2, and nearly a Dr, Nick who kept me entertained 
especially during the latter stages.
I would also like to thank my friends and family because they are the ones who had to 
put up with me especially in the last few months. And I really mean they are the ones 
who had to put up with me and put me up! The list in long but it needs mentioning and a 
special thankyou...Kristy, Ollie, Helen, Robbie, Jane, Gary, Mum, Dad, Ian and Rachel. 




1.1 Cytokines and the Regulation of Haemopoiesis 2






1.3 The Functions of Cytokines 9
1.3.1 Proliferation 9
1.3.2 Apoptosis 12
The Bcl-2 Family 15
Caspases 17
1.4 Signalling pathways activated by cytokines 18
1.4.1 The Jak/STAT Pathway 18
1.4.2 Src Kinases 21
1.4.3 The MAP Kinase Pathway 22
The ERK Pathway 22
The p38 Pathway 26
The JNK Pathway 26
1.5 Phosphoinositide-3 Kinases (PI3K) 27
3.5.1 Class I 28
3.5.2 Class II 28
3.5.3 Class III 30
1.5.4 Class IA PI3K 30
1.6 The Activation of Class Ia PI3K 31
1.6.1 SCF-induced activation of PI3K 32
1.6.2 Insulin-induced activation of PI3K 32
1.6.3 IL-4-induced activation of PI3K 34
1.6.4 IL-3- and GM-CSF-induced activation of PI3K 35
1.7 The Functions of PI3K 36
iv
1.8 Downstream Effectors of PI3K 37
1.9 Lipid Phosphatases 38
1.9.1 PTEN 38
1.9.2 SHIP 39
1.10 Protein Kinase B 39
1.11 Activation of PKB 41
1.11.1 PDK-1 42
1.11.2 ILK (Integrin-Linked Kinase) 42
1.11.3 PH Domain 43
1.12 Funtions of PKB 45
1.13 Downstream of PKB 46




1.12.5 IkB Kinase 51
1.13 Aims and Objectives 52 
Chapter 2
Materials and Methods 53
2.1 Molecular Biology Techniques 54
2.1.1 Phenol/Chloroform extractions 54
2.1.2 Ethanol precipitation of DNA 54
Preparation of competent E. coli 54
2.1.4 Transformation ofE. coli 55
2.1.5 Small-scale plasmid preparation 55
2.1.6 Large-scale plasmid preparation 55
2.1.7 Restriction enzyme digestion 56
2.1.8 Conversion of 5’ protruding ends to blunt ends 56
v
2.1.9 Treatment of plasmid DNA with
Calf Intestinal Phosphatase (CIP) 57
2.1.10 Ligations 57
2.1.11 Agarose gel electrophoresis 57
2.1.12 Gel purification of DNA fragments 58
2.1.13 Polymerase chain reaction 58
2.2 Tissue Culture Techniques
2.2.1 Cell Culture 58
2.2.2 Preparation of Conditioned Media 59
2.2.3 Transfections 59
2.2.4 Screening for tetracycline-regulated expression 60
2.2.5 Cell Storage 60
2.2.6 XTT Assays 60
2.2.7 Cell Viability 61
2.2.8 FACS Analysis 61
2.3 Protein Chemistry Techniques 63
2.3.1 Cell stimulation and growth factors 63
2.3.2 Immunoprecipitation of Bad 63
2.2.3 SDS Polyacrylamide Gel Electrophoresis (SDS PAGE) 64
2.3.4 Immunoblotting 64
2.3.5 Stripping of Blots 65
2.3.6 In vitro kinase assays 65








Comparison of PKB Signalling in BaF/3, FD6 and MC9 Cells 73
3.1 Introduction 74
3.2 Cytokine induced activation of PKB. 75
3.3 Kinetics of PKB activation in FD6 Cells 75
3.4 Kinetics of PKB activation in MC9 Cells 78
3.5 Kinetics of PKB activation in BaF/3 cells 82
3.6 Dose Response Analyses 84
3.7 Dose Response Analysis in FD6 Cells 84
3.8 Dose Response Analysis in MC9 Cells 84
3.9 Dose Response Analysis in BaF/3 Cells 84
3.10 Effect of PI3K Inhibition on PKB activation 89
3.11 Effect of PI3K Inhibition on PKB activation in FD-6 Cells 89
3.12 Effect of PI3K Inhibition on PKB activation MC9 Cells 89
3.13 Effect of PI3K Inhibition on PKB activation BaF/3 Cells 90
3.14 Comparison of the levels of PKB phosphorylation 95
3.15 Cytokine induced phosphorylation of BAD 97
3.16 Hyper-Phosphorylation of Bad in MC9 Cells 97
3.17 Hyper-Phosphorylation of Bad in FD-6 Cells 97
3.18 Hyper-Phosphorylation of Bad in BaF/3 Cells 98
3.19 Cytokine induced Survival and Proliferation 100
3.20 Survival and proliferation of FD-6 Cells 100
3.21 Survival of BaF/3 Cells 100
3.22 Discussion 104
Chapter 4
The Role of the PI3K/PKB Pathway in Proliferation 109
4.1 Introduction 110
4.2 The Effects of PI3K inhibition on cytokine induced proliferation 111
4.3 Effect of LY294002 on the Proliferation of FD-6 Cells 111
4.4 Effect of LY294002 on the Proliferation of BaF/3 Cells 111
4.5 Effect of PI3K inhibition on Apoptosis in BaF/3 Cells 114
4.6 Dominant-Negative PI3K (Ap85) 114
4.7 The Tetracycline-Regulated Expression System 116
vii
4.8 Effect of dominant-negative PI3K (Ap85)
Expression on PKB phosphorylation 118
4.9 Dose response analysis of PKB Phosphorylation 118
4.10 Kinetic analysis of PKB Phosphorylation 118
4.11 Effect of Ap85 Expression on PKB Activity 121
4.12 Effect of Ap85 Expression on Proliferation 121
4.13 Expression of gagPKB in Ap85 expressing cells 124
4.14 Effect of Ap85 and gagPKB expression on PKB phosphorylation 124
4.15 Dose-response analysis of PKB Phosphorylation 127
4.16 Kinetic analysis of PKB Phosphorylation 127
4.17 Effect of Ap85 and gagPKB expression on proliferation 130
4.18 Discussion 132 
Chapter 5
The Effects of PKB Variants Expression on IL-3 Signalling 137
5.1 Introduction 138
5.2 The Effects of PKB Variants on IL-3 Signalling 139
5.3 Construction of pUHD10-3hygro Expression Vectors 140
5.4 Expression of PKB Mutants in BaF/3 Cells 140
5.5 Activity of PKB Mutants 143
5.6 The Effects of PKB Variants on PKB Phosphorylation 145
5.7 Effect of PKB Variant Expression on Bad Phosphorylation 152
5.8 Effects of PKB Variants on the
IL-3-Induced Proliferation of BaF/3 Cells 153
5.9 Effects of PKB Variants on the Viability of BaF/3 Cells 161





Figure 1.1 Hierarchy of haemopoietic stem and prgenitor cells 3
Figure 1.2 Structire of Receptor Complexes 5
Figure 1.3 Cyclin/Cdk activity through the cell cycle 10
Figure 1.4 The roles of Bcl-2 family members and caspases in apoptosis 14
Figure 1.5 Structure of the Bcl-2 Family 16
Figure 1.6 Structure of Jaks and STATs 20
Figure 1.7 Structure of c-Src Kinase 21
Figure 1.8 Mitogen-activated protein kinase cascades 23
Figure 1.9A Cycling of p21ras between GTP and GDP bound states 24
Figure 1.9B Activation of Ras/MAPK pathway by activated receptors 24
Figure 1.10 Cytokine activation of PI3K 33
F igurel.il Schematic representation of PKB 41
Figure 3.1 IL-3-induced activation of PKB in FD-6 cells 76
Figure 3.2 IL-4-induced activation of PKB in FD-6 cells 77
Figure 3.3 IL-3-induced activation of PKB in MC9 cells 79
Figure 3.4 IL-4-induced activation of PKB in MC9 cells 80
Figure 3.5 SCF-induced activation of PKB in MC9 cells 81
Figure 3.6 IL-3-induced activation of PKB in BaF/3 cells 83
Figure 3.7 Dose-resonse analysis in FD-6 cells 85
Figure 3.8 Dose-resonse analysis of MC9 cells to IL-4 and SCF 86
Figure 3.9 Dose-resonse analysis of MC9 cells to IL-3 87
Figure 3.10 Dose-resonse analysis of BaF/3 cells to IL-3 88
Figure 3.11 Effect of LY294002 on PKB activation in FD-6 cells 91
Figure 3.12 Effect of LY294002 inhibition on
insulin-induced PKB activation in FD-5 cells 92
Figure 3.13 Effect of LY294002 on PKB activation in MC9 cells 93
Figure 3.14 Effect of LY294002 on PKB activation in BaF/3 cells 94
Figure 3.15 Cytokine-induced phosphoylation of Bad 99
Figure 3.16 Viability and proliferation of FD-6 cells in response to cytokines 101 
Figure 3.17 Viability of BaF/3 cells in response to cytokines 102
Figure 4.1 Effect of LY294002 on proliferation of FD6 cells 112
Figure 4.2 Effect of LY294002 on proliferation of BaF/3 cells 113
Figure 4.3 Effect of LY294002 on apoptosis 115
Figure 4.4 Two-vector tetracycline controlled
regulatory gene expression system 117
Figure 4.5 Effect of Ap85 on PKB phosphorylation:
Dose-response analysis 119
Figure 4.6 Effect of Ap85 on PKB phosphorylation:
Kinetic analysis 120
Figure 4.7 Effect of Ap85 expression on PKB activity 122
Figure 4.8 Effect of Ap85 expression on IL-3-induced
proliferation of BaF/3 cells 123
Figure 4.9 Screening blot of gagPKB in Ap85 cells 125
Figure 4.10 Expression of gagPKB in Ap85 cells 126
Figure 4.11 Effect of Ap85 and gagPKB expression on PKB phosphorylation
Dose-response analysis 128
Figure 4.12 Effect of Ap85 and gagPKB expression on PKB phosphorylation
Kinetic analysis 129
Figure 4.13 Effect of Ap85 and gagPKB expression on IL-3-induced
Proliferation of BaF/3 cells 131
Figure 5.1 Cloning of PKB variants into pUHD 10-3 141
Figure 5.2 Expression of PKB variants in BaF/3 cells 142
Figure 5.3 Activity of PKB variants in BaF/3 cells 144
Figure 5.4 Effect of gagPKB expression on PKB phosphorylation
Dose response analysis 147
Figure 5.5 Effect of kdPKB expression on PKB phosphorylation 148
Figure 5.6 Effect of cxPKB expression on PKB phosphorylation 150
Figure 5.7 Effect of wtPKB expression on PKB phosphorylation 151
Figure 5.8 Effect of gagPKB expression on Bad phosphorylation 154
Figure 5.9 Effect of kdPKB expression on Bad phosphorylation 155
Figure 5.10 Effect of gagPKB expression on IL-3-induced
proliferation of BaF/3 cells 156
Figure 5.11 Effect of kdPKB expression on IL-3-induced
proliferation of BaF/3 cells 158
Figure 5.12 Effect of cxPKB expression on IL-3-induced
proliferation of BaF/3 cells 159
Figure 5.13 Effect of wtPKB expression on IL-3-induced
proliferation of BaF/3 cells 160
Figure 5.14 Effect of gagPKB expression on viability of BaF/3 cells 162
Figure 5.15 Effect of kdPKB expression on viability of BaF/3 cells 163
Figure 5.16 Effect of cxPKB expression on viability of BaF/3 cells 164
Figure 5.17 Effect of empty vector expression on apoptosis 166
Figure 5.18 Effect of gagPKB expression on apoptosis 167
Figure 5.19 Change in apoptotic cell number
induced by PKB variant expression 169
Figure 5.20 Possible feedback loop of PKB activation 173
Figure 6.1 IL-3-induced survival of BaF/3 Cells 182
List of Tables
Table 1.1 E2F/RB-family complexes through the cell cycle 10
Table 1.2 Classification of PI3K family members 29
Table 1.3 PKB substrates 47
Table 2.4.1 Antibodies used for Blotting and Precipitation 67
Table 2.4.2 Primers used for PCR 67
Table 2.4.3 Plasmids used for Cloning and Transfection 68
Table 2.4.4 Reagents used and their Suppliers 69
Table 3.1 Fold-Activation of PKB in response to cytokine-stimulation 96




1.1 Cytokines and the Regulation of Haemopoiesis
All cells of the blood system are derived from a population of self-renewing 
multipotential haemopoietic stem cells located in the bone marrow (Metcalf, 1989). As 
the multipotential haemopoietic stem cells differentiate they become committed to 
specific lineages that go on to form myeloid and erythroid lines as well as the lymphoid 
lineages. The earliest progenitor precursors are the CLD (common lymphoid 
progenitor), which form the B- and T-cell lines, and the CMD (common myeloid 
progenitor), which give rise to granulocytes, erythroid, monocytes and megakaryocytes. 
More mature and specialised progenitors are termed CFUGM (CFU= colony-forming 
unit in agar culture medium; GM= granulocytes and monocytes), CFUE 0  (eosinophils), 
CFUBaso (basophils), CFUMeg (megakaryocytes), BFUE (burst forming unit, erythroid) 
and CFUe (erythroid) (Figure 1.1). These progenitor cells differentiate to form all the 
mature cells of the haemopoietic system (Figure 1.1) (Miyajima et al.9 1992).
Many haemopoietic cells have a high turnover rate. Therefore, to ensure that the 
correct balance between cell types is maintained, the survival, differentiation and 
proliferation of each is tightly regulated. The stem cell has the ability to self-renew, so 
although in adult mammals the bone marrow is a major site of new cell production, the 
overall levels of cells in the bone marrow remain constant. Progenitor cells must be 
able to maintain the correct balance of cell types under normal conditions and also be 
able to meet the requirements for increased and rapid production in infectious states or 
after blood loss. This tightly regulated process is termed haemopoiesis.
Haemopoiesis is regulated by cell-cell interactions and by a family of glycoproteins 
termed cytokines (Miyajima et al., 1988; Arai et ah, 1990). These cytokine growth 
factors regulate haemopoiesis by controlling the differentiation, survival and 
proliferation of haemopoietic progenitor cells as well as mature cells. The actions of 







































Hierarchy o f haemopoietic stem and progenitor cells Mast cel1
The stem cell gives rise to a common lymphoid stem cell and a myeloid precursor 
(CFUgemm) which gives rise to more mature and specialised progenitors: CFUgm 
(granulocytes and monocytes), CFUeo (eosinophils), CFUe (erythroid), CFUBaso 
(basophils) and CFUMeg (megakaryocytes). BFUe (burst-forming unit, erythroid) refers 
to an earlier erythroid progenitor than the CFUe (adapted from Miyajima et al., 1992).
1.2 Cytokines and Their Receptors
Haemopoeisis is controlled in part by a family of growth factors termed cytokines 
(cyto meaning cell and kine meaning movement). Most cytokines were either identified 
by their ability to promote the formation of colonies in semi-solid cultures of bone 
marrow cells and are therefore termed colony-stimulating factors (CSF’s) (Metcalf,
1989) or by their actions on lymphocytes and are therefore termed interleukins (IL) 
(reviewed in Arai et al., 1990). Cytokines are a diverse group of acidic glycoproteins 
with molecular mass ranging from 14-39 kDa. Little sequence homology exists 
between family members but analyses of their three-dimensional molecular structures 
indicate that they share many similar structural features (Bazan, 1990). Multiple 
cytokines have been identified and they include IL-1 to IL-20, stem cell factor (SCF), 
granulocyte-macrophage CSF, granulocyte CSF and erythropoietin.
The roles of cytokines in haemopoiesis are generally pleiotropic, influencing more 
than one cell type and many have overlapping activities. This means that specific 
cytokines can interact with more than one cell type and that the same effect on a 
particular haemopoietic cell lineage can be elicited by several cytokines (Arai et al.,
1990). The roles that the various cytokines play in each stage of development of the 
haemopoietic lines are summarised in Figure 1.1.
Cytokines elicit their effects by binding to discrete receptors that are expressed on the 
surface of responsive cells. The cloning of these receptors has revealed many 
similarities between the receptors and indeed many share receptor subunits. This may 
explain the functional pleiotropy and redundancy observed among several of the 
cytokines.
All the subunits of the IL-3R, GM-CSFR and IL-4R belong to the type I cytokine 
receptor family whose features include N-terminal CX9 .j2 CXWX2 2 .3 0 CXg.2 5 C (Cys motif) 
and WSXWS motifs, a single transmembrane domain and two regions of homology, 
termed the box 1  and box 2  regions, in the intracellular membrane proximal domain 
(Figure 1.2) (Cosman, 1993). Despite the cytokine-induced phosphorylation of the 
receptors and other cellular proteins in response to growth factor stimulation, the 
receptors in this family do not have intrinsic tyrosine kinase activity. Members of the 
type I cytokine receptor family utilise kinases of the Jak and Src families to transmit 
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The subunits which make up the receptor complexes for IL-3, IL-4, GM-CSF, SCF 
and insulin are shown. All the subunits of the receptors for IL-3, IL-4 and GM-CSF 
belong to the class I cytokine receptor family which do not have any intrinsic catalytic 
activity. In murine cells an additional IL-3-specific p subunit, AIC2A, exists. In 
haemopoietic cells IL-4 appears to signals through a Yc/IL-4Ra complex, while in 
non-haemopoietic cells it signals through an IL-4Ra/IL-13Ral complex. The 
receptor for SCF, c-kit, and the insulinRp subunit have intrinsic tyrosine kinase 
activity.
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The receptors for SCF, PDGF and insulin belong to a family of receptors known as 
the protein tyrosine kinase receptor family. They are a family of more than 50 different 
transmembrane polypeptides with a tyrosine kinase domain in their intracellular portion. 
These receptor tyrosine kinases (RTK’s), with the exception of insulin, consist of a 
single polypeptide chain with a large extracellular ligand-binding region, a single 
membrane spanning domain and large intracellular domain with intrinsic tyrosine 
kinase activity (Ullrich and Schlessinger, 1990). The structures of the receptor subunits 
are shown in Figure 1.5.
1.2.1 IL-3
Interleukin-3 (IL-3) is a 25kDa glycoprotein produced by activated T-lymphocytes 
and mast cells. It is involved in the early stages of development of multipotential 
progenitors and haemopoietic stem cells and can influence the development of 
macrophages, granulocytes, megakaryocytes, erythrocytes, eosinophils and mast cells. 
It also acts as a growth factor for these mature, differentiated cells (Arai et al., 1990). 
Studies of IL-3 -/- mice showed that these mice are viable and no abnormalities in 
haemopoiesis were observed. However when these mice were infected with the parasite 
Stronglyoides venezuelensis fewer basophils and mast cells were produced than in wild 
type mice. This indicates that IL-3 is involved in immunity to parasites and one of its 
functions in host defence is to expand populations of haemopoietic effector cells (Lantz 
et al., 1998).
IL-3 exerts its physiological effects by binding to its receptor on the surface of cells 
(Figure 1.2). The high affinity IL-3 receptor complex is composed of two distinct 
subunits a  and p. IL-3Ra is a 70kDa glycoprotein that specifically binds IL-3 with low 
affinity. The p subunit is unable to bind IL-3 by itself, but together with IL-3Ra it 
forms a high affinity complex. IL-3Rp, often referred to as Pcommon (Pc)> also forms part 
of the receptor complexes for IL-5, and GM-CSF. In mice two p subunits exist: 
AIC2B is homologous to the human pc while AIC2A is IL-3 specific. This additional 




GM-CSF is a 14-35kDa glycoprotein produced by endothelial cells and fibroblasts 
upon stimulation with TNF or IL-1; by macrophages activated with bacterial toxin or 
adherence; and by antigen-stimulated T cells. It acts on intermediate progenitor cells 
and in conjunction with other growth factors to support the differentiation of 
neutrophils, eosinophils, moncytes, erythrocytes and megakaryocytes (Demetri, 1992).
Like the IL-3 receptor complex GM-CSFR is composed of two subunits (Figure 1.2). 
The GM-CSF receptor complex uses the same pc chain as the IL-3 (Miyajima et al.,
1992) and an 80kDa GM-CSFRa subunit. As with the IL-3R complex, Pc does not bind 
GM-CSF itself but together with the low affinity GM-CSFRa forms a high affinity 
receptor complex (Hayashida et al., 1990).
1.2.3 IL-4
Interleukin-4 (IL-4) is a 20kDa glycoprotein produced by activated T-cells and mast 
cells. It acts on a number of haemopoietic cells e.g. B cells, T lymphocytes and mast 
cells, often in synergy with other cytokines. Other biological effects include induction 
of IgE class switching of B cells and expression of class II major histocompatibility 
complexes on resting B cells (Paul, 1991).
The receptor complex for IL-4 is composed of a high affinity 140kDa glycosylated a  
subunit (Mosley et al., 1989) and a 64kDa ycommon (yc) subunit, which is shared with the 
receptors for IL-2, IL-7, IL-9 and IL-15 (Figure 1.2) (Russell et al., 1993; Kondo et al.,
1993). Association of yc with IL-4Ra increases the IL-4 binding affinity 2-4 fold 
(Russell et al., 1993). There is evidence to suggest that IL-4 and IL-13 also share a 
common receptor subunit. This is not the yc subunit (He and Malek, 1995), and in some 
haemopoietic cells the IL-4Ra subunit appears to be shared with IL-13 (Welham et al., 
1995; Smerzbertling and Duschl, 1995; Obiri et al., 1997; Murata et al., 1997). An 
additional 65-70kDa protein (IL-13Ral) has been identified and appears to be a 
component of both receptor complexes in non-haemopoietic cells (Obiri et al., 1997; 
Murata et al., 1997).
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1.2.4 SCF
Stem cell factor (SCF) is a 248 amino acid residue glycoprotein produced by stromal 
cells. It is the gene product of the steel locus, mutations of which cause defects in 
pigmentation, fertility and haemopoiesis in affected mice (Zsebo et al., 1990; Flanagan 
and Leder, 1990). SCF is involved in the early events of the proliferation and 
differentiation of multipotential haemopoietic stem cells to various lineages. In 
particular, the proliferation of haemopoietic stem cells and the differentiation to mast 
and erythroid cell lineages (Williams et al., 1992).
The receptor for SCF, c-kit, is a 160kDa glycoprotein (Figure 1.2) which belongs to a 
family of protein tyrosine kinase receptors whose members include the PDGF (platelet- 
derived growth factor) receptor and the CSF-1 (colony stimulatory factor-1) receptor, c- 
fms. c-kit is the gene product of the dominant spotting (W) locus, mutations in which 
display a similar phenotype to those seen when the steel locus is mutated (Chabot et al., 
1988). Upon ligand binding, c-kit dimerises, resulting in the activation of its intrinsic 
tyrosine kinase domains, autophosphorylation and signal transduction via tyrosine 
kinase pathways. Structural features shared with PDGF-R and c-fms include an 
extracellular region of 5 immunoglobulin loops and a cytoplasmic kinase region split by 
an interkinase domain (Qiu et al., 1988).
1.2.5 Insulin
Insulin is a peptide growth factor that is composed of a 21 amino acid a  and 30 amino 
acid p-chain. It is synthesised by the p cells of the pancreas and its major physiological 
role is the regulation of blood glucose levels. Insulin also acts as a survival and growth 
factor for some cells.
Insulin exerts its biological effects by binding to its receptor on the surface of 
responsive cells. The insulin receptor is a heterotetrameric structure comprising of two 
a  and p subunits that are connected by disulfide bonds (Figure 1.2). The a  subunit is 
extracellular and involved in ligand binding, while the p subunits traverse the plasma 
membrane. The intracellular region of the p-subunit contains an intrinsic tyrosine 
kinase. This activity is activated upon ligand binding and the subsequent receptor 
subunit heterotetramerisation (Yarden and Ullrich, 1988).
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1.3 The Functions of Cytokines
1.3.1 Proliferation
Cytokines regulate haemopoiesis by controlling the differentiation, survival and 
proliferation of both progenitor and mature haemopoietic cells. During differentiation, 
when progenitor cells are irreversibly committed to one of the haemopoietic lineages, a 
massive expansion of progenitor cells also occurs. The haemopoietic system must also 
respond to acute situations such as infection or blood loss. This is accomplished by the 
rapid expansion and maturation of a specific set of haemopoietic cells at the affected 
site. This process of expansion, or proliferation, is stimulated by the actions of specific 
cytokines binding to their receptors on the surface of responsive cells and thus 
triggering the signalling pathways, which lead to cellular proliferation.
The proliferation of all eukaryotic cells, including those of the haemopoietic system, 
follows a specific program, which is known as the cell cycle. The cell cycle governs the 
progression of cells through their growth and their segregation into daughter cells. It 
also plays a pivotal role in determining whether a cell proliferates or withdraws into a 
quiescent state. The cell cycle can be divided into 4 successive phases: M phase, where 
mitosis occurs; G1} which is the gap between M phase and S phase; S phase, where 
DNA synthesis occurs; and G2, which is the gap between S phase and M phase. Before 
the cell can progress to the next phase of its cycle, regulatory mechanisms are in place 
to ensure that all the necessary events have taken place. These are termed checkpoints. 
For example, major checkpoints exist at the G2/M phase interface to ensure that DNA 
synthesis has occurred correctly before mitosis, and at the Gj/S phase interface, which is 
sensitive to such things as DNA damage, growth factor withdrawal, contact inhibition 
and death receptor activation. A family of proteins termed cyclins regulate the 
progression of a cell through these checkpoints. These act as positive regulatory 
subunits to a family of cyclin-dependent protein kinases (CDKs). Specific cyclins bind 
to specific CDKs activating the complex at specific times during the cell cycle. CDKs 
are generally constitutively expressed while the expression of cyclins oscillates in 
respect to the cell cycle suggesting that the cyclins control the timing of the activation. 
Both the expression and degradation of cyclins are tightly regulated and dependent on 
the cell cycle. For example, several cyclins have been implicated in feedback and 
feedforward loops which regulate the transcription of other cyclins (Cross et al., 1995).
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Figure 1.3
Cyclin/Cdk Activity through the Cell Cycle
Growth factor signalling
CvcE/Cdk2 DNA replication




The Cdks associate with cyclin subunits at different stages of the cell cycle. D-type 
cyclins link G1 progression to growth control. Cyclin D levels remain high as long as 
growth factor is present in the media. Cyclins E, A and B oscillate. Cyclin E/Cdk2 and 
Cyclin A/Cdk2 seem to have a role in DNA replication. Cyclin A/Cdkl and Cyclin 
B/Cdkl promote the onset of mitosis. Adapted from Arello and Moreno 1997.
Table 1.1
E2F/RB-Family Complexes Through the Cell Cycle
RB Family 
Member E2F Protein Cell Cycle Stage
pRB E2F-1, -2, -3, -4 G0, G1# S
P107 E2F-4 g „ s , g 2
P130 E2F-4, -5 G0 ) G,
Summarised are the RB family members, the E2F proteins that they interact with and 
the stages of the cell cycle that these complexes are detected. Adapted from Dyson 
1998.
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Cyclins are subject to proteolytic degradation by the ubiquitin-dependent proteosome 
pathway and this also appears to be dependent on the cell cycle (Hochstrasser, 1995). 
The cyclin/CDK complexes and where they act in the cell cycle are summarised in 
Figure 1.3.
The activation of the cyclin/CDK complex is regulated both by phosphorylation and 
by its association with specific inhibitors. CDK activity is positively regulated by 
phosphorylation of Thr16 0 (in CDK2) by CDK-activating kinase (CAK), while the 
phosphoryation of Thr and Tyr residues near the N-terminus negatively regulates CDK 
activity (Morgan, 1995). Two major classes of CDK inhibitors have been identified in 
mammalian systems. The INK4 family specifically inhibit CDK4 and CDK6  thereby 
preventing cyclin D association. The Cip/Kip proteins bind to and inhibit a number of 
cyclin/CDK complexes. They can inhibit each of the cyclin/CDK complexes required 
for Gj progression and entry into S phase.
Each of the cyclin/CDK complexes has a unique substrate specificity. One of the best 
characterised substrates of the cyclin/CDK complex is the retinoblastoma tumour 
suppressor pRB and the two other members of this family p i 07 and pl30/RB2 (Hinds et 
al., 1992). This family are sometimes referred to as pocket proteins because of their 
highly conserved pocket region that is necessary for the RB proteins to interact with 
other proteins and to repress transcription. RB proteins regulate cell cycle progression 
through their interactions with the E2F family of transcription factors. These 
interactions, and where they primarily occur in the cell cycle are summarised in Table 
1.1.
When RB proteins are hypo-phosphorylated they interact with the E2F family of 
transcription factors and this inhibits the activity of the E2F proteins. For example, 
throughout Gj phase the activity of the E2F transcription factors are repressed by the 
hypo-phophorylated pRB protein. Towards the end of G! pRB is phosphorylated by 
cyclin-D/CDK4/6 and cyclin-E/CDK2. This results in the release of free E2F, which in 
turn activates the transcription of cell cycle-regulated genes (Weinberg, 1995). One way 
in which pRB is thought to control E2F driven transcription is by acting as a bridge 
between E2F and histone deacetylase (HDAC1). HDAC1 mediates the removal of 
charged acetyl groups from core histones. This results in a tight association of DNA 
with the nucleosomes, which decreases the accessibility of transcription factors, in this 
case E2F, to promoters. The E2F family of transcription factors regulate the 
transcriptional activity of a number of genes that regulate cell cycle progression. These 
either encode functions that are important for DNA synthesis (for example DNA
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polymerasea (295) and thymidine kinase (Ogris et al., 1993) or cell cycle regulators 
(including cyclin E (Botz et al., 1996; Geng et al., 1996), cyclin A (Schulze et al., 
1995) and cdk2). It is thought that the transcriptional activation of the cyclin genes by 
E2F creates a feed-forward loop, allowing amplification of the signals that drive the 
progression of the cell cycle. For example, at the end of G l9  the cyclin-E/CDK2 
complex phosphorylates pRB, which results in the release of E2F. E2F can then 
upregulate the expression of cyclin-E, and this amplifies the signal to progress through 
to S phase.
1.3.2 Apoptosis
Prevention of cell death is also an important function of cytokines during 
haemopoiesis. Apoptosis (or programmed cell death) plays a crucial role in regulating 
cell numbers. It is an essential process not only in haemopoiesis but also for developing 
normal embryos, maintenance of homeostasis in all adult tissues and suppression of 
carcinogenesis. Apoptosis is the ordered disassembly of the cell from within. It is 
characterised by changes in the phospholipid content of the plasma membrane, 
membrane blebbing, cell shrinkage, mitochondrial changes, chromatin condensation 
and DNA fragmentation. The mitochondria are thought to be pivotal in controlling the 
apoptotic process. In the mitochondria of apoptotic cells electron transport and ATP 
production are disrupted, redox potential is lost and proteins that are involved in the 
downstream events of apoptosis (for example cytochrome c) are released. The process 
of apoptosis does not provoke an inflammatory response. Instead, phagocytic cells 
recognise the presence of phosphatidylserine on the outer leaflet of the plasma 
membrane and engulf the apoptotic cell.
Contrasting with apoptotic cell death is necrotic death, which is usually the result of 
severe cellular insult. Both internal organelle and plasma membrane integrity are lost, 
resulting in spilling of the cytosolic contents into the surrounding environment. 
Immune cells are attracted to the area and begin producing cytokines that generate an 
inflammatory response.
The apoptotic process can be triggered by a number of stimuli including growth factor 
withdrawal, death receptor activation, UV irradiation and stress. Broadly speaking 
these can be separated into two pathways: positive induction by death receptor 
engagement or negative induction by loss of suppressor activity (for example upon 
growth factor withdrawal).
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Most of what we understand about the mechanisms of apoptosis has come from 
developmental studies in the nematode worm Caenorhabditis elegans. Studies of C. 
elegans mutations have identified three C. elegans gene products that are essential for 
apoptosis: CED-3 (where CED stands for cell death abnormal) and CED-4 promote 
apoptosis while CED-9 inhibits apoptosis. Mammalian homologues for these genes 
have been identified and CED-3 belongs to a family of proteases called cytosolic 
aspartate-specific proteases or caspases (Thomberry, 1999), CED-4 and its homologue 
Apaf-1 (apoptotic protease activating factor-1) are cytochrome-c binding adaptor 
proteins (Zou et al., 1997) and CED-9 is an anti-apoptotic member of the Bcl-2 family 
(Vaux et al., 1992). The roles that these proteins play in the apoptotic pathway are not 
fully understood but recently much progress has been made in understanding their 
functions. An overview of the roles that the Bcl-2 family and caspases play in 
apoptosis is shown in Figure 1.4 and they are discussed in more detail below.
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Figure 1.4
The Roles o f Bcl-2 family members and caspases in apoptosis
Death Recepter
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fragmentation
Apoptosis is a regulated physiological process, which can be induced by the withdrawal of a 
survival signal or by a specific signal to die. Caspases are central to the apoptotic process and 
once activated induce the cleavage of specific cytoskeletal and nuclear proteins leading to the 
characteristic cell shrinkage and DNA fragmentation of apoptotic cells.
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The Bcl-2 Family
The Bcl-2 protein family are intracellular regulators of cell survival. This family 
consists of both pro-apoptotic and anti-apoptotic members. The homology within the 
family is restricted to 4 Bcl-2 homology (BH) domains of which all members have at 
least one (Figure 1.4). Most anti-apoptotic members have at least BH1 and BH2 while 
the pro-apoptotic members can be further classified into those that consist of the BH3 
domain only (eg Bad) and those that consist of BH1-BH3 domains (e.g. Bax). The pro- 
and anti-apoptotic family members can heterodimerise and seemingly titrate one 
anothers function, suggesting that their relative concentrations may act to control entry 
into the apoptotic pathway. The activity and interactive ability of some family 
members is also controlled by phosphorylation (Reed, 1997; Adams and Cory, 1998; 
Antonsson and Martinou, 2000).
Structural studies of the anti-apoptotic member Bcl-XL show that the BH1, BH2 and 
BH3 domains form a-helices that create an elongated hydrophobic cleft to which an 
amphipathic BH3 a-helix can bind (Muchmore et al., 1996). The overall structure of 
Bcl-XL shows a remarkable similarity to membrane insertion domains of some bacterial 
toxins leading to the hypothesis that it is a membrane pore forming protein. In support 
of this theory, Bcl-2, Bcl-XL, and Bax have all been shown to form ion channels in lipid 
bilayers in vitro (Schendel et al., 1997; Antonsson et al., 1997).
How the anti-apoptotic members of the Bcl-2 family act to prevent the action of 
caspases and CED-4/apaf-l is not well understood. The BH4 domain of Bcl-2 is 
required for its interaction with CED-4 (Huang et al., 1998), as well as its anti-apoptotic 
activity (Cheng et al., 1997). Cytochrome-c is released from the mitochondria into the 
cytosol during many types of apoptosis (Rosse et al., 1998; Bossy-Wetzel and Green, 
1999). When in the cytosol, cytochrome-c forms a complex with Apafl and caspase-9 
and this leads to the activation of caspase 9 (Li et al., 1997). The pro-apoptotic Bcl-2 
family member Bax can directly induce the release of cytochrome-c from the 
mitochondria (Jurgensmeier et al., 1998; Eskes et al., 1998), while expression of Bcl-2 
prevents the release of cytochrome-c (Kluck et al., 1997). Therefore, it seems likely 
that the Bcl-2 family regulate apoptosis at least in part by controlling the release of 
cytochrome-c from the mitochondria and its interaction with Apafl and caspase-9.
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Figure 1.5 
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The sub families of the Bcl-2 family. The anti-apoptotic members promote the 
survival of cells, while the pro-apoptotic members facilitate apoptosis. The Bel 
homology (BH) domains of sequence homology, and membrane anchoring 
domains are indicated. The a-helices as determined by structural studies of Bcl-XL 
are indicated a l-a7 . This is not a comprehensive list and is adapted from Adams 
and Cory, 1998.
Caspases
Caspases are a family of highly specific cysteine proteases that have distinct roles in 
both inflammation and apoptosis. They are expressed as pro-enzymes that contain 3 
domains: an N-terminal domain, a large subunit and a small subunit. Activation 
involves proteolitic processing between domains followed by association of the large 
and small subunits to form a heterodimer. Caspases are involved in apoptosis pathways 
resulting from both positive and negative induction. Caspase-8 activity is induced by 
the death receptors, while caspase-9 activity is induced by the dATP-dependent 
formation of a complex with Apafl and cytochrome-c upon the release of cytochrome-c 
from the mitochondria (Li et al., 1997; Zhang et al., 1993). Caspase 8 and 9 are 
referred to as initiator caspases. Activation of either of these initiator caspases leads to 
the activation of the effector caspase, caspase-3. This in turn can activate other effector 
caspases and thus amplify the apoptotic signal (Thomberry, 1999). Caspases contribute 
to the apoptotic process by the cleavage of various cellular proteins. A number of these 
are involved in the degradation of DNA, which is a hallmark of apoptosis. For 
example, targets of caspases include ICAD, an inhibitor of the nuclease responsible for 
DNA fragmentation (Paradis and Ruvkun, 1998; Liu et al., 1998) and PARP (poly 
(ADP-ribose) polymerase) (Demurcia and Demurcia, 1994; Lippke et al., 1996). PARP 
is a DNA repair enzyme whose expression is triggered by DNA-strand breaks. In cells 
undergoing apoptosis PARP is cleaved and this is thought to facilitate the degradation 
of DNA. Other targets of caspases include focal adhesion kinase (FAK), which is 
involved in cytoskeleton regulation (Wen et al., 1997) and Bcl-2. The BH4 domain of 
Bcl-2 is cleaved during apoptosis by a caspase action, and this accelerates the apoptotic 
process (Grandgirard et al., 1998).
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1.4 Signalling pathways activated by cytokines
Cytokines regulate haemopoiesis by modulating the differentiation, proliferation and 
survival of haemopoietic lineages and their precursors. These effects are mediated 
through the activation of several signalling pathways. Receptor binding leads to the 
rapid activation of a number of signalling proteins and pathways, most notably the src 
kinases, and the MAP kinase, Jak/STAT, and PI3K pathways. These will be reviewed 
in turn.
1.4.1 The Jak/STAT Pathway
Jaks are cytoplasmic tyrosine kinases that participate in signaling from a range of cell- 
surface receptors, particularly members of the cytokine family, which lack tyrosine 
kinase activity. Jak was originally an acronym for just another kinase, but has also been 
proposed as an acronym for Janus (the two-faced Roman God of gates and doorways) 
kinase. Four members of the Jak family have been identified: Jakl, Jak2, Jak3 
(Witthuhn et al., 1994) and Tyk2, which vary in size from llOkDa to 140kDa. Jakl, 
Jak2 and Tyk2 are all ubiquitously expressed, while Jak3 is predominantly found in 
myeloid cells, natural killer cells and T lymphocytes (Rane and Reddy, 1994; Johnston 
et al., 1994).
Amino acid sequence alignment of the Jak family show that they possess seven highly 
homologous Jak homology domains (JH1-JH7) and have no protein interacting SH2 or 
SH3 domains (Figure 1.6A). The C-terminal region consists of a tandem kinase (JH1) 
and psuedo kinase (JH2) domain, only one of which (JH1) is catalytically active 
(Leonard and O'Shea, 1998).
All the cytokines whose receptors belong to the class I receptor family, which lack 
intrinsic kinase activity, induce the phosphorylation and activation of Jak family 
members. Stimulation with IL-4 leads to the activation of both Jakl and Jak3 
(Witthuhn et al., 1994; Yin et al,. 1994) where as IL-3 (Silvennoinen et al., 1993), GM- 
CSF (Quelle et al., 1994) and SCF (Weiler et al., 1996) stimulation results in the 
activation of Jak2.
Jaks are associated with the cytoplasmic domain of cytokine receptors but are 
catalytically inactive in resting cells. Studies using cytokine receptor mutants have 
shown that the membrane proximal boxl conserved motif is required for Jak association 
with receptor subunits (Quelle et al., 1994; Tanner et al., 1995). The Jak kinases bind 
to the receptor subunits through their N-terminal region. The JH6 and JH7 domains are 
necessary and sufficient for binding of Jakl and 3 to yc (Zhou et al., 1997) and Jak2 to
18
pc (Li et al., 1997). Upon ligand binding, Jaks become rapidly activated by 
phosphorylation on tyrosine residue(s) within the activation loop of their kinase 
domain. It is believed that Jaks activate each other by cross-phosphorylation when they 
are brought into contact with each other through receptor homo- or hetero-dimerisation.
Cytokine-induced activation of the Jak family of kinases results in the tyrosine 
phosphorylation of a number of cellular proteins including the cytokine receptors 
themselves and a family of proteins known as STATs (signal transducers and activators 
of transcription).
STATs are latent cytoplasmic transcription factors that upon activation translocate to 
the nucleus where they regulate gene expression. Seven members of this family have 
been identified, STAT1-6 (including STAT5a and 5b), which vary in size from 734-851 
amino acids. They are composed of a central DNA binding domain and an SH2 domain 
in the C-terminal region (Figure 1.6B). A conserved tyrosine residue exists near the C- 
terminus and its phosphorylation by Jak leads to STAT activation (Leonard and O'Shea,
1998).
STAT proteins are recruited to the active cytokine receptor complex through their 
SH2 domain, where they either interact directly with phospho-tyrosine residues on the 
receptor or indirectly through other STATs or Jaks. The SH2 domain seems to direct 
the specificity of cytokine-induced STAT activation. STAT6 is activated by IL-4 
treatment and has been shown to bind through its SH2 domain to IL-4Ra (Hou et al.,
1994). IL-3 and GM-CSF have been shown to activate both STAT5a and STAT5b, 
which interact with Pc through their SH2 domains (Mui et al., 1995). Interestingly, 
SCF has been reported to induce the phosphorylation and activation of STAT la , 
STAT5a and STAT5b (Brizzi et al., 1999). The mechanism of activation and whether 
Jak proteins are needed is unclear.
Once phosphorylated and activated by Jak, STAT proteins form homo- or hetero­
dimers through the interaction of a phosphorylated tyrosine on one STAT molecule with 
the SH2 domain of another. The dimerised STAT proteins then translocate to the 
nucleus where they bind to DNA sequences most of which are related to the gamma 
interferon activated site (GAS), a regulatory element in the promoter of IFN-y-inducible 
genes (Darnell et al., 1994).
In addition to activating STATs, Jaks are also involved in the activation of a number 
of other proteins. Perhaps the most important function of the Jak family is the tyrosine 
phosphorylation of the class I cytokine receptors. Receptor phosphorylation is required 
for the recruitment (either directly or indirectly) and activation of a number of
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signalling proteins to the receptor complex including the adaptor proteins She, Grb2, 
Gab2, the IRS family, the tyrosine phosphatases SHP1 and SHP2, and the lipid kinase 
PI3K.
Figure 1.6 
Structure of Jaks and STATs
A
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SH2
(A) The overall structure of Jak family members. The seven conserved domains, 
designated JH1 to JH7 are indicated. The C-terminal domain, JH 1 is the functional 
kinase domain, the pseudo-kinase domain, JH 2 lies immediately N-terminal to JH 1.
(B) The functional domains of STATs are indicated, including a conserved region in the 
amino terminus (C), the DNA binding domain, the SH2 domain (SH2) and the C- 
terminal transcriptional activation domain (Tr). The conserved Tyrosine residue that is 
essential for STAT activation is shown.
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1.4.2 Src Kinases
The src family of tyrosine kinases were named after their first member to be identified 
v-src, the first characterised oncogene from the Rous sarcoma virus (Purchio et al., 
1978). Nine kinases of the Src family have now been identified: Src, Fyn, Yes, Fgr, 
Lyn, Hck, Lck, Yrk and Blk. They are characterised by four regions of homology 
referred to as src homology (SH) domains (Figure 1.7). SHI is a C-terminal tyrosine 
kinase domain, SH4 an N-terminal membrane localisation sequence. Src homology 
regions 2 (SH2) and 3 (SH3) mediate the interactions of src kinases with other proteins. 
SH2 domains bind phospho-tyrosine residues in the motif YEEI, while SH3 domains 
interact with proline rich regions in a left handed helical conformation. Both the SH2 
and SH3 domains are present in many other proteins where they are again involved in 
the interaction between proteins (Brown and Cooper, 1996).
Src kinases are activated in response to stimulation by a number of growth factors. 
The Src kinase family members Fyn, Lyn and Hck are activated in response to IL-3 
stimulation (Anderson and Jorgensen, 1995), while Lyn (Linnekin et al., 1997), Lck and 
Yes (Krystal et al., 1998) have been shown to be activated in response to SCF.
Figure 1.7 
Structure of c-Src Kinase
K in as t ;  H n m a i n
SH4 SH3 SH2 SHI
The overall structure of the Src family of protein kinases is shown. The regions of Src 
homology domains are indicated SHI to SH4. SHI is the kinase domain, SH2 is a 
region of protein-protein interactions, which binds phospho-tyrosine residues in the 
motif YEEI, SH3 domains interact with proline rich regions and the SH4 domain 
contains a myristylation motif. N2, the site of myristylation, Y416, which is the site of 
autophosphorylation and Y527, the negative regulatory site are indicated.
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1.4.3 The MAP Kinase Pathway
The MAP (mitogen-activated protein) kinase cascades are characterized by their core 
three-component protein kinase cascade, which consists of a MAP kinase kinase kinase, 
which phosphorylates and activates a MAP kinase kinase, which in turn phosphorylates 
and activates MAP kinases (Figure 1.8). The MAP kinases are proline directed 
serine/threonine kinases that are characterized by their activation through the dual 
phosphorylation of tyrosine and threonine residues. The classical example of a MAP 
Kinase pathway is the Ras/Raf/MEK/ERK pathway, which results in the activation of 
the extracellular regulated kinases-1 and -2 (ERK-1 and -2). Two other MAK kinase 
cascades leading to the activation of c-Jun amino-terminal kinase (JNK) and p38 MAP 
kinase also exist.
The ERK Pathway
The classical MAP kinase pathway, which results in the activation of Erk-1 and -2, is 
activated in response to growth factor and cytokine stimulation through the activation of 
Ras. The Ras proteins are 21kDa plasma membrane associated proteins, which bind 
guanine nucleotides and have intrinsic GTPase activity. Three isoforms have been 
identified to date: c-H-ras, c-K-ras and c-N-ras. They were first identified as the 
transforming agents of the Harvey and Kirsten sarcoma viruses (Harvey, 1964; Kirsten 
and Mayer, 1967). Ras proteins act as regulatory switches whose activity is controlled 
by cycling between an active guanosine triphosphate (GTP)-bound and an inactive 
guanosine diphosphate (GDP)-bound state (Figure 1.9) (Polakais and McCormick,
1993). Ras bound GDP is exchanged for GTP, which is hydrolysed by Ras to GDP. 
The exchange of GDP for GTP is regulated by guanine nucleotide exchange factors (eg 
sos and Ras-GRF), which accelerate the exchange of Ras-GDP for Ras-GTP and hence 
activate Ras (Feig, 1994). It is thought that upon growth factor receptor engagement 
Ras is activated primarily by the translocation of Sos to the plasma membrane where 
Ras is located. Sos interacts with the adaptor protein Grb2 (Rozakis-Adcock et al., 
1993; Egan et al., 1993; Li et al., 1994), which can interact with activated growth factor 
receptors either directly (Lowenstein et al., 1992; Rozakis-Adcock et al., 1993; Buday 
and Downward, 1993; Skolnik et al., 1993) or through the adaptor protein She (Ruff- 
Jamison et al., 1993; Welham et al, 1994a; Salcini et al., 1994) or the 
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The MAP kinase cascades leading to the activation of the MAP kinases Erk, JNK 
and p38 are illustrated schematically. Growth factor activation lead to the 
activation of the Erk kinases by MEK1 and 2. Cellular stress results in the 
activation of the JNK and p38 MAPKs through MKK4/7 and MKK3/6 
respectively. Once activated the MAPKs can transcription factors (Elk-1, c-Jun, 
ATF-2), other kinases (MAPKAP kinasel and 2) and other regulatory enzymes 
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(A) In its inactive state, Ras is bound to GDP. Guanine nucleotide exchange factors 
(GNEF) accelerate the exchange of GDP for GTP, activating Ras. GTPase activating 
proteins (GAPs) increase the the intrinsic GTPase activity of Ras, converting the 
active GTP-bound Ras, back to the inactive GDP-bound state. (B) Ras activity is 
regulated through the translocation of the Grb2-Sos complex to the membrane. This 
may occur (1) through the direct association of Grb2 with the activated receptor or 
(2) through the association of an adapter protein with the activated receptor.
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The activation of Ras leads to the activation of the MAP kinase kinase kinase Raf-1. 
Raf is a ubiquitously expressed 72-76kDa cytoplasmic serine/threonine kinase, which 
was first identified as the cellular counterpart of the oncogenic v-raf from the murine 
sarcoma virus 3611 (Rapp et al., 1983). Two other mammalian Raf family members 
have been identified: A-Raf (Beck et al., 1987) and B-Raf (Eychene et al., 1992).
Expression of a dominant inhibitory Raf-1 or Raf-1 anti-sense mRNA inhibits \-ras- 
induced transformation of fibroblasts indicating that Raf-1 functions downstream of Ras 
(Kolch et al., 1991). Using the yeast two-hybrid system and in vitro binding studies it 
has been shown that Raf-1 can directly interact with Ras and this interaction is 
dependent on Ras being in its GTP-bound active state (Vanaelst et al., 1993; Vojtek et 
al., 1993; Zhang et al., 1993). However, this direct association does not lead to Raf-1 
activation, rather the recruitment of Raf-1 to the membrane is needed for activation but 
is not sufficient for the stable activation of Raf-1 (Leevers et al., 1994; Stokoe et al.,
1994). The observation that Raf-1 is hyper-phosphorylated in response to many 
signalling events has suggested that phosphorylation may play a role in regulating Raf-1 
activity (Morrison et al., 1993). Phosphorylation could directly modulate Raf-1 kinase 
activity or it could act by mediating protein-protein interactions. Phosphorylation on 
Ser338 and Tyr341 synergize to activate Raf-1 (Mason et al., 1999), but the 
phosphorylation of Raf-1 on other sites, also appears to regulate Raf-1 activity. Raf-1 
interacts with the adaptor protein 14-3-3 through phosphorylated Ser259 and Ser621 
(Tzivion et al., 1998) and this appears to positively regulate Raf-1 as over-expression of 
14-3-3 in fibroblasts resulted in Raf-1 activation (Li et al., 1995). However the 
mechanism by which 14-3-3 regulates Raf-1 is poorly understood.
The MAP kinase kinase, MEK (Map kinase/Erk activating kinase) is activated by the 
phosphorylation of residues Ser217 or Ser221 by Raf-1 (Alessi et al., 1994). Two 
mammalian MEK isoforms have been identified: MEK1 and MEK2 (Crews and 
Erikson, 1992; Zheng and Guan, 1993). The activity of MEK is thought to be enhanced 
by MP1 (MEK partner 1) binding (Schaeffer et al., 1998). The MEK kinases catalyse 
the phosphorylation of the MAP kinases, Erkl and Erk2, on Thr183 and Tyr185 (Payne et 
al., 1991). Upon growth factor stimulation, a proportion of the erk kinases are rapidly 
translocated from the cytoplasm to the nucleus (Lenormand et al., 1993). MAP kinases 
are proline-directed kinases that phosphorylate the consensus sequence Pro-X-Ser/Thr- 
Pro (Gonzalez et al., 1991). Their substrates include downstream kinases 
(eg.phospholipase A (Lin et al., 1993) and the ribosomal S6 kinase p90rsk (Sturgill et al., 
1988), transcription factors (eg. Elk-1, which is involved in c-fos induction (Marais et
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al., 1993) and the protein kinases that lead to the activation of Erks. Erkl has been 
shown to phosphorylate MEK1 on Thr386, which has been suggested to act as a negative 
feedback control reducing MEK1 activity (Brunet et al., 1994). Rafl is also 
phosphorylated by the Erk kinases and again this phosphorylation has been suggested to 
play a negative regulatory role (Anderson et al., 1991; Lee et al., 1992).
Ras (Duronio et al., 1992) and the MAP kinases (Erk-1 and Erk-2) (Welham et al.,
1992), have been shown to be activated in response to IL-3, GM-CSF, and SCF. 
However, IL-4 is does not induce the activation of Ras nor the Erk kinases (Duronio et 
al., 1992; Welham et al., 1992).
The p38 Pathway
The MAP kinase pathway leading to the activation of the p38 kinase is activated in 
response to cellular stresses such as changes in osmolarity, DNA damage, UV 
irradiation and heat-shock as well as by the pro-inflammatory cytokines TNFa and IL- 
1. p38 is activated by the MAP kinase kinases MKK3 and MKK6, which catalyse the 
dual phosphorylation of p38 on the motif Thr-Gly-Tyr. Activated p38 subsequently 
phosphorylates and activates the transcription factors ATF-2 and Elk-1 and the MAP 
kinase activated protein kinase-2 (MAPKAP kinase-2) (Herlaar and Brown, 1999).
The JNK Pathway
The JNK kinases, also known as the stress-activated protein kinases (SAPKs) are 
activated in response to environmental stress and inflammatory cytokines. They are 
activated by the dual phosphorylation within the motif Thr-Pro-Tyr by the MAP kinase 
kinases MKK4 and MKK7. Activation of the JNK kinases results in the activation of 
the transcription factors c-Jun, ATF-2 and Elk-1 (Ip and Davis, 1998).
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1.5 Phosphoinositide-3 Kinases (PI3K)
PI3K was first discovered through the observation that a PI kinase activity associated 
with the oncogenic pp60v‘src (Sugimoto et al., 1985). At first this was thought to be an 
intrinsic catalytic activity, but it was subsequently discovered that the PI kinase activity 
could be separated from the middle T pp60csrc complex by a high salt and detergent 
solution (Kaplan et al., 1986; Whitman et al., 1987). This PI kinase activity was found 
to catalyse the phosphorylation of the D3 position of the inositol ring thus generating a 
previously unknown class of lipids (Whitman et al., 1988b). Interest in this new class 
of lipid kinase grew when it was discovered that all the mutants of the polyoma middle 
T that failed to associate with PI3K also failed to transform 3T3 fibroblasts ( Kaplan et 
al., 1986; Courtneidge and Heber, 1987; Whitman et al., 1988a). This suggested a role 
for PI3K in oncogenic and mitogenic signal transduction.
PI3Ks phosphorylate the hydroxyl group at the 3’ position on the inositol ring of 
phosphatidyl inositols. Phosphatidylinositol (PI), phosphatidylinositol-4-phosphate 
(PI(4)P) and phosphatidylinositol-4,5-bisphosphate (PI(4,5)P2) are converted to 
phosphatidylinositol-3-phosphate (PI(3)P), phosphatidylinositol-3,4-bisphosphate 
(PI(3,4)P2) and phosphatidylinositol-3,4,5-trisphosphate (PI(3,4,5)P3) respectively. 
PI(3)P is constitutively present in cells and its levels are largely unchanged by 
stimulation with a variety of ligands. In contrast PI(3,4)P2 and PI(3,4,5)P3 are almost 
absent from resting cells and are produced upon cellular stimulation. This makes 
PI(3,4)P2 and PI(3,4,5)P3 likely second messengers. Unlike the hydrolysis of PI(4,5)P2 
by phospholipase-C to IP3 and diacylglyceraol, the lipid products of PI3K are not 
substrates for phospholipases, instead their 3 or 5 phosphate groups are removed by 
phosphatases such as PTEN and SHIP (Section 1.9).
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Numerous PI3K isoforms exist and these can be divided into 3 classes based on their 
substrates and the adaptor proteins with which they interact (Table 1.2).
3.5.1 Class I (refer to Section 1.6 for more detail)
These PI3Ks phosphorylate all the above phospholipids in in vitro assays, although 
their preferred substrate is thought to be PI(4,5)P2. Members of this class interact with 
active GTP-bound Ras and form heterodimers with adaptor proteins. They can be 
divided into two types (Class IA and IB) according to the nature of the interactions with 
adaptor proteins (Reviewed in Vanhaesebroeck et al., 1997, Wymann and Pirola, 1998, 
Leevers et al., 1999, Vanhaesebroeck and Alessi, 2000). Class IA PI3Ks catalytic 
subunits vary in size from 110-130kDa and interact with SH2 domain containing 
adaptor proteins. They include the mammalian p i 10a, p and 8 isoforms that interact 
with p85 adaptor subunits. Class IB interact with stimulated G-protein Py subunits 
including pllOy. A regulatory p i01 subunit has been found which interacts with this 
subunit (Stephens et al., 1997).
3.5.2 Class II
This class of PI3K are larger (>170kDa), and in vitro prefer PI and PI(4)P over 
PI(4,5)P2 as substrates (Macdougall et al., 1995; Domin et al., 1997). They are 
characterised by a synaptotagmin C2 domain in their C-terminal region. C2 domains 
are involved in the regulation of synaptotagmin by Ca2+, however, in the class II PI3Ks 
this domain is mutated at a critical Asp residue and Ca2+ is not required for phospholipid 
binding (Macdougall et al., 1995; Arcaro et al., 1998). As with the class I PI3Ks, class 
II PI3Ks are activated in response to extracellular signals. In vitro kinase assays have 
demonstrated that class II PI3Ks are activated in response to growth factors such as 
insulin (Brown et al., 1999), EGF (Arcaro et al., 1998), PDGF (Arcaro et al., 1998), and 
integrins (Zhang et al., 1995) and chemokines (Turner et al., 1998). However, 
fractionation studies have shown that in contrast to class I PI3Ks, class II PI3Ks are 
primarily membrane associated (Arcaro et al., 1998; Domin et al., 1997). Recently, it 
has been reported that clathrin functions as an adaptor for the class II PI3K, PI3K 
C2a, binding to its N-terminal and stimulating its catalytic activity (Gaidarov et al., 
2001). Furthermore, exogenous expression of PI3K-C2a was found to affect clathrin- 
mediated endocytosis and sorting of the trans-Golgi network, suggesting a role for class 
II PI3Ks in membrane trafficking (Gaidarov et al., 2001).
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Table 1.2
Classification of PI3K Family Members
Class Catalytic Subunit
Substrate











1 Proline-rich domain Kinase domain □  SH3 domain 1 ...I rhoGap homology domain
H  PIK domain H  C2 domain ®  Proline-rich motif d  SH2 domain
H  Ras binding
The classes of PI3K and the defining features of their subunits are shown. The assignment of the catalytic subunits to 
each class is based on their structural features, substrate specificity and the adapter subunits with which they associate.
3.5.3 Class III
A single class III catalytic subunit has been identified in all eukaryotic species, which 
exists as a complex with a serine/threonine kinase adaptor molecule (p i50 in 
mammals). PI3K and its adaptor p i50 are homologous to the yeast vps34p (vacuolar 
protein sorting 34p) and vpsl5p respectively. Vpsl5p is myristolated at its N-terminus 
and this targets the PI3K complex to the membrane (Panaretou et al., 1997). Vsp34p is 
involved in the sorting of carboxypeptidase from the late golgi to the intermediate 
endosomal compartment, suggesting a role for class III PI3Ks in the sorting of proteins 
to the yeast vacuole (Schu et al., 1993). Class III PI3Ks phosphorylate only PI in vitro 
to produce PI3P (Schu et al., 1993). Levels of PI3P remain relatively constant in the 
cell, which suggests that the physiological processes that are controlled by this class of 
PI3Ks are constitutive and not activated in response to cellular stimulation.
1.5.4 Class Ia PI3K
Three mammalian class IA PI3K have been identified to date, p i 10a (Hiles et al.,
1992) and pllOP (Hu et al., 1993) appear to be ubiquitously expressed while 
p i 108 (Vanhaesebroeck et al., 1997) is found mainly in haemopoietic cells. The p i 10 
subunits are 1 lOkDa proteins that interact with the p85 adaptor subunits through amino 
acids 20-108 of their N-terminal domain (Dhand et al., 1994b). They contain a Ras 
binding domain and a C-terminal lipid kinase core. In addition to their lipid kinase 
activity, class IA PI 3K also possess serine/threonine protein kinase activity. p85 is a 
substrate of the kinase activity of pi 10a and phosphorylation of p85 on Ser608 results in 
a marked decrease in kinase activity of PI3K (Dhand et al., 1994a; Carpenter et al.,
1993). Interestingly p i 108 is unable to phosphorylate p85 but undergoes 
autophosphorylation which inhibits its lipid kinase activity (Vanhaesebroeck et al., 
1997; Vanhaesebroeck et al., 1999). A schematic diagram of the p i 10 PI3K subunit is 
shown in Table 1.2.
There are two mammalian isoforms of the p85 adaptor subunit a  and p (Otsu et al., 
1991; Escobedo et al., 1991) and a p55y adaptor subunit (Pons et al., 1995). In 
addition, alternatively spliced variant (p55a and p50a) of p85a have been identified 
(Fruman et al., 1996; Antonetti et al., 1996; Inukai et al., 1997). The 85kDa proteins 
contain two Src homology (nSH2 and cSH2) regions, which are linked by an inter-SH2 
(iSH2) domain, a Src homology 3 (SH3) domain and a break point cluster region (BCR) 
(Table 1.2). The p55 subunit is highly homologous to the C-terminal half of the p85
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subunits, but lacks the SH3 and BCR homology regions. SH2 domains mediate protein- 
protein interactions by binding phospho-tyrosine residues within a pYXXM motif. 
Amino acid residues 479-513 in the inter-SH2 domain have been shown to be the region 
of p85 which interacts with the p i 10 subunit (Klippel et al., 1993; Dhand et al., 1994a; 
Dhand et al., 1994b). The roles of the SH3 and BCR domains are not well defined. SH3 
domains bind proline rich regions containing the motif PXXP and the SH3 domain of 
p85 has been shown to bind to the adaptor protein She (Harrisonfindik et al., 1995), the 
tyrosine kinase Lyn (Pleiman et al., 1994) and the oncogene cbl (Soltoff and Cantley,
1996).
1.6 The Activation of Class IA PI3K
Class IA PI3Ks are activated in response to a number of cytokines and growth factors 
including IL-3, IL-4, SCF, GM-CSF and IL-5 (Gold et al., 1994), insulin (Ruderman et 
al., 1990), PDGF (Kaplan et al., 1987), EGF, bFGF (Raffioni and Bradshaw, 1992). 
The p85 subunit is believed to regulate PI3K activity in two ways. Binding of p85 to 
p i 10 through the interaction of its iSH2 domain stabilises p i 10, protecting it from 
degradation, but also inhibits its kinase activity (Yu et al., 1998). The p85 SH2 
domains have a high selectivity for binding phosphorylated YXXM sequences that are 
present on some activated growth factor receptors. This targets PI3K to the membrane 
where its substrates are located. Phospho-tyrosine binding of the N-SH2 domain to the 
YXXM motif induces a conformational change that results in p i 10 catalytic activity 
(Yu et al., 1998). For example, in the case of PDGF, ligand binding to the receptor 
results in autophosphorylation of the receptor on tyrosine residues in the YXXM motif 
in the interkinase domain. PI3K is activated by the interaction of p85 SH2 domains 
with these phosphotyrosine residues, which targets PI3K to its substrates in the 
membrane and causes a conformational change to the p i 10 subunit, which activates its 
catalytic activity (Coughlin et al., 1989; Kazlauskas and Cooper, 1990; Escobedo et al., 
1991).
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1.6.1 SCF-induced activation of PI3K
SCF activates PI3K by a similar mechanism to that of PDGF (Figure 1.10B). SCF 
binds to c-kit, which activates its tyrosine kinase domain resulting in the 
autophosphorylation of tyrosine residues. The kinase activity of c-kit is required for the 
activation of PI3K. In cells derived from mice homologous for the W42 mutant allele, 
in which c-kit does not possess intrinsic tyrosine kinase activity and therefore is not 
tyrosine phosphorylated, PI3K activity does not associate with c-kit upon SCF 
stimulation (Rottapel et al., 1991). However, when a constitutively phosphorylated c- 
kit is expressed in cells, PI3K activity is bound in the absence of SCF stimulation 
(Rottapel et al., 1991). The interaction of PI3K with c-kit is mediated through p85 
association with phospho-Tyr719 in the motif pYMDM in the interkinase domain (Serve 
et al., 1994). This is thought to activate PI3K by inducing the conformational change in 
p i 10 and by targeting PI3K to the membrane where it can interact with its lipid 
substrates. Mutation of c-kit residue Tyr719 to phenylalanine in mast cells results in the 
inhibition of SCF stimulated PI3K activity, as well as a partial inhibition of SCF 
induced proliferation and survival (Serve et al., 1995). This implicates a role for PI3K 
in SCF supported growth and survival.
Other growth factor receptors do not contain YXXM docking sites for p85 SH2 
domains. Instead they use adaptor proteins to target p85 to the receptor complex thus 
activating PI3K.
1.6.2 Insulin-induced activation of PI3K
Insulin and insulin-like growth factor-1 (IGF-1) activate PI3K by recruiting it to the 
receptor via the insulin receptor substrate (IRS) proteins (Figure 1.10A). IRS1 (Sun et 
al., 1991) and IRS2 (also known as 4PS (Sun et al., 1995) associate with the insulin and 
IGF-1 receptors through the interaction of their protein tyrosine binding (PTB) domain 
with an NPEY motif in the juxtamembrane region of the receptor (Wolf et al., 1995). 
This results in the phosphorylation of the IRS proteins within YXXM motifs, which 
form sites for p85 SH2 domain association. This results in the translocation of PI3K to 
the membrane and the activation of the p i 10 catalytic subunit (Backer et al., 1992).
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Figure 1.10 
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The mechanism of activation of PI3K by (A) Insulin, (B) SCF, (C) IL-4 and (D) 
IL-3/GM-CSF are shown. Ligand binding to their receptors on the cell surface 
results in the tyrosine phosphorylation of the receptors and the recruitment of the 
p85 subunit of PI3K to the activated receptor complex either directly or through 
adapter proteins. See Section 1.18 details.
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1.6.3 IL-4-induced activation of PI3K
Like insulin, IL-4 utilises the IRS proteins to target p85 via its SH2 domains and thus 
activate PI3K Figure 1.10C). However, unlike insulin, whose receptor contains 
intrinsic tyrosine kinase activity, the IL-4 receptor has no tyrosine kinase activity. IL-4 
stimulation results in the activation of the kinases Jakl and Jak3 (Witthuhn et al., 1994; 
Welham et al., 1995). In T-lymphocytes, IL-4 stimulation results in a complex 
formation between Jakl, IL-4R and IRS2 leading to the phosphorylation of all these 
proteins (Yin et al., 1994). Studies in the haemopoietic cell line FDCP-2 found PI3K 
activity associated with the phosphorylated 170kDa IRS2 protein after IL-4, insulin and 
IGF-1 stimulation (Wang et al., 1992) and p85 has also been shown to co-precipitate 
with IRS1 and IRS 2 after stimulation with IL-4 (Welham et al., 1997; Jackson et al.,
1998). Collectively, these data suggest that PI3K might be sequestered to the 
membrane through the formation of a complex between p85, IRS 1/2 and the IL-4R.
In common with the receptors for insulin and IGF-1, IL-4R contains an I4R motif 
(PLX4NPXYXSXSD) in the juxtamembrane region that has been implicated in IRS 
binding to these receptors. Indeed, transfection of IRS-1 into 32D cells (which express 
neither IRS-1 or IRS-2) enables these cells to proliferate in response to a combination 
of IL-4 and insulin. However mutation of Y497 in the I4R domain of the IL-4 receptor 
to phenylalanine blocked the IL-4 induced IRS1 phosphorylation and proliferation of 
this cell line (Keegan et al., 1994). Taken together these data point to a mechanism of 
IL-4 activation of PI3K whereby IL-4 binding to the IL-4R results in activation of Jakl 
and its subsequent phosphorylation as well as receptor phosphorylation on a number of 
tyrosine residues including Y497 in the I4R domain. This creates a receptor-binding 
site for IRS2/IRS1 and results in phosphorylation in the YXXM motif that is recognised 
by the p85 adaptor subunit SH2 domains. This recruits PI3K to the membrane and 
results in the activation of the p i 10 catalytic PI3K subunit.
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1.6.4 IL-3- and GM-CSF-induced activation of PI3K
Pc is a common signalling component of the receptor complexes of both IL-3 and 
GM-CSF and for this reason the activation of PI3K by these cytokines will be discussed 
together (Figure 1.1 OD). IL-3 (Silvennoinen et al., 1993) and GM-CSF (Quelle et al.,
1994) binding to their receptor complexes results in the tyrosine phosphorylation and 
activation of Jak2 and to a lesser extent Jakl, and this results in the tyrosine 
phosphorylation of a number of proteins including pc. Two of these sites, Tyr577 and 
Tyr612 are thought to be important for the activation of PI3K as mutation of both these 
sites inhibited the IL-3 and GM-CSF-induced activation the downstream target of PI3K, 
PKB (Dijkers et al., 1999). However, like the insulin and IL-4 receptors, Pc does not 
possess the YXXM motif required for p85 binding and it instead uses adaptor molecules 
to recruit p8-5 (Fantl et al., 1992). Over recent years, with the cloning of the adaptor 
protein Gab2 (Gu et al., 1998), much progress has been made in understanding the 
mechanisms by which IL-3 and GM-CSF activate PI3K. In response to IL-3 
stimulation, Gab2 is heavily phosphorylated and binds to p85 (Shaw et al., 1997; Gu et 
al., 1998). It has also been shown to associate constitutively with Grb2, and after 
cellular stimulation with IL-3, to associate with the adaptor protein She and the 
phosphatase SHP2 (Shaw et al., 1997; Gu et al., 1998). She binds to pc through 
interactions with phosphorylated Tyr577 and to a lesser extent Tyr612 (Bone and Welham, 
2000), while SHP2 binds to phosphorylated Tyr612 (Bone et al., 1997) and these sites 
have been shown to be important for the phosphorylation of Gab2 in response to GM- 
CSF (Gu et al., 2000). These data point towards two possible mechanisms by which the 
Pc receptor can recruit p85 to the membrane: through She association with 
phosphorylated Tyr577 and/or Tyr612, or through SHP2 association with phosphorylated 
Tyr612. There is some evidence to suggest that Grb2 is required for the interaction of 
She with p85 (Gu et al., 2000). In NIH 3T3 cells expressing the hGM-CSFR cells, co­
transfection of wild type Gab2 with wild type Grb2 resulted in the phosphorylation of 
Gab2. However, when Gab2 was co-transfected with Grb2 variants, which are 
defective in their SH2 or SH3 protein binding domains, Gab2 was not phosphorylated. 
This suggests that Grb2 may be required for the interaction of Gab2 and therefore p85 
with pc.
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1.7 The Functions of PI3K
The study of PI3Ks and their role within the cell have been aided considerably by two 
unrelated specific pharmacological inhibitors wortmannin and LY294002. Wortmannin 
is a fungal metabolite that binds irreversibly to the p i 10 catalytic subunit (Ui et al.,
1995). LY294002 was discovered as an inhibitor of PI3K in a screen of quercetin (a 
naturally occurring bioflavaniod, which also inhibits PI3K activity) analogues. 
LY294002 inhibits PI3K by competing with ATP for binding to the active site and its 
effects are reversible (Vlahos et al., 1994). These inhibitors have allowed the 
physiological responses, which are regulated by PI3Ks to be investigated. However, 
these compounds are active against most PI3Ks and therefore do not distinguish the 
functions of the different PI3K classes. In recent years a number of class IA subunit 
variants have been constructed and these have provided insights into the functions of 
the class IA PI3Ks. Of particular interest is the dominant negative Ap85 mutant. Ap85 
does not bind the pi 10 catalytic subunit, but competes with endogenous p85 for binding 
to either receptor or adaptor YXXM motifs. Thus, when an excess of Ap85 is expressed 
the endogenous p85/pl 10 complex is not recruited to the membrane and activated.
Using these approaches, PI3Ks have been implicated in the regulation of many 
physiological processes. These include proliferation and mitogenesis (Brennan et al., 
1997; Craddock et al., 1999; Hinton and Welham, 1999), cell survival (Yao and 
Cooper, 1995; Scheid et al., 1995; Minshall et al., 1996; Datta et al., 1997; Dudek et 
al., 1997; Khwaja et al., 1997; Kennedy et al., 1997; Songyang et al., 1997; Scheid and 
Duronio, 1998), cytoskeletal reorganisation (Janmey, 1995; Hartwig, 1992), cell cycle 
regulation (Brennan et al., 1997; Weinkove et al., 1999), membrane trafficking (Brown 
et al., 1995; Davidson, 1995) and membrane ruffling (Wennstrom et al., 1994).
Recently, gene knockouts of a number of class IA PI3K subunits have been made and 
these have given valuable insights into the functions of this class of PI3K. Gene 
targeted deletion of the first exon of p85a, which still allows the expression of p50a 
and p55a, gave rise to mice that were viable but had a B cell immunodeficiency. No 
impact was observed on T cells, which may be due to an increased expression of p50a 
in these cells (Suzuki et al., 1999). However, p85a-p55a-p50a -/- mice die within days 
of birth (Fruman et al., 1996). The survival and proliferation of chimeric B cells, which 
were in effect p85a-p55a-p50a -/- was also affected (Fruman et al., 1996). Disruption 
of the p i 10a catalytic subunit resulted in embryonic lethality approximately halfway 
through term due to a severe defect in the proliferative capacity of the embryo (Bi et al.,
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1999). However, p85a expression was upregulated in these embryos. This is thought 
to have a dominant negative effect on PI3K activity and may contribute to the lethal 
phenotype observed. Similarly, the expression of the p i 10a subunit was also affected 
in lymphocytes lacking p85a-p55a-p50a (Fruman et al., 1996). Thus it appears that 
the knock out of any PI3K class IA subunit will affect the expression of the other 
subunits and this should be remembered when interpreting the results of these studies.
1.8 Downstream Effectors of PI3K
The activation of PI3K leads to the production of 3’phosphoinositides, and these 
phospholipids act as second messengers and modulate the activity and/or location of 
downstream effectors of PI3K. Many of these proteins contain Pleckstrin homology 
(PH) domains, which facilitate their interaction with phospholipids. These include the 
Ser/Thr kinases PKB and PDK-1 (which will be discussed in detail later, Section 1.10 
and 1.11.1), the Tec family of Tyr kinases, PLCy2, PKC isoforms and the nucleotide 
exchange factor Vav.
The Tec proteins are a family of tyrosine kinases related to the src family. Unlike the 
src kinases they are not targeted to the membrane by an N-terminal myristylation 
sequence. However, they contain an N-terminal PH domain, which seems to substitute 
for N-myristylation to target Tec kinases to the membrane. Two members of this 
family are Brutons tyrosine kinase (BTK) and inducible T-cell kinase (ITK). The PH 
domains of both have been reported to bind to 3’phosphoinositides (August et al., 1997; 
Bottomley et al., 1998). Btk is critical for B-cell development and function and 
interestingly B-cells from Btk null mice have a similar phenotype to p85a knockouts 
(Khan et al., 1995; Kemer et al., 1995; Suzuki et al., 1999; Fruman et al., 1996).
PLCy2 activity is also a regulated by phosphoinositides. The PLCy2 PH domain is 
specific for PI(3,4,5)P3. PLCy2 has been reported to be a target of Btk (Scharenberg et 
al., 1998) and it has been proposed that PI(3,4,5)P3 may promote the association of 
PLCy2 with Btk through the interactions the PH domain of each protein with PI(3,4,5)P3 
(Falasca et al., 1998).
The lipid substrates and products of PI3K have been implicated in the regulation of 
some PKC family members. PKC isoforms, which have been implicated in PI3K 
signalling pathways, include 5 (Le Good et al., 1998), 6 (Moriya et al., 1996), r| (Le 
Good et al., 1998) and C, (Standaert et al., 1997; Le Good et al., 1998).
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The lipid products of PI3K have also been implicated in the regulation of GTP/GDP 
exchange factors (GEF) and GTPase-activating proteins (GAPS). For example, Vav, a 
GEF for Rac that stimulates the exchange of bound GDP for GTP, bound to and was 
directly controlled by substrates and products of phosphoinositide (PI) (Han et al.,
1998). This may explain why Rac acts downstream of PI3K in pathways leading to 
chemotaxis and membrane ruffling (Wennstrom et al., 1994; Hawkins et al., 1995).
1.9 Lipid Phosphatases
PI3K phosphorylates the 3’position of the inositol ring of phosphoinositides and these 
phospholipids act as second messengers that regulate a number of signalling pathways, 
some of which are discussed above. Unlike the hydrolysis of PI(4,5)P2 by 
phospholipase-C to IP3 and diacylglycerol (Kim et al., 2000), the lipid products of 
PI3Ks are not substrates for phospholipases, instead their 3 or 5 phosphate groups are 
removed by phosphatases. Two phosphatases, PTEN and SHIP, have been identified 
which catalyse the removal of phosphate groups from PI3K lipid products.
1.9.1 PTEN
PTEN (phosphatase and tensin homologue deleted from chromosome 10, also known 
as MMAC1 and TEP1) was first identified in a search for new dual-specificity 
phospatases (Li et al., 1997) and as a tumour suppressor gene (Li et al., 1997; Steck et 
al., 1997). It is one of the most common targets of mutation in human cancer (reviewed 
in Cantley and Neel, 1999). For example, germ-line mutations in PTEN cause the rare 
autosomal dominant inherited cancer syndromes Cowden disease, Lhermitte-Duclos 
disease and Bannayan-Zonana syndrome. These diseases are characterised by benign 
tumours in which differentiation is normal but cells are highly disorganised.
Sequence analysis of PTEN revealed a 47kDa dual-specificity phosphatase. However, 
PTEN was found to possess only weak tyrosine and serine/threonine phosphatase 
activity (Li and Sun, 1997; Myers et al., 1997). Studies by Maehama and Dixon 
showed that PTEN could de-phosphorylate PI(3,4,5)P3 and to a lesser extent other 
phosphoinositols in vitro (Maehama and Dixon, 1998). They showed that 
overexpression of PTEN decreased the levels of PI(3,4,5)P3 produced following insulin 
stimulation without affecting the activity of PI3K, and overexpression of phosphatase- 
inactive PTEN led to the accumulation of PI(3,4,5)P3.
Embryonic fibroblasts from PTEN -/- mice exhibit a marked decrease in sensitivity to 
apoptosis induced by a variety of stimuli including UV, heat shock and TNFa
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(Stambolic et al., 1998). This sensitivity is restored by introduction of wtPTEN. PTEN 
-/- cells also had increased PKB activity that was reduced by re-introduction of PTEN. 
Similarly, an active mutant of PKB suppressed apoptosis induced by PTEN over­
expression.
PTEN over-expression also results in a decrease in cell proliferation and the 
accumulation of cells in G1 with decreased progression into S phase (Li and Sun, 1997). 
This was accompanied by an increase in the protein level of the cyclin-CDK inhibitor 
p27/Kipl and followed the PTEN mediated inhibition of PKB activity. Co-expression 
of a constitutively active form of PKB in a renal carcinoma cell line was sufficient to 
over-ride a PTEN induced G1 block (Ramaswamy et al., 1999). These results suggest 
that one function of PTEN is to negatively regulate the PI3K pathways leading to both 
proliferation and survival.
1.9.2 SHIP
SHIP-1 (SH2-containing Inositol 5’-Phosphatase-1) was first identified as a tyrosine- 
phosphorylated protein observed following stimulation of haemopoietic cells by various 
cytokine and growth factors (Rohrschneider et al., 2000). A number of SHIP splice 
variants have been identified and they encode proteins of between 108 and 145kDa. 
SHIP catalyses the removal of the phosphate group from the 5’ position of both 
PI(3,4,5)P3 and PI(1,3,4,5)P4 (Damen et al., 1996; Lioubin et al., 1996). It is believed 
that the activity of SHIP is regulated through its location in the cell and that upon 
growth factor stimulation cytoplasmic SHIP is targeted to the plasma membrane near its 
lipid substrates.
The 3* position of the inositol phospholipid must be phosphorylated before SHIP can 
dephosphorylate the 5’ position, and this has lead to the idea that SHIP may act 
sequentially with PI3K (Damen et al., 1996). Studies of SHIP-1 knock out mice found 
an increase in myeloid cell proliferation that was associated with increased PI(3,4,5)P3 
production and wortmannin sensitive activation of PKB (Liu et al., 1999). Neutrophils 
and bone marrow-derived mast cells from SHIP-1 null mice were also more sensitive to 
apoptosis (Liu et al., 1999). Therefore, SHIP appears to play a negative role in myeloid 
proliferation perhaps through the down regulation of the PI3K/PKB pathway.
1.10 Protein Kinase B
Over recent years, PKB has been the focus of intense research. The reasons for this 
are manifold; PKB is a major target of the PI3K signalling pathway and has been
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implicated in the regulation of many PI3K-mediated events including proliferation, 
survival, and several metabolic actions of insulin. However, the area, where perhaps 
most interest has focussed, is in characterising the role of PKB in cellular survival.
Protein kinase B (PKB, also known as Akt and Rac), was isolated by three 
independent groups in 1991. Two of these (Coffer and Woodgett, 1991; Jones et al., 
1991) identified PKB from its homology to PKA and PKC hence the names were 
coined PKB and RAC (related to A and C). The third group (Bellacosa et al., 1991) 
isolated the cellular homologue of v-Akt, an oncogene from the AKT8 acutely 
transforming retrovirus isolated from a rodent T-cell lymphoma (Staal, 1987). PKB is a 
serine/threonine kinase, which has 68% and 73% homology to PKA and PKC 
respectively. Three isoforms have been identified PKBa (Jones et al., 1991; Coffer and 
Woodgett, 1991; Bellacosa et al., 1991), PKBp (Cheng et al., 1992) and PKBy (Konishi 
et al., 1995; Nakatani et al., 1999b; Brodbeck et al., 1999) which are 60 kDa proteins 
although a C-terminal truncated 55kDa PKBy isoform was isolated from rat cells 
(Konishi et al., 1995). All three isoforms are ubiquitously expressed in mammals, 
although the levels of expression vary among tissues. PKBa is the predominant 
isoform in most tissues, the highest levels of PKBp expression is in skeletal muscle, 
heart, liver and kidney (which suggests a role in insulin signalling), and PKBy 
expression levels are highest in testis and brain (Jones et al., 1991; Bellacosa et al., 
1993; Altomare et al., 1995; Konishi et al., 1995; Brodbeck et al., 1999; Nakatani et al., 
1999a).
There is approximately 80% homology between the three isoforms and they share the 
same structural features (Figure 1.11). They contain an N-terminal pleckstrin homolgy 
(PH) domain (residues 1-106). PH domains bind the charged headgroups of 
phosphatidylinositols and are involved in mediating interactions with phospholipids. 
The PH domain is within a region often referred to as the AH (Akt homology) region 
which spans residues 1-148. The catalytic Ser/Thr kinase domain (residues 148-412) 
lies between the AH domain and the C-terminal tail region. This domain belongs to the 
AGC subfamily of protein kinase domains (where AGC is short for the cyclic AMP- 
dependent protein kinase, cyclic GMP-dependent protein kinase and protein kinase C). 
The C-terminal of PKB consists of a hydrophobic tail region, which is thought to be 
involved in the regulation of PKB activity.
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Figure 1.11 
Schematic representation of PKB
AH domain I Thr308 
1 1
S^ r4731
PH domain Kinase Domain Tail
The overall structure of PKB is shown. The Pleckstrin homology (PH) domain, which 
is involved in phospholipid binding, the Akt homology region (AH domain), the kinase 
domain and the C-terminal tail regions are indicated. Phosphorylation at Thr308 (Thr309 
in PKBp, Thr305 in PKBy) and Ser473 (Ser474 in PKBp and Ser472 in PKBy) are needed for 
maximal activation.
1.11 Activation of PKB
PKB is activated in response to numerous stimuli including growth factors, 
phosphatase inhibitors, cAMP agonists and stress conditions (Reviewed in Coffer et al., 
1998; Datta et al., 1999; Vanhaesebroeck and Alessi 2000). Growth factors that 
activate PKB include PDGF (Franke et al., 1995), insulin (Cross et al., 1995), EGF, 
bFGF (Burgering and Coffer, 1995), IL-3, (Franke et al., 1995; Burgering and Coffer, 
1995; Songyang et al., 1997; del Peso et al., 1997; Datta et al., 1997; Scheid and 
Duronio, 1998; Hinton and Welham, 1999; Craddock et al., 1999), SCF (Scheid and 
Duronio, 1998; Blume-Jensen et al., 1998; Hinton and Welham, 1999), IL-4, and GM- 
CSF (Scheid and Duronio, 1998; Hinton and Welham, 1999). The activation of PKB is 
inhibited by the PI3K inhibitors wortmannin and LY294002 as well as Ap85 (a 
dominant negative PI3K mutant) which indicates that the growth factor-induced 
activation of PKB is mediated through PI3K (Kauffman-Zeh et al., 1997; Kennedy et 
al., 1997; Songyang et al., 1997; Khwaja et al., 1997; Craddock et al., 1999; Hinton and 
Welham, 1999).
Both phosphorylation and the PH domain appear to be important for the growth factor- 
induced activation of PKB. PKB is phosphorylated on 4 sites: Ser124, Thr308, Thr450 and 
Ser473 (Alessi et al., 1996a). Ser124 and Thr450 are phosphorylated under basal conditions 
while phosphorylation of Thr308 and Ser473 is induced by growth factor stimulation. 
Thr308 (Thr309 in PKBp and Thr305 in PKBy) is located in the activation loop of the kinase
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domain and Ser473 (Ser474 in PKBp and PKBy) is in the C-terminal tail region. 
Phosphorylation of both these residues is required for optimal activation of PKB (Alessi 
et al., 1996a). Mutation of either Ser473 or Thr308 to alanine reduces the growth factor 
induced PKB activation, while mimicking the negative charge of the phosphate group, 
by mutation to aspartate, results in PKB activation in unstimulated cells (Alessi et al., 
1996a). In recent years much work has been done to identify the kinase(s) responsible 
for the phosphorylation of Ser473 and Thr308, and some candidates have been identified.
1.11.1 PDK-1
A kinase which phosphorylates PKB on Thr308 was identified and purified and named 
PI(3,4,5)P3 dependent kinase-1 (PDK-1) because of its apparent dependence on 
phosphoinositides (Alessi et al., 1997; Stokoe et al., 1997). PDK-1 is a ubiquitously 
expressed 63kDa protein consisting of a PH domain and a kinase domain belonging to 
the AGC protein kinase subfamily. While PDK-1 is dependent on the lipid products of 
PI3K to phosphorylate PKB (Alessi et al., 1997), PDK-1 itself appears to be 
constitutively active (Alessi et al., 1997; Pullen et al., 1998; Casamayor et al., 1999). 
PDK1 activity is dependent on its phosphorylation at Ser241. However, IGF-1 does not 
increase the phosphorylation of PDK-1 at Ser241 or indeed any site (Casamayor et al.,
1999). This suggests that PDK1 is constitutively active, which is surprising given that 
PKB and other substrates of PDK-1 are not phosphorylated in the absence of growth 
factor.
On its own PDK-1 is incapable of phosphorylating PKB at Ser473 but there is evidence 
to suggest that under some conditions it becomes a Ser473 kinase. Balandran et al. 
(2000) reported that PDK-1 can interact with a C-terminal fragment of PRK-2 (protein 
kinase C related kinase-2), and this interaction converts PDK-1 to a kinase that is 
capable of phosphorylating PKB at Ser473. This interaction also converts PDK-1 into a 
form that is activated by the presence of the PI3K products PtdIns(3,4,5)P3 and 
PtdIns(3,4)P2. However, in PDK-1 -/- ES cells PKB was constitutively phosphorylated 
at Ser473, which suggests that other kinases must exist that phosphorylates this site in 
vivo (Williams et al., 2000).
1.11.2 ILK (Integrin-Linked Kinase)
ILK is a serine/threonine kinase that was first identified by its binding to the 
cytoplasmic domain of the pi, p2, and P3 integrin subunits and is involved in the 
integrin signalling pathway (Altomare et al., 1995). Over-expression of ILK in
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epithelial cells results in anchorage-independent cell survival and cell cycle progression 
(Radeva et al., 1997) and tumorigenesis in nude mice (Wu et al., 1998). ILK has also 
been implicated as a regulator of the Wnt-signalling pathway, which is involved in cell 
fate determination (Novak et al., 1997).
The intergrin linked kinase (ILK) has also been reported to phosphorylate PKB on 
Ser473 (Delcommenne et al., 1998). In vitro kinase assays showed that ILK can directly 
phophorylate PKB on Ser473 and cotransfection of PKB and a kinase deficient ILK into 
293 cells inhibited Ser473 phosphorylation. Wortmannin and LY294002 inhibited the 
insulin and cell-fibronectin-induced activation of ILK in epithelial cells indicating that 
the activation of ILK by these stimuli is mediated by PI3K. However, Lynch et al. 
(1999) have reported that ILK regulates the phosphorylation of Ser473 through an 
indirect mechanism, perhaps by acting as an adaptor. Taken together these data suggest 
that ILK may be involved in the insulin- and integrin-induced phosphorylation of PKB 
and it will be interesting to see if it plays a similar role in the activation of PKB by 
cytokines.
1.11.3 PH Domain
The PH domain of PKB has been shown to be critical to the activation of PKB 
(Franke et al., 1995; Franke et al., 1997; Sable et al., 1998). PKB binds to the 
phospholipid products of PI3K through an interaction with the PH domain of PKB 
(James et al., 1996; Freeh et al., 1997; Franke et al., 1997), which results in the 
translocation of PKB from the cytosol to the inner surface of the plasma membrane 
(Andjelkovic et al., 1997; Meier et al., 1997; Wijkander et al., 1997; Sable et al., 1998; 
Currie et al., 1999). Oncogenic v-Akt, which is constitutively active, contains an N- 
terminal membrane targeting gag fusion derived from a retroviral gag protein 
(Bellacosa et al., 1991). Similarly, targeting PKB to the cellular membrane either by 
the fusion of a gag or sre myristylation sequence results in the constitutive activation of 
PKB through increased phosphorylation (Franke et al., 1995; Andjelkovic et al., 1997; 
Kohn et al., 1996a). These data suggest that translocation to the plasma membrane is 
important for the activation of PKB, perhaps because it targets PKB to its activating 
kinases. In resting cells PDK-1 is mostly cytosolic (Anderson et al., 1998; Currie et al.,
1999) and is constitutively active (Alessi et al., 1997; Pullen et al., 1998; Casamayor et 
al., 1999). However, it is dependent on the presence of PI(3,4,5)P3 or PI(3,4)P2 to 
catalyse the phosphorylation of Thr308 on PKB (Alessi et al., 1997). Upon cellular 
stimulation, PDK-1 has been reported to translocate to the plasma membrane and the
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co-localisation of PKB and PDK-1 may allow for the activation of PKB (Anderson et 
al., 1998).
The PH domain of PKB is also believed to regulate the activity of PKB by controlling 
the access of kinase(s) to the phosphorylation sites Ser4 7 3  and/or Thr308. In the absence 
of PI(3,4,5)P3 PKB is not phosphorylated by PDK-1 (Alessi et al., 1997). Mutants with 
an R25C mutation, that prevents the PH domain from binding phospholipids, are not 
activated insulin (Sable et al., 1998). However, when the PH domain is deleted (APH- 
PKB) this PKB variant is constitutively active due to increased phosphorylation (Kohn 
et al., 1996a; Stokoe et al., 1997; Sable et al., 1998). These findings are consistent with 
the hypothesis that phospholipid binding of the PH domain results in a conformational 
change in PKB that allows the activating kinase(s) access to Ser4 7 3  and/or Thr308. The 
deletion of the PH domain is thought to release the conformational restraints on PKB 
allowing the activating kinase(s) access to Ser4 7 3 and Thr308.
The PH domain has also been reported to facilitate the formation of PKB homo- 
multimers (Datta et al., 1995; Franke et al., 1997). PKB has been reported to interact 
with TCL1 (T-cell leukaemia/lymphoma 1), the product of the oncogene Tell, which is 
involved in the development of T-cell leukaemia (Pekarsky et al., 2000; Laine et al.,
2000). The interaction of PKB with TCL1 increases PKB activity and translocation to 
the nucleus, which leads to the suggestion that it acts as a coactivator, enhancing PKB 
activity (Pekarsky et al., 2000; Laine et al., 2000). In vivo, TCL1 forms trimers, which 
associate with PKB and thus facilitate the oligermerisation of PKB (Laine et al., 2000).
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1.12 Funtions of PKB
Many potential substrates of PKB have now been identified, and these have implicated 
PKB in the regulation of a number of physiological processes including cell-cycle 
regulation (Medema et al., 2000), survival (Dudek et al., 1997; Kennedy et al., 1997; 
Songyang et al., 1997; Datta et al., 1997; Sabbatini and McCormick, 1999; Tang et al.,
2000), annoikis (Khwaja et al., 1997), proliferation (Brennan et al., 1997), glycogen 
synthesis (Cross et al., 1994), glucose transport (Kohn et al., 1996b; Tanti et al., 1997; 
Hajduch et al., 1998) glycolysis (Deprez et al., 1997) and protein synthesis (Ueki et al., 
1998; Gingras et al., 1998).
Much interest and research has focussed on the effects of PKB on cell survival. PKB 
was first shown to be involved in the regulation of apoptosis when it was found that the 
expression of a dominant negative PKB inhibited the IGF-1-mediated survival of 
cultured cerebellar granule cells (Dudek et al., 1997). Conversely, the expression of 
wild type PKB or a constitutively active PKB variant negated the dependence of these 
cells on IGF-1 for survival. Since then, PKB has been implicated in the prevention of 
apoptosis induced by growth factor withdrawal (Dudek et al., 1997; Kennedy et al., 
1997; KauffmanZeh et al., 1997; Songyang et al., 1997; Datta et al., 1997), uv 
irradiation and DNA damage (Kulik and Weber, 1998), matrix detachment (Khwaja et 
al., 1997), fas ligand (Rohn et a l, 1998) and TGFp (Chen et al., 1998).
In the absence of a growth signal (ie cytokine) haemopoietic cells cease to proliferate 
and undergo apoptosis. In the mid nineties Scheid and coworkers had demonstrated that 
the stimulation of the mast cell line MC9, with various cytokines resulted in the 
activation of PI3K (Gold et al., 1994). Using the PI3K inhibitors, wortmannin and 
LY294002, this group then demonstrated that PI3K was required for the survival of 
MC9 cells mediated by IL-3, IL-4 and SCF (Scheid et al., 1995). With the discovery 
that PKB is activated by PDGF through a PI3K-mediated pathway (Franke et al., 1995), 
groups began to investigate PKB as a potential downstream regulator of the cytokine- 
induced and PI3K mediated survival of haemopoietic cells.
Two groups demonstrated that the expression of a constitutively active PKB variant 
was sufficient to delay the onset of apoptosis induced by cytokine withdrawal in the 
pre-B cell line BaF/3 (Ahmed et al., 1997) and the myeloid progenitor cell line 32D 
(Songyang et al., 1997). These results suggested that PKB might be involved in the 
PI3K-mediated survival signal, which is generated by cytokines, but the mechanisms of 
this were not known. Del Peso et al., (1997), showed that in the lymphoid progenitor 
cells line FL5.12, the IL-3-induced phosphorylation of the pro-apoptotic Bcl-2 family
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member, Bad, was blocked by the PI3K inhibitors, LY294002 and wortmannin. They, 
and others (Datta et al., 1997), then identified Bad as a direct substrate of PKB. 
Collectively, these results suggested that the PI3K/PKB pathway is important to the 
cytokine-mediated survival of haemopoietic lineages.
The role that PKB plays in regulating the proliferation of cells is less well defined 
than the one it plays in apoptosis. However, there is some evidence to suggest that it 
may be involved in the proliferation of haemopoietic lineages. Ahmed et al., (1997) 
showed that the expression of a constitutively active PKB variant in BaF/3 cells 
transfected with an IL-2 R mutant that is defective in PI3K signalling, increased the 
number of cells that became factor independent. While in T lymphocytes, the 
expression of an active PKB variant was shown to be sufficient to induce E2F activity 
(Brennan et al., 1997). PI3K inhibition in these cells was shown to inhibit the 
phosphorylation of pRb, induction of cyclin D3, and degradation of p27ldpl. These 
results suggested that the PKB might also be involved in the proliferation of 
haemopoietic cells.
1.13 Downstream of PKB
Many potential substrates of PKB have now been identified. The evidence 
implicating these proteins as effectors of PKB is varied and may include the effects of 
dominant negative and positive PKB variants, the effects of PI3K inhibition and 
activation and the identification of the phosphorylation sites. Ideally, several lines of 
evidence should be considered when identifying substrates. The minimum sequence 
motif that is recognised and phosphorylated by PKB has been determined as 
RXRXXS/TH where X is any amino acid and H is a bulky hydrophobic residue 
(phenylalanine or leucine) (Alessi et al., 1996b) and many of the substrates that have 
been identified contain motifs that conform to this consensus sequence. Table 1.3 lists 
the potential substrates of PKB identified to date and some of the key downstream 
targets of PKB and the implications of their activation or inactivation in relation to cell 
physiology are discussed below.
1.13.1 Glycogen Synthase Kinase-3
Glycogen synthase kinase-3 (GSK-3) was first identified as an enzyme that regulates 
glycogen synthesis in response to insulin stimulation. Subsequently, it has also been 
implicated in a number of biological processes including metabolism, gene expression, 
cell fate determination, proliferation and survival. GSK-3 is a ubiquitously expressed
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protein of 51kDa (GSK-3a) and 47kDa (GSK-3p). On stimulation with growth factor, 
GSK-3 is rapidly phosphorylated resulting in the inhibition of GSK-3 kinase activity 
and the subsequent increase in glycogen synthesis (Cross et al., 1994). PKB was shown 
to phosphorylate GSK3 on Ser21 (GSK-3a) or Ser9  (GSK-3P), and phosphorylation of 
this site results in the inhibition of GSK3 (Cross et al., 1995; Shaw et al., 1997).
Table 1.3 
PKB Substrates
Protein Target Function Reference
GSK3a/p Glycogen synthesis Cross et al., 1995
6 -phosphofiuctose-2 -kinase Glycogen synthesis Deprez et al., 1997
Phosphodiesterase 3B Inhibition of glycogen 
degradation
Kitamura et al., 1999
Forkhead Survival/proliferation Brunet et al., 1999 
Kops et al., 1999
BAD Survival Del peso etal., 1997
Caspase-9 Survival Cardone et al., 1999
IKKa Survival/proliferation Ozes et al., 1999 
Romashkova et al., 1999
Endothelial nitric oxide 
synthase
NO production Fulton et al., 1999 
Dimmeler etal., 1999
Mammalian Target of 
Rapamycin
Proliferation Scott et al., 1998
IRS Insulin signalling Li et al., 1999
BRAC1 DNA repair Altiok etal., 1999
Raf Survival/proliferation Zimmermann et al., 1999
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1.13.2 Bad
Another direct substrate of PKB identified, Bcl-2/Bcl-XL-antagonist, causing cell 
death (Bad), is a member of the Bcl-2 family of proteins that are intracellular regulators 
of programmed cell death/apoptosis (refer to Section 1.3). Overexpression of the anti- 
apoptotic members (e.g. Bcl-2, Bcl-XL) prevents cell death, while overexpression of the 
pro-apoptotic members (e.g. Bax, Bak, Bad) promotes cell death. Family members are 
able to form homo- and hetero-dimers through the interactions of their Bcl-homology 3 
(BH3) domains. These interactions and the relative level of each protein in the cell, is 
thought to determine the fate of the cell. Bcl-2 family members are also regulated by 
survival factor-induced phosphorylation. Phosphorylation of Bcl-2 family members 
alters their binding properties thus providing the appropriate signal for survival or 
apoptosis.
Bad forms heterodimers with both Bcl-2 and Bcl-XL, neutralising their anti-apoptotic 
affects and thus promoting cell death (Zha et al., 1997, Ottalie et al., 1997, Kelekar et 
al., 1997). However, after stimulation with growth factor, BAD becomes 
phosphorylated on a number of residues including Ser112, Ser1 3 6 (Zha et al., 1996), Ser155 
(Lizcano et al., 2000; Zhou et al., 2000) and Ser1 7 0 (V. Duronio, Canada, personal 
communication). The phosphorylation of Bad results in Bad associating with the 
protein adaptor 14-3-3 (Zha et al., 1996). This prevents its interaction with Bcl-XL 
allowing Bcl-XL to promote survival of the cell. There has been great interest in 
identifying the kinases that phosphorylate each of these residues. Early reports 
indicated that Bad is phosphorylated on Ser13 6 by PKB in response to stimulation by IL- 
3 and PDGF (del Peso et al., 1997; Datta et al., 1997) but the kinase(s) responsible for 
phosphorylation at the other sites were unknown.
Recently, a number of papers have been published identifying at least some of the 
other kinases involved. Ser1 1 2 phosphorylation is dependent on the integrity of the 
MAPK pathway (Scheid et a l, 1999; Bonni et al., 1999; Tan et al., 1999; Fang et a l, 
1999; Lizcano et a l, 2000). MAPKAP-Kl (mitogen-activated protein kinase activated 
protein kinase-1, also known as RSK), which is an immediate downstream target of 
Erkl and 2, was found to phosphorylate Ser1 1 2 in co-transfection experiments in 293 
cells (Bonni et al., 1999; Tan et al., 1999; Fang et al., 1999). Bad is phosphorylated 
preferentially at Ser1 5 5 by PKA in vitro and is the only residue that becomes 
phosphorylated when cells are exposed to cAMP-elevating agents such as forskolin and
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IBMX (Lizcano et al., 2000; Tang et al., 2000). In addition to this, phosphorylation of 
Bad at Ser155 was prevented by H89, an inhibitor of PKA (Zhou et al., 2000).
1.12.3 Caspase-9
Caspases are the mammalian homologues of the C. elegans Ced-3 (refer to Section 
1.3). They are activated from their inactive pro-forms to their active forms by a 
sequential cascade of cleavage by caspase family members. Caspase-3, which is an 
effector caspase, is activated by cleavage of procaspase-3 into its active form, caspase- 
3, by the initiator caspase-9 (Slee et al., 1999). Association of caspase-9 with Apaf-1 (a 
ced-4 homologue) and cytochrome c binding protein results in its activation by an auto­
cleavage mechanism (Li et al., 1997; Zou et al., 1997). One way that PKB may 
regulate the activity of caspase-9 is through Bcl-XL. PKB phosphorylation of Bad 
prevents its association with Bcl-XL (Zha et al., 1996). This prevents the release of 
cytochrome c from the mitochondria (Kennedy et al., 1999), which prevents the 
formation of the cytochrome c/Apaf-1/caspase-9 complex that results in the activation 
of caspase-9 (Li et al., 1997). However, caspase-9 may also be a direct target of PKB 
(Cardone et al., 1998). Caspase-9 is phosphorylated by PKB at Ser1 9 6 and extracts from 
cell lines over-expressing PKB block cytochrome c-mediated caspase-9 activation in 
vitro. It is not clear how phosphorylation of caspase-9 results in its inactivation, 
although it appears to inactivate the intrinsic catalytic activity of caspase-9. However, 
PKB phosphorylation sites are not found in murine, monkey and rat caspase-9 and 
activated PKB will not phosphorylate murine caspase-9 in vitro (Fujita et al., 1999). 
This suggests that inhibition of caspase-9 activation by PKB-dependent phosphorylation 
may not be relevant to all species.
1.12.4 Forkhead
Studies in Caenorhabditis elegans showed that mutation in either the insulin/IGF 
receptor homologue daf-2 or the PI3K homologue age-1 cause animals to 
developmentally arrest in the dauer lavae stage, and to live longer. Mutations in the 
forkhead transcription factor homologue DAF-16, suppressed the developmentally 
arrested larval, or dauer, and the longevity phenotypes of both the daf-2 and age-1 
mutants, indicating that DAF-16 is a negatively regulated downstream target of insulin­
like signalling in C. elegans. Genetic screens of these mutants revealed that the PKB 
homologues AKT-1 and AKT-2 are required for signalling from both DAF-2 and AGE- 
1 (Paradis and Ruvkun, 1998). Inhibition of AKT-1 and AKT-2 resulted in constitutive
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dauer formation but this effect was not seen in animals containing daf-16 null 
mutations. This was significant because it identified the DAF-16 (forkhead) 
transcription factor as a major target of the PI3K/PKB pathway in C. elegans.
In mammalian systems three members of the forkhead family have been identified; 
FKHR, FKHRLl/AF6q21 and AFX. They share a forkhead domain of lOOaa, which 
mediates their interaction with DNA and a C-terminal transcriptional activation domain 
(Kops and Burgering, 1999). There are three PKB phosphorylation consensus sites 
within the Forkhead proteins, Thr24, Ser2 5 6  and Ser3 1 9  in FKHR (Tang et al., 1999). PKB 
is able to phosphorylate all of them in vitro although Ser2 5 6  appears to be the major site 
(Rena et al., 1999; Nakae et al., 1999). The expression of a constitutively active PKB is 
sufficient to induce the phosphorylation of the Forkhead proteins at all three sites (Rena 
et al., 1999). Phosphorylation of forkhead isoforms FKHR/ FKHRL1 at Ser^/Ser2 5 3  
and Thr3 2  is induced by insulin, IGF-1, EPO and inhibited by the PI3K inhibitor 
LY294002 (Guo et al., 1999; Kashii et al., 2000).
PKB is thought to mediate forkhead family member function by regulating its 
subcellular localization. Non-phosphorylated forkhead proteins are located in the 
nucleus but when phosphorylated they are found in the cytoplasm (Biggs et al., 1999; 
Brunet et al., 1999; Kops and Burgering, 1999). A mutant of FKHRL1, in which all 
three PKB phosphorylation sites are mutated to alanine, is located in the nucleus even in 
the presence of survival factors (Biggs et al., 1999). This indicates that the subcellular 
localization of forkhead proteins is regulated by their phosphorylation by PKB. 
Phosphorylated FKHRL1 has been shown to interact with 14-3-3 proteins (Brunet et al., 
1999). In the absence of phosphorylation, forkhead family members in the nucleus bind 
to specific DNA elements. FKHRL1 binds to sites in the Fas ligand (FasL) promoter 
and induces expression of a reported gene driven by the FasL promoter (Brunet et al., 
1999). This points to a hypothesis whereby in the absence of survival factors, PKB is 
inactive allowing forkhead family members to induce the transcription of FasL that 
induces apoptosis.
There is also evidence to suggest that forkhead proteins mediate gene expression 
through Insulin Response Sequences (IRS). These sequences are contained within the 
promoter regions of a number of insulin-regulated genes including those that encode 
insulin-like growth factor binding protein-1 (IGFBP-1), apolipoprotein CIII, 
phosphoenolpyruvate carboxykinase (PEPCK) and glucose-6 -phosphatase. Reporter 
gene studies using the IGFBP-1 promoter demonstrate that FKHR stimulates promoter 
activity through an IRS motif and that phosphorylation of Ser2 5 6  by PKB is necessary
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and sufficient for insulin to disrupt IRS-dependent transactivation by FKHR (Guo et al. 
1999). This suggests that the PKB/forkhead pathway may be important in regulating 
the transcriptional activity of genes containing IRS sequences.
A recent report has linked PKB regulation of forkhead proteins with proliferation. 
Expression of AFX blocks cell-cycle progression at Gj by transcriptionally upregulating 
the cell-cycle inhibitor p27kipl. Insulin stimulation resulted in activation of PKB, 
phosphorylation of FKHR-L1 and a reduction of p27kipl expression. Inhibition of PI3K 
and PKB with LY294002 caused a reduction in FHKR-L1 phosphorylation and an 
increase in p27ldpl levels (Medema et al., 2000).
1.12.5 IkB Kinase
PKB has been reported to phosphorylate IkB kinasea (IKKa) on Thr2 3 resulting in its 
activation by both TNF and PDGF (Ozes et al., 1999; Romashkova and Makarov, 
1999). This pathway is inhibited by LY294002, wortmannin and the dominant negative 
PI3K Ap85 indicating that it is mediated through PI3K. The activation of IKK leads to 
the phosphorylation of IkB and targets it for degradation. The degradation of IkB 
results in the activation and translocation to the nucleus of the transcription factor 
NFkB. NFkB regulates the transcription of a number of factors including pro- 
inflammatory cytokines and the induction of c-myc (Baldwin, 1996).
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1.13 Aims and Objectives
Over recent years PKB has been widely implicated as a positive regulator of cellular 
proliferation and survival in a number of systems (Reviewed in Vanhaesebroeck and 
Alessi 2000, Coffer et al., 1998, Datta et al., 1999). This has lead to the generally 
accepted view that PKB is both necessary and sufficient to drive the long-term growth 
and survival of cells. However, whether this is indeed the case in all systems had not 
been investigated. This project aimed to address this issue by investigating the role of 
PKB in the survival and proliferation of haemopoietic cells in response to specific 
cytokines. To achieve this broad objective, two lines of investigation were undertaken. 
The first compared the cytokine-induced activation of endogenous PKB to the growth 
and survival of haemopoietc cells, and the second focussed on the role of PKB in the 
IL-3-mediated growth and survival of BaF/3 cells by expressing PKB variants in these 
cells and to characterise their effects.
Using the first approach, I hoped to determine
• If PKB is activated in these haemopoietic cells in response to cytokine-stimulation
• If this PKB activation is mediated through PI3K
• Whether PKB activity correlated with the cytokine-induced growth and proliferation 
of these cells
• What downstream effectors of PKB are involved in PKB signalling in these cells
I also hoped to focus specifically on the role of PKB in the IL-3 dependent BaF/3 cell 
line. My objectives here were to
• Create BaF/3 cell lines which inducibly express PKB variants
• To use these variants to investigate the dependence of these cells on IL-3 for their
continued proliferation and survival





2.1 Molecular Biology Techniques
2.1.1 Phenol/Chloroform extractions
The DNA solution was extracted in an equal volume of buffer-saturated 
phenol:chloroform (1:1) and centrifuged for 1 minute at full speed in a Heraeus 
microcentrifuge. The aqueous phase was then transferred to a clean tube and re-extracted 
with an equal volume of chloroform. After centrifugation for 1 minute, the aqueous phase 
was transferred to a clean tube, ready for ethanol precipitation.
2.1.2 Ethanol precipitation of DNA
2 volumes of 100% ethanol and 0.1 volume of sodium acetate (3M, pH 5.5) were added to 
the solution containing the DNA to be precipitated. The solution was mixed by inversion, 
cooled on ice for 1-5 minutes and the precipitated DNA pelleted in a Heraeus 
microcentrifuge at 4°C for 10 minutes at full speed. The ethanol was aspirated off and the 
pellet washed once in 70% ethanol. The pellet was left to air dry at room temperature 
before being resuspended in water and stored at -20°C or resuspended in electroporation 
buffer for transfection.
2.1.3 Preparation of competent E. coli
A frozen stock of XL-1BL (Stratagene) was streaked onto a luria broth agar plate (lOg 
bacto-tryptone, 5g yeast extract, 5g NaCl, 15g bacto-agar), inverted and incubated 
overnight at 37°C. A single colony was then used to inoculate 5ml LB (lOg bacto-tryptone, 
5g yeast extract, 5g NaCl), and was incubated overnight at 37°C in a shaking incubator. 
The following day, the bacteria were subcultured 1:100 in 100ml LB broth and grown until 
an OD5 5 0  of 0.48 was reached. The culture was then chilled on ice for 5 minutes and 
centrifuged in Beckman M5 centrifuge with a JA-14 rotor at 5000rpm at 4°C for 10 
minutes. The supernatant was removed and the bacteria resuspended in 0.4 volume (40 ml) 
of Tfbl (30mM KC1, lOOmM RbCl, lOmM CaCh, 50mM MnCk, 15% (v/v) glycerol, 
adjusted to pH5.8 with 0.2M acetic acid and filter sterilised), incubated on ice for 5 minutes 
and centrifuged at 5000rpm for 5 minutes at 4°C. The bacterial pellet was then resuspended 
in 0.4 volume (5ml) cold Tfbll (lOmM MOPS, 75mM CaCl2, lOmM RbCl, 15% (v/v) 
glycerol, adjusted to pH6.5 with KOH and filter sterilised) and incubated on ice for 15 
minutes. Aliquots of 200 pi were stored at -80°C.
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2.1.4 Transformation of E, coli
Competent cells were thawed at room temperature and placed on ice for 10 minutes. 
<50ng of DNA was added to lOOpl of cells, mixed gently and left on ice for 30-45 minutes. 
The cells were heat shocked at 37°C for 2 minutes, returned to ice for 2 minutes and 400pi 
of LB broth added. The cells were incubated for 1 hour at 37°C and plated out onto LB 
agar plates containing appropriate antibiotic (100 pg/ml ampicillin). For ligations the entire 
transformation was plated out, by first pelleting the cells and then resuspending them in 1 0 0  
pi LB broth, otherwise, 100 pi of the total transformation was plated. The plates were 
inverted and incubated at 37°C overnight.
2.1.5 Small-scale plasmid preparation
A single bacterial colony was used to inoculate 5 ml LB containing lOOpg/ml ampicillin. 
The culture was incubated overnight at 37°C with vigorous shaking. The following day,
1.5 ml of culture was removed into an eppendorf tube and cells pelleted for 1 minute at full 
speed in a Heraeus microfuge. The pellet was resuspended in 100 pi solution I (50 mM 
glucose, 10 mM EDTA, 25 mM Tris-HCl pH 8.0) prior to the addition of 200 pi fresh 
solution II ( 0.2 M NaOH, 1% (w/v) SDS) and incubated on ice for 5 minutes. 150 pi cold 
solution III ( 3 M potassium acetate, 2 M acetic acid) was added, the samples vortexed and 
incubated on ice for a further 5 minutes. The precipitate was removed by centrifugation at 
full speed for 10 minutes at 4°C in a Heraeus microcentrifuge, and the supernatant 
transferred to a clean tube. The supernatant was extracted with phenol and chloroform as 
described in section 2.1 and the DNA ethanol precipitated as described in section 2.2. The 
DNA pellet was solublised in 30 pi water with 20pg/ml RNAse A and stored at -20°C.
2.1.6 Large-scale plasmid preparation
Large-scale plasmid preparations were performed using the QIAGEN Plasmid Midi 
Preparation protocol (QIAGEN) that is based on a modified alkaline lysis procedure. 
Briefly, 100 ml LB with lOOpg/ml ampicillin was inoculated with a culture carrying the 
appropriate plasmid and incubated overnight at 37°C with vigorous shaking. The bacteria 
were pelleted by centrifugation in a Beckman M5 centrifuge with a JA-14 rotor at 5000 
rpm for 10 minutes. The supernatant was discarded and the pellet resuspended in 4 ml
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buffer PI. 4 ml of buffer P2 was then added, the solution mixed and incubated at room 
temperature for 5 minutes, after which 4 ml of chilled buffer P3 was added, mixed and 
incubated on ice for 15 minutes. The majority of the precipitated material was removed by 
centrifugation in the JA-14 rotor at 4°C for 5 minutes at 5000 rpm. The supernatant was
transferred to 12 ml Beckman tubes for a further centrifugation in the JA-20.1 rotor at 4°C
for 30 minutes at 15 500 rpm. The supernatant was applied to a QIAGEN-tip 100 that had 
been equilibrated with 4 ml of the low salt buffer, QBT. The tip was washed 2 times with 
10 ml buffer QC, which is a medium salt buffer used to remove RNA, proteins, dyes and 
low molecular weight impurities. The DNA was then eluted with 5 ml of the high salt 
buffer, QF. Finally, the DNA was concentrated and desalted by precipitation with 0.7 
volumes of isopropanol and pelleted at lOOOOrpm for 10 minutes. The DNA pellet was 
washed in 70% ethanol. Air dried and resuspended in 500pl of milliQ water.
For transfections, the Qiagen Endofree Plasmid Maxi-prep was used for plasmid 
preparations. This procedure is the same as above except the DNA is eluted from the 
Qiagen tip with the endofree buffer QN.
2.1.7 Restriction enzyme digestion
New England Biolabs recommendations were followed with respect to appropriate buffers 
for each of the enzymes. A typical reaction was carried out in a volume of 20 pi, 
containing 2 pi 10 x restriction buffer, 1-5 pi (approx. 1-5 pg) DNA, and 1 pi restriction 
endonuclease, made up to 20 pi with water. The reaction was mixed gently by flicking the 
side of the tube and then centrifuged briefly before being incubated at 37°C (room 
temperature for Smal digestions) for 1-16 hours.
2.1.8 Conversion of 5’ protruding ends to blunt ends
To the 20pl restriction enzyme digestion (containing l-5pl DNA), 3pi lOx Klenow buffer 
was added and the reaction made up to 30pl with water. 1.5pi each dNTPs (2 mM) were 
added along with 2pl Klenow and incubated at room temperature for 15 minutes. The 
reaction was then terminated by the addition of lpl 0.5 M EDTA and heat inactivated at 
75°C for 10 minutes prior to gel purification.
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2.1.9 Treatment of plasmid DNA with Calf Intestinal Phosphatase (CIP)
After restriction digestion DNA was phosphatase treated as follows: lOpl lOx low salt 
restriction enzyme buffer, the 20pl restriction digest, distilled water to lOOpl and lpl (10U) 
Calf Intestinal Phosphatase (CIP). The reaction was incubated at 37°C for 30 minutes. To 
stop the reaction, 1 pi of 0.5M EDTA, pH 8.0 was added. The CIP was heat inactivated at 
70°C for 10 minutes. The DNA was then gel purified. The phosphatase treated plasmids 
were stored in distilled water at -20°C.
2.1.10 Ligations
Ligations were carried out in 15 pi volumes, typically containing 1.5pl lOx T4 DNA 
ligase buffer, 1-10 pi DNA insert, lp l DNA vector, and lpl T4 DNA ligase. The mix was 
briefly centrifuged in the Heraeus microcentrifuge and ligations incubated overnight at 
room temperature (approximately 18°C).
2.1.11 Agarose gel electrophoresis
Agarose gel solutions were prepared by boiling the appropriate quantity of agarose (for 1- 
2 % (w/v) gels) in lx TAE buffer (50x stock: 242 g Tris, 57.1 ml glacial acetic acid, 100 
ml 0.5 M EDTA pH 8.0). The solution was allowed to cool to approximately 60°C before 
casting. The ends of the gel tray were sealed with masking tape and a comb inserted 
approximately 0.5cm from one end. Once set, the comb and tape were removed and the gel 
and tray submerged in a tank containing lx TAE buffer. 1 /6 th volume of a 6 x gel-loading 
buffer (30% (v/v) glycerol, 0.05% (w/v) Xylene/Cyanol, 0.05% (w/v) bromophenol blue) 
was added to the samples, centrifuged briefly and loaded on the gel. Electrophoresis was 
performed at 80V with the DNA running towards the positive electrode. The gel was then 
stained in a solution of approx. 0.5pg/ml ethidium bromide in lx TAE buffer for 
approximately 1 0  minutes, visualised under ultra violet light and photographed.
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2.1.12 Gel purification of DNA fragments
DNA fragments were isolated from agarose gels using the QIAquick gel extraction kit 
(QIAGEN). Briefly, restricted DNA was separated by agarose gel electrophoresis and the 
ethidium bromide stained gel visualised with ultraviolet light (see previous section). The 
required DNA fragment was excised from the agarose gel with a clean, sharp scalpel and 
transferred to an eppendorf tube. Approximately 800 pi buffer QX1 was added to the gel 
slice and incubated at 50°C for approximately 10 minutes, until the agarose was completely 
dissolved. The sample was then loaded onto the QIAquick spin column and centrifuged for 
1 minute at full speed in a Heraeus microcentrifuge. The column was washed once in 0.75 
ml buffer PE and centrifuged in the microcentrifuge for 1 minute. Residual wash buffer 
was removed with a further 1 minute spin. The DNA was eluted with 30-50 pi distilled 
water.
2.1.13 Polymerase chain reaction
PCR reactions were carried out in 50pl volumes, containing lx Vent buffer, 1 pi 10 mM 
dNTPs, ImM sense oligonucleotide, ImM antisense oligonucleotide, 2mM MgSC>4 , 1 pi 
template, 2 pi Vent DNA polymerase. The reaction was carried out in a Perkin Elmer 
GeneAmp PCR System 2400 for 25 cycles with a denaturation temperature of 94°C for 45 
seconds, and annealing temperature of 60°C for 30 seconds and a polymerisation 
temperature of 72°C for 60 seconds. The primers used are listed in Table 2.2 and the 
plasmid templates used are listed in Table 2.3.
2.2 Tissue Culture Techniques
2.2.1 Cell Culture
Cells were maintained at 37°C, 5% (v/v) CO2  in a humidified incubator in RPMI 1640 
medium supplemented with 10% (v/v) foetal bovine serum (Life Technologies), 20 pM 2- 
mercaptoethanol, lOOu penicillin/streptomycin and 2 mM glutamine. BaF/3 and MC/9 
cells were cultured with the addition of 5% (v/v) conditioned media from JWW3 cells as a 
source of murine IL-3 (see Section 2.2.15). FD- 6  cells were cultured with the addition of 
5% (v/v) conditioned media from X63omIL-4 as a source of murine IL-4. Cells were 
passaged weekly by 1:5 dilution in 5x5ml falcon dishes.
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2.2.2 Preparation of Conditioned Media
JWW3 cells expressing murine IL-3 (mIL-3) or X63omIL-4 cells expressing murine IL-4 
wereseeded at lx l0 5/ml in 175 cm2  tissue culture flasks and cultured for approximately 5 
days. The media was then centrifuged for 5 minutes at 5000rpm in a Beckman M5 
centrifuge with a JA-14 rotor to remove cells and cell debris and then sterilised through a 
0.2 pm bottle top filter (Nalgene). Sterilised conditioned media was stored in bottles and 
frozen at -20 °C until required.
XTT dye reduction assays (see Section 2.2.19) were performed with Ba/F3 or FD- 6  cells 
to test the JWW3 and X63omIL-4 conditioned media respectively. Briefly, a serial dilution 
series of conditioned media in RPMI 1640 was prepared across a 96 well tray and washed 
cells were added at 1000 per well. Cells were grown for 72 hours at 37°C before 
developing with XTT. The concentration of conditioned media required for maximum 
growth was determined and for future work, the media was supplemented with that 
concentration of conditioned media: typically 5% -10% v/v.
2.2.3 Transfections
10-15pg of the DNA to be transfected (pUHD10-3hygro vector containing cDNA of 
interest) was linearized by digestion with 3 pi of FspI or Pvul overnight at 37°C in a volume 
of lOOpl. After digestion, the DNA was purified by phenol/chloroform extraction (see 
section 2.1) and ethanol precipitation (see section 2.2). The DNA pellet was resuspended 
in 10 pi sterile electroporation buffer ( 25 mM HEPES, pH 7.2, 140 mM KC1, 10 mM 
NaCl, 2 mM MgCl2 , 0.5% Ficoll 400, filtered through 0.2 pM). Ba/F315-1 cells were 
washed twice in 10 ml electroporation buffer and then pelleted at 1500 rpm for 5 minutes in 
a Jouan CR412 centrifuge and resuspended in electroporation buffer at lx l0 7  cells / 0.8 ml. 
1x10 cells and 10-15pg of DNA were added to a sterile 0.4 cm electroporation cuvette 
(gap 50, BioRad) and electroporated in a BioRad Gene Pulser at 960 pF and 450V. The 
cells were left to stand at room temperature for 2 0  minutes, before being plated out into 2 0  
ml RPMI 1640 with 5% (v/v) JWW3 conditioned medium, and 2 pg/ml tetracycline and 
incubated at 37°C. After 48 hours the number of viable cells was determined using trypan 
blue, and cells were suspended in RPMI 1640 with 5% (v/v) JWW3 conditioned medium, 2 
pg/ml tetracycline, 1.5 pg/ml puromycin, and hygromycin at a concentration of 105 viable 
cells/ml. The cells were plated into 3, 96 well flat-bottomed trays (Nunc) at 2xl0 4 /well.
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The remaining cells were plated into a falcon 100 x 20 mm dish as a polyclonal population. 
After approximately 10 days, hygromycin and puromycin resistant clones from the 96 well 
trays were apparent and transfered into 1 ml of the same selective media in a 24 well tray 
(Nunc). Clones were then expanded and screened for inducible expression of the 
introduced cDNAs (see section 2.17). After approximately two weeks in complete 
selection media, selected clones were passaged in RPMI 1640 with 5% JWW3 conditioned 
medium and 2  pg/ml tetracycline only.
2.2.4 Screening for tetracycline-regulated expression
Hygromycin and puromycin resistant clones were expanded in RMPI 1640 with 5% (v/v) 
JWW3 conditioned medium in the presence of 2 pg/ml tetracycline. Cells were then 
washed three times in HANKS/HEPES (1:10 dilution of lOx Hank’s balanced salts; 20mM 
HEPES, Life Technologies) buffer and pelleted at 1500 rpm for 5 minutes in a Jouan 
CR412 centrifuge, to remove all traces of tetracycline. The cells were resuspended at lx l 05  
cells/ml in the presence or absence of 2pg/ml tetracycline. After 24 hours, cells were 
washed once in phosphate buffered saline (PBS) and cell extracts prepared at 5 x 105 cells 
per 50 pi solubilisation buffer (see). The amount of protein was determined by Bradford 
analysis (see section 2.28) and 15pg of each sample separated by SDS PAGE (see section 
2.24).
2.2.5 Cell Storage
Cells from an exponentially growing dish were pelleted at 1500 rpm for 5 minutes in a 
Jouan CR412 centrifuge. The cell pellet was resuspended in 90% (v/v) foetal calf serum 
and 10% (v/v) DMSO at a concentration of greater than 2xl0 6  cell/ml. 1ml aliquots were 
transferred into 1ml Nunc cryotubes, wrapped in tissue, placed in a polystyrene box and 
frozen to -80°C. After 24 hours, the vials were transferred into liquid nitrogen.
2.2.6 XTT Assays
Serial 1:2 dilutions of growth factors in either AIM-V (a serum-free lymphocyte medium) 
or in RPMI 1640 medium supplemented with 10% (v/v) foetal bovine serum (Life 
Technologies), 20 pM 2-mercaptoethanol, lOOu penicillin/streptomycin and 2 mM 
glutamine were performed in triplicate in 96 well flat-bottomed nunc trays. The initial
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growth factor concentrations used were: IL-3, 2ng/ml; IL-4, lOng/ml; and insulin, 1 pg/ml. 
Cells were washed 3 times in HANKS/HEPES buffer and plated at a concentration of 
lx l0 5/ml (total volume lOOpL), with or without 2pg/ml tetracycline or the appropriate 
concentration of LY294002 (Calbiochem) or carrier (DMSO) alone. 25pi of a solution of 
1 mg/ml XTT and 25pM phenazine methosulphate (PMS) was added for the final 4 hours of 
incubation. Cells were harvested after 72 hours, and the metabolic activity of the cells 
determined by reduction of XTT. The soluble formazan compound was measured at 450nm 
on a Dynatech MR5000 plate reader.
The XTT assay system measures the bioreduction of the XTT compound to its coloured 
formazan compound. Thus it can be used to measure a combination of the cell number and 
metabolic activity of these cells, which correlates to cellular proliferation. The drawback of 
this assay is that a cell could be metabolically active without actual proliferation. This is in 
contrast to thymidine incorporation assays, which directly measure the cells use of 
thymidine in DNA synthesis and directly correlate to proliferation. However, in BaF/3 
cells grown in response to IL-3, proliferation curves obtained by both thymidine 
incorporation and XTT assays were comparable (Craddock et al., 1999). This indicates that 
in this system XTT assays are a reliable assay system with which to measure cellular 
proliferation.
2.2.7 Cell Viability
Cells were washed 3 times in Hanks buffer (1:10 dilution of lOx Hank’s balanced salts; 
20mM HEPES, Life Technologies) and plated at lx l0 5/ml in RPMI 1640 medium 
supplemented with 10% (v/v) foetal bovine serum (Life Technologies), 20 pM 2- 
mercaptoethanol, lOOu penicillin/streptomycin and 2 mM glutamine. Growth factor 
concentration were: IL-3, 2ng/m; IL-4, lOng/ml; and insulin, 1 pg/ml and tetracycline was 
used at 2pg/ml. Cells were counted in duplicate on a haemocytometer and live cells were 
distinguished by their exclusion of the dye trypan blue.
2.2.8 FACS Analysis
Cells were washed 3 times in Hanks/HEPES buffer and set up at lx l05/ml in complete 
RPMI with 5% JWW3 in the presence or absence of 2pg/ml tetracycline or the appropriate 
concentration on LY294002. After the indicated times 106  cells were washed twice in PBS
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then resuspended in lOOpl of labelling solution (lOmM Hepes/NaOH pH7.4, 140mMNaCl, 
5 mMCaCl2 , 5pg/ml propidium iodide, 20pl/ml annexin-V-FLUOS, Roche) and incubated 
in the dark for 15 minutes. 4ml of incubation buffer (lOmM Hepes/NaOH pH7.4, 
140mMNaCl, 5 mMCaCl2 ) was added before the analysis of 10 000 events per sample on a 
Becton-Dickenson FACS Vantage system. Annexin staining was detected on channel FL1 
and propidium iodide on FL3.
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2.3 Protein Chemistry Techniques
2.3.1 Cell stimulation and growth factors
Cytokine stimulations were carried out using concentrations of factor previously shown to 
produce maximal tyrosine phosphorylation (Welham and Schrader, 1992); IL-3, 20ng/ml; 
SCF, 50ng/ml (murine recombinant, purchased from R&D Systems); IL-4, 20|ig/ml; GM- 
CSF, 5ng/ml (synthetic, gifts from Dr I. Clark-Lewis, Biomedical Research Centre, 
Vancover, Canada); insulin, 5ng/ml (purchased from Sigma). Before stimulation MC9 
cells were starved overnight of serum and factor; cells were pelleted and resuspended in 
serum free media (RPMI 1640, 20|iM 2-mercaptoethanol, lOOu penicillin/streptomycin and 
2 mM glutamine) to the original concentration. To stimulate, cells were washed 3 times in 
HANKS/HEPES buffer. Cells were then resuspended in serum free media at the indicated 
concentration and incubated at 37°C for 1 hour. After stimulation with the appropriate 
cytokine at 37°C, cells were pelleted for 20 seconds at 4°C in a Heraeus microcentrifuge at 
full speed. The supernatant was aspirated off and the cell pellets were lysed in solublisation 
buffer (50mM Tris-HCl pH 7.5,10% (v/v) glycerol, 1% (v/v) Nonidet P-40, 150mM NaCl, 
5mM EDTA, ImM sodium orthovanadate, ImM sodium molybdate, lOmM sodium 
fluoride, 40ng/ml aprotinin, 10jig/ml soybean trypsin inhibitor, 10ng/ml leupeptin, 0.7|ig/ml 
pepstatin). The solublised cells were pelleted at 4°C for 2 minutes and the supernatants 
transferred to a clean tube.
2.3.2 Immunoprecipitation of Bad
Bad was immunoprecipitated from the equivalent of 2x107  cell extracts with 4pg of anti- 
Bad mAb (B36420, Transduction Laboratories) overnight at 4°C. Immunocomplexes were 
captured with 30pl of 50% (v/v) slurry of Protein-G Sepharose beads at 4°C with rotation 
for 1 hour. Immunoprecipitates were washed 3 times in solublisation buffer, and bound 
protein eluted by boiling in lx SDS PAGE sample buffer (10%(w/v) SDS; 50%(v/v) 
glycerol; 0.2 M Tris-HCL, pH 6 .8 ; bromophenol blue to colour) containing 2- 
mercaptoethanol.
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2.2.3 SDS Polyacrylamide Gel Electrophoresis (SDS PAGE)
The Bio-Rad mini protean II system was used with a procedure similar to that of Laemlli 
(1970). Glass plates were cleaned with 70% ethanol and the apparatus assembled 
according to the manufacturers instructions. Gels were prepared as follows:
Cell extracts were fractionated on either a 7.5% polyacrylamide gel (PKB, 9E10, 4G10), 
or a 20% polyacrylamide gel (Bad) with a acrylamide:bisacryiamide ratio of 37.5:1. Bad 
immunoprecipitates were fractionated in a 12.5% polyacrylamide gel with a 
acrylamide:bisacrylamide ratio of 118:1 (low bis). For in vitro kinase assays samples were 
fractionated on a 15% polyacrylamide gel with a ratio of 37.5:1.
The separating gel was cast immediately after the addition of 20ul TEMED and 50 pi 10% 
APS by pouring 4.5ml of the acrylamide solution between the two glass plates. This was 
overlaid with water and allowed to polymerise (approximately 20 minutes). Once the gel 
had polymerised the water was aspirated off and the stacking gel (5% polyacrylaminde gel 
with an acrylamide to bis ratio of 37.5:1) cast over the separating gel, and a 15 well comb 
inserted to form wells. After polymerisation the comb was removed and the wells washed 
with water. The gels were the set in the tank and covered with lx SDS running buffer 
(25mM Tris base, 192mM glycine, 0.1% (w/v) SDS). Samples were then loaded and run at 
80V through the stacking gel followed be 150V through the separating gel. When the dye 
front reached the bottom of the gel, the gel was removed and placed in lx semi-dry transfer 
buffer (39mM glycine, 48mM Tris base, 0.0375% (w/v) SDS, 20% methanol).
2.3.4 Immunoblotting
A Pharmacia LKB NovaBlot was used to transfer proteins by semi-dry transfer to 
nitrocellulose membranes. A sandwich was formed by placing 4 pieces of dampened 
(semi-dry transfer buffer, see Section 2.2.3) 3 MM Whatman filter paper on the positive 
(lower) electrode, followed by the wet nitrocellulose, the gel and a further 4 pieces of damp 
filterpaper. The negative (upper) electrode was positioned on top and the gel transferred at 
0.8 mA/cm2  for 1 hour. After transfer the membranes were rinsed in water, and stained 
with Ponceau S to allow the position of the molecular weight standard to be marked and the 
transfer efficiency and protein loading to be assessed. The stain was removed by washing in 
Tris-buffered saline (TBS (20mM Tris-HCL, pH 7.5; 150 mM NaCL). Membranes were 
blocked in blocking buffer (5% (w/v) BSA, 1% (w/v) ovalbumin, 0.05% sodium azide 
solution in TBS) for at least 1 hour. Primary antibodies were prepared in a 1:5 dilution of
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blocking buffer and used at the concentrations outlined in Table 2.1. The blots were 
incubated overnight with all primary antibodies except for 4G10 and 9E10, which were 
incubated for 3 hours. After incubation with primary antibody, blots were washed 1 x 10 
minutes in TBS, 3 x 10 minutes in TBSN (TBS with 0.05% (v/v) NP-40), and 1 x 10 
minutes in TBS. Blots were then incubated for 1-2 hours with the secondary antibody. 
Both goat anti-rabbit and goat anti-mouse horseradish peroxidase-conjugated secondary 
antibodies (Dako) were used at a concentration of 0.05 pg/ml (1:20 000 dilution) in TBSN. 
Secondary antibody was washed from the blots as for the primary antibody with a final 10 
minute wash in TBS. After the final washing, the blots were placed in a clean container 
and developed in enhanced chemiluminescence (ECL) or enhanced chemilluminescence 
plus (ECLplus) (AmershamPharmacia) for 1 minute (ECL) or 5 minutes (ECLplus). Kodak 
XAR-5 film was used for detection of ECL signals and films were developed in a Fuji X- 
ray Processor RG2. The films were scanned using a Mustek 1200CU scanner for 
presentation in this thesis.
2.3.5 Stripping of Blots
To strip immunoblots completely of protein, nitrocellulose membranes were incubated in 
stripping solution (62.5 mM Tris-HCl, pH 6.7,2% (w/v) SDS, 100 mM P-mercaptoethanol) 
at 55°C for 60 minutes with periodic agitation. Blots were extensively washed in TBSN 
prior to being blocked in blocking buffer and probed with antibody as described above.
2.3.6 In vitro kinase assays
Cells were stimulated as described above. PKB was immunoprecipitated from cell lysates 
with lpg anti-PKB (Santa Cruz) or 5pg 9E10 for 1 hour at 4°C. Immunocomplexes were 
captured with 30pl of Protein G Sepharose at 4°C with rotation for 1 hour. Beads were 
washed twice in solublisation buffer, twice in LiCl wash buffer (500mM LiCl; lOOmM Tris 
HC1, pH 7.5; ImM EDTA) followed by one wash in kinase buffer (50mM Tris HC1, pH 
7.5; lOmM MgCL; ImM DTT). Kinase assays were performed by suspending beads in 
kinase buffer containing 2.5pg histone2B, 0.5pM protein kinase inhibitor, 50pM ATP, 
3pCi ATPy32P at room temperature for 30 minutes. Reactions were stopped by the 
addition of 5x SDS PAGE sample buffer containing 2 mercaptoethanol followed by boiling 
for 5 minutes. Samples were fractionated and immunoblottted as described in section 2.3.5.
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After transfer membranes were cut in half, the upper part was immunoblotted for PKB (see 
Section 2.3.4) and the lower part wrapped in cling film and subjected to autoradiography. 
Kodak XAR-5 film was used for detection and films were developed in a Fuji X-ray 
Processor RG2. After autoradiography, the H2B bands were excised, placed into 5ml of 
scintilation fluid and the counted on a Wallac 1215 Rackbeta liquid scintillation counter.
2.3.8 Bradford Protein Estimations
BSA of known concentration or samples of cell lysates were added to 0.5 ml aliquots of 
water in Eppendorf tubes. 0.5 ml of the Bradford reagent (200 mg Coomassie Blue G-250 
in 2 0 0  ml 85% (v/v) H3 PO4 , made up to 1 . 0  L with water and then filtered) was added to 
each tube and vortexed. 100 pi was then added to wells in a 96 well round bottom tray 
(Falcon) and the optical density at 595 nm determined on a Dynatech MR5000 plate reader. 
A standard curve was constructed from the BSA standards and the protein concentrations of 
the cell lysates determined. This procedure was adapted from Bradford (1976).
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2.4 M ate ria ls  
2.4.1 Antibodies
Table 2.4.1
Antibodies used for Blotting and Precipitation
Antibody Source Usage
4G10 (monoclonal, anti- 
phosphotyrosine)
Upstate Biology Inc 
(cat. #05-321)
Blot: 0.1 pg/ml
9E10 (monoclonal anti-myc-tag) ATCC hybridoma line Blot: 0.5 pg/ml 
I.P.: 5 pg/sample
anti-phosphoPKBSer4 7 3 New England Biolabs 
(cat. # 9271)
Blot: 1:1000
anti-phosph-PKBThr30* New England Biolabs 
(cat. # 9275)
Blot: 1:1000
anti-PKB New England Biolabs 
(cat. # 9272)
Blot: 1:1000
PKB (PHdomain) Upstate Biology Inc 
(cat #06-885)
Blot: lpg/ml
anti-PKB C20 Santa Cruz (cat. # sc-1618) IP-: IPS
anti-Bad Santa Cruz (cat. # sc-943) Blot: 0.5 pl/ml
anti-Bad Transduction Labs 
(cat. # B36420)
I.P.: 4pg/ml
anti-phospho-BadSer1 1 2 New England Biolabs 
(cat. # 9290)
Blot: 1:1000
anti-phospho-BadSer1 3 6 New England Biolabs 
(cat. # 9295)
Blot: 1:1000
Anti-phospho-Bad Ser1 3 6 Upstate Biology Inc 
(cat. # 06-799-MN)
Blot: 2pg/ml
anti-Bad R&D (cat. # AF819) Blot: lpg/ml
goat-anti-rabbit-HRP conjugated Dako 1 : 2 0 0 0 0
goat-anti-mouse-HRP conjugated Dako 1 : 2 0 0 0 0
2.4.2 Primers
Table 2.4.2 
Primers used for PCR








Plasmids used for Cloning and Transfection
Vector Use Source
PSG5gagPKB Source of gagPKB 
construct
van Weeren et al., 1998, 
Burgerring and Coffer, 1995
PSG5kdPKB Source of kdPKB 
construct
PSG5PKB Source of wtPKB 
construct
PSG5cxPKB Source of cxPKB 
construct
pBS.Nmyc2 Source of N-terminal 
myc-tag
Craddock et al., 1999
pUHD 10-3 (hygro) Hygromycin resistant 
response plasmid
Mui et al., 1996






Reagents used and their Suppliers
Reagents Supplier*
1 Kb DNA ladder Life Technologies
3 -mercoptoethanol Bio-R.ad
rY-32Pi a t p NEN
Acetic acid (glacial) BDH
30% Acrylamide/Bis solution 37.5:1 Bio-Rad
agarose (electrophoresis grade) Life Technologies
AIM-V Life Technologies
Albumin, Chicken Egg (Grade III) Sigma
Ammonium persulphate Fisons Scientific
Ampicillin Sigma




Bovine Serum Albumin (BSA) Roche
Bromophenol Blue Fisons Scientific
Calcium chloride (CaCl2 ) Fisons Scientific
Calf intestinal phosphatase (CIP) New England Biolabs
Chloroform BDH
Diaminoethanetetra acetic acid (EDTA) Sigma
Dideoxy nucleotide triphosphates 
(dNTPs)
New England Biolabs




Fetal calf serum Autogen Bioclear
Ficoll 400 SIGMA
Geneticin (G418) Life Technologies
Glutathione Sepharose 4B Pharmacia Biotech
Glycerol SIGMA
Glycine SIGMA
GM-CSF Dr Ian Clarke-Lewis
HANKS buffered saline (lOx) Life Technologies
HEPES Life Technologies
Histone 2B Sigma
IL-3 R & D Systems
IL-4 Dr Ian Clarke Lewis
Insulin Sigma
Klenow New England Biolabs
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L-Glutamine (100X) Life Technologies
Leupeptin Sigma
Lysozyme Sigma
Magnesium chloride (MgCL) Sigma
Magnesium sulphate (50X) New England Biolabs








Phenazine methosulphate (PMS) Sigma
Phenol (buffer-saturated) Life Technologies
Phenylmethylsulphonyl fluoride (PMSF) Sigma
Phosphate Buffered Saline (PBS) Life Technologies
Phosphoric Acid (85% (v/v)) H3 PO4 Sigma
Ponceau S Sigma
Potassium acetate (KAc) Sigma
Potassium Chloride (KC1) Sigma
Potassium Hydoxide (KOH) Sigma
Propidiun Iodide Sigma
Protein-G Sepharose Pharmacia Biotech
Puromycin Calbiochem
Recombinant mouse IL-3 (rmIL-3) R&D Systems
Restriction Endonuleases New England Biolabs
RNase A Roche
RPM I1640 Life Technologies
Rubidium chloride Sigma
SCF R & D  Systems
SDS-PAGE standards (broad range) Bio-Rad
Sodium acetate (NaAc) Sigma
Sodium azide Fisons Scientific
Sodium chloride (NaCl) Sigma
Sodium dodecyl sulphate (SDS) BDH
Sodium hydroxide (NaOH) Fisons Scientific
Sodium fluoride (NaF) Sigma
Sodium molybdate BDH
Sodium orthovanadate Sigma
Soybean Trypsin Inhibitor Sigma
T4 DNA ligase New England Biolabs
Tetracycline Sigma
Tetramethylethylenediamine (TEMED) Bio-Rad
Trizma base (Tris) Sigma
Vent DNA polymerase New England Biolabs
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X-ray film (XAR-5) Kodak
XTT Sigma
Xylene/Cyanol Sigma
Yeast extract Difco Laboratories
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*Full name and location of Suppliers:
Dr Ian Clarke-Lewis, BRC, Vancover, Canada 
Amersham Pharmacia Biotech, Herts, U.K. 
Autogen Bioclear, Wilts, U.K.
BDH Chemicals Ltd., Poole, U.K.
Bio-Rad, Richmond, California, USA 
Calbiochem, Nottingham, U.K.
Dako, Denmark
Difco Laboratories, Detroit, Michigan, USA 
Eastman Kodak Company, Rochester, NY, USA 
Fisons Scientific, Leiscester, U.K.
Life Technologies Ltd., Paisley, U.K.
NEN Life Science Products, Holland 
New England Biolabs Inc., MA, USA 
R&D Systems Europe Ltd., Abringdon, U.K. 
Roche, East Sussex, UK 
Sigma Chemicals, Poole, U.K.
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Chapter 3
Comparison of PKB Signalling in BaF/3, FD6 and MC9 Cells
73
3.1 Introduction
When this study was initiated the effects of cytokine stimulation on PKB were largely 
unknown. PKB was first shown to be activated downstream of PI3K in response to 
PDGF (Franke et al., 1995; Burgering and Coffer, 1995), insulin (Cross et al., 1995; 
Burgering and Coffer, 1995), EGF and bFGF (Burgering and Coffer, 1995) and the IL-3 
stimulated activation of PKB had been demonstrated in FL5.12 (del Peso et al., 1997) 
and 32D (Datta et al., 1997; Songyang et al., 1997; Songyang et al., 1997) cells (Datta 
et al., 1997; Songyang et al., 1997) but the effects of SCF and IL-4 had not been 
investigated. PKB had been implicated in the PI3K mediated survival and proliferative 
pathway (Dudek et al., 1997; Kauffman-Zeh et al., 1997; Kennedy et al., 1997; Khwaja 
et al., 1997; Songyang et al., 1997), but it was unclear whether PKB activation was 
sufficient to provide a survival signal or indeed necessary for survival and proliferation.
Haemopoietic cell lines are dependent on the presence of the appropriate cytokine(s) 
for their continued growth and survival. In the absence of cytokine, cells cease to 
proliferate and undergo programmed cells death or apoptosis. This feature makes them 
a good model in which to investigate the signal transduction mechanisms leading to 
proliferation and apoptosis.
Therefore, the objective of this chapter was to investigate the stimulation of 
haemopoietic cells by IL-3, IL-4 and SCF with respect to the activation of PKB and 
relate this to the functional responses of proliferation and/or survival. Three 
haemopoietic cell lines were utilised:
• MC9, an IL-3 dependent mast cell line which is responsive to IL-4, SCF, insulin 
and GM-CSF (Nabel et al., 1981).
• FD-6, a myeloid progenitor cell line which is dependent on IL-4 and responsive 
to IL-3, insulin and GM-CSF (Welham et al., 1994a).
• BaF/3 a pre B-cell line that is IL-3 dependent and responds to IL-4 and insulin 
(Palacios and Steinmetz, 1985).
74
3.2 Cytokine induced activation of PKB.
The first objective was to determine whether PKB is activated in response to various 
cytokines in BaF/3, FD-6 and MC9 cell lines. Extensive time-course analyses were 
performed and the activation of PKB assessed firstly by examining the phosphorylation 
of Ser473 using phospho-specific antibodies and secondly by directly examining the 
kinase activity of PKB by looking at the incorporation of y32P (phosphate group) into 
the substrate histone2B. Ser473 is one of two sites on PKB that is phosphorylated in the 
active form (Alessi et al., 1996a) hence looking directly at the phosphorylation of this 
site gives an indication of the activation state of PKB. Histone2B was used as the 
substrate in in vitro kinase assays as it is phosphorylated by active PKB at Ser36, which 
lies within a PKB consensus sequence (Alessi et al., 1996b). To ensure that the 
cytokine-induced stimulation of cells was efficient, the overall level of tyrosine 
phosphorylation was also examined. Duplicate gels were run and these were 
immunoblotted with 4G10 antibody, which recognises phosphorylated tyrosine 
residues.
3.3 Kinetics of PKB activation in FD6 Cells
FD6 cells are dependent on either IL-3 or IL-4 for their continued growth and survival. 
Given that PKB was thought to have a role downstream of PI3K in proliferation and 
survival, it was of interest to see what effect the stimulation of FD6 cells with IL-3 and 
IL-4 had on PKB activation. Both IL-3 (Figure 3.1 A, middle panel) and IL-4 (Figure 
3.2A, middle panel) induce the phosphorylation of PKB at Ser473 as determined by 
immunoblotting with an antibody specific to the phosphorylated form of PKB-Ser473. 
Maximum phosphorylation was observed at 10 minutes and phosphorylation had 
returned to basal levels by 30 minutes with both IL-3 and IL-4. The IL-3 and IL-4 
induced phosphorylation of Ser473 mimicked the patterns of tyrosine phosphorylation 
induced by these factors (Figure 3.1 A and 3.2A, upper panels).
Ser473 is one of two sites on PKB phosphorylated in its activated form. Therefore, 
studying the phosphorylation at this site gives an indication of the activity of PKB but 
does not measure its activity directly. In vitro kinase assays were performed to look 
directly at the activity of PKB and to confirm that Ser473 phosphorylation mirrors the 
activation state of PKB. Both IL-3 (Figure 3.IB) and IL-4 (Figure 3.2B) induced the 
activation of PKB in FD6 cells and the kinetics of activation followed the kinetics of 
Ser473 phosphorylation. This confirms firstly that PKB is activated in response to IL-3 
and IL-4 in FD6 cells and secondly that the phosphorylation status of Ser473 is a good 
indicator of the activity of PKB.
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Figure 3.1
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FD-6 cells were starved of serum and factor for lhr before stimulation with 20ng/ml 
rmIL-3 for the indicated times. (A) Cells were lysed and whole cell extracts (8xl05 cell 
equivalents) were separated on SDS-PAGE and transferred to nitrocellulose. These 
were immunoblotted for a-phospho-tyrosine (a-PY, upper panel) or a-phosph-Ser473 
PKB (a-pPKB, middle panel). The PKB blots were stripped and reprobed with a-PKB 
(lower panel). (B) Cells were lysed (107 cell equivalents) and immunoprecipitated with 
a-PKB. In vitro kinase assays were performed using histone2B (H2B) as the substrate 
and the products were separated by SDS-PAGE and transferred to nitrocellulose. The 
membranes were cut in half, the upper immunoblotted with a-PKB (upper panel) and 
the lower subjected to autoradiography (lower panel). This experiment is representative 
of (A) 2 and (B) 3 independent experiments. The experiments shown in (A) and (B) 
are not performed on cell extracts from the same stimulation.
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Figure 3.2
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FD-6 cells were starved of serum and factor for lhr before stimulation with 20pg/ml 
synthetic IL-4 for the indicated times. (A) Cells were lysed and whole cell extracts 
(8xl05 cell equivalents) were separated on SDS-PAGE and transferred to 
nitrocellulose. These were immunoblotted for a-phospho-tyrosine (a-PY, upper 
panel) or a-phosph-Ser473 PKB (a-pPKB, middle panel). The PKB blots were 
stripped and reprobed with a-PKB (lower panel). (B) Cells were lysed (107 cell 
equivalents) and immunoprecipitated with a-PKB. In vitro kinase assays were 
performed using histone2B (H2B) as the substrate and the products were separated by 
SDS-PAGE and transferred to nitrocellulose. The membranes were cut in half, the 
upper immunoblotted with a-PKB (upper panel) and the lower subjected to 
autoradiography (lower panel). This experiment is representative of (A) 3 and (B) 4 
independent experiments. The experiments shown in (A) and (B) are not performed 
on cell extracts from the same stimulation.
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3.4 Kinetics of PKB activation in MC9 Cells
MC9 cells are dependent on IL-3 for their continued growth and survival and are also 
responsive to IL-4 and SCF. To examine the role that PKB may play in these functions 
the activity of PKB in response to IL-3, IL-4 and SCF was examined. Firstly, the 
phosphorylation of Ser473 was examined. Phosphorylation induced by IL-3 reached a 
maximum by 2-5 minutes and was relatively short-lived, being back to basal levels by 
20-30 minutes (Figure 3.3A). IL-4 induced phosphorylation of Ser473 was more 
prolonged with high levels of phosphorylation still observed at 30 minutes (Figure 
3.4A, middle panel). The SCF induced phosphorylation was very rapid, high levels 
were observed at 1 minute, it reached a peak at 2 minutes and was back to basal levels 
by 30 minutes (Figure 3.5A, middle panel). As seen in the FD6 cell line the 
phosphorylation of Ser473 closely followed the pattern of overall tyrosine 
phosphorylation (Figures 3.3-3.5A, upper and middle panels). To confirm that Ser473 
phosphorylation correlates with an increased activity of PKB, in vitro kinase assays 
were performed (Figure 3.3B, 3.4B, 3.5B). These confirmed that all three growth 
factors induce the activation of PKB in MC9 cells, with similar kinetics observed with 
both IL-3 and SCF. Interestingly, IL-4-induced a sustained phosphorylation at Ser473 
with near maximal phosphorylation observed at 30 minutes but this was not reflected in 
the kinase assays where the activity observed 30 minutes after stimulation was 
markedly less than maximal (Figure 3.4A, middle panel and 3.4B, lower panel).
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Figure 3.3
IL-3-Induced Activation of PKB in MC9 Cells
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MC9 cells were starved of serum and factor for lhr before stimulation with 20ng/ml 
rmIL-3 for the indicated times. (A) Cells were lysed and whole cell extracts (8x105 
cell equivalents) were separated on SDS-PAGE and transferred to nitrocellulose. 
These were immunoblotted for a-phospho-tyrosine (a-PY, upper panel) or a-phosph- 
Ser473 PKB (a-pPKB, middle panel). The PKB blots were stripped and reprobed with 
a-PKB (lower panel). (B) Cells were lysed (107 cell equivalents) and 
immunoprecipitated with a-PKB. In vitro kinase assays were performed using 
histone2B (H2B) as the substrate and the products were separated by SDS-PAGE and 
transferred to nitrocellulose. The membranes were cut in half, the upper 
immunoblotted with a-PKB (upper panel) and the lower subjected to autoradiography 
(lower panel). This experiment is representative of (A) 3 and (B) 2 independent 
experiments. The experiments shown in (A) and (B) are not performed on cell 
extracts from the same stimulation.
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Figure 3.4
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MC9 cells were starved of serum and factor for lhr before stimulation with 20pg/ml 
synthetic IL-4 for the indicated times. (A) Cells were lysed and whole cell extracts 
(8xl05 cell equivalents) were separated on SDS-PAGE and transferred to 
nitrocellulose. These were immunoblotted for a-phospho-tyrosine (a-PY, upper 
panel) or a-phosph-Ser473 PKB (a-pPKB, middle panel). The PKB blots were 
stripped and reprobed with a-PKB (lower panel). (B) Cells were lysed (107 cell 
equivalents) and immunoprecipitated with a-PKB. In vitro kinase assays were 
performed using histone2B (H2B) as the substrate and the products were separated by 
SDS-PAGE and transferred to nitrocellulose. The membranes were cut in half, the 
upper immunoblotted with a-PKB (upper panel) and the lower subjected to 
autoradiography (lower panel). This experiment is representative of (A) 2 and (B) 3 
independent experiments. The experiments shown in (A) and (B) are not performed 
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MC9 cells were starved of serum and factor for lhr before stimulation with 50ng/ml 
SCF for the indicated times. (A) Cells were lysed and whole cell extracts (8xl05 cell 
equivalents) were separated on SDS-PAGE and transferred to nitrocellulose. These 
were immunoblotted for a-phospho-tyrosine (a-PY, upper panel) or a-phosph-Ser473 
PKB (a-pPKB, middle panel). The PKB blots were stripped and reprobed with a- 
PKB (lower panel). (B) Cells were lysed (107 cell equivalents) and 
immunoprecipitated with a-PKB. In vitro kinase assays were performed using 
histone2B (H2B) as the substrate and the products were separated by SDS-PAGE and 
transferred to nitrocellulose. The membranes were cut in half, the upper 
immunoblotted with a-PKB (upper panel) and the lower subjected to autoradiography 
(lower panel). This experiment is representative of (A) 4 and (B) 2 independent 
experiments. The experiments shown in (A) and (B) are not performed on cell 
extracts from the same stimulation.
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3.5 Kinetics of PKB activation in BaF/3 Cells
In BaF/3 cells, a cell line that is dependent of IL-3 for its continued growth and 
survival, stimulation with IL-3 resulted in the rapid phosphorylation of PKB at Ser473 
(Figure 3.6, middle panel). Maximum phosphorylation was observed at 2 minutes and 
levels were still high at 30 minutes. The IL-3 induced phosphorylation of Ser473 closely 
mimicked the overall pattern of tyrosine phosphorylation induced with this factor.
In the three cell lines examined all the cytokines tested were able to induce the 
phosphorylation of Ser473 and histone2B indicating that PKB is activated (Figures 3.1- 
3.6). The kinetics of PKB activation varied according to each cytokine and cell line but 
followed closely to the patterns of total cellular tyrosine phosphorylation. These cell 
lines are dependent on particular cytokines for their continued growth and survival, and 
they will also respond to stimulation by others. Given that PKB has been reported to be 
involved in growth and survival, it is interesting that all the cytokines tested were able 
to stimulate the activation of PKB in these cells yet not all of these cytokines are able to 
support their long-term survival: IL-3 is required for the long-term growth and survival 
of BaF/3 and MC9 cells, while IL-3 or IL-4 is needed for the survival of FD-6 cells.
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Figure 3.6






BaF/3 cells were starved of serum and factor for lhr before stimulation with 
20ng/ml rmIL-3 for the indicated times. For immunoblotting cells were lysed 
and whole cell extracts (8xl05 cell equivalents) were separated on SDS-PAGE 
and transferred to nitrocellulose. These were immunoblotted for a-phospho- 
tyrosine (a-PY, upper panel) or a-phosph-Ser473 PKB (a-pPKB, middle panel). 
The PKB blots were stripped and reprobed with a-PKB (lower panel). This 
experiment is representative of 3 independent experiments.
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3.6 Dose Response Analyses
The concentration of growth factor used in the above experiments was that previously 
found to induce maximal tyrosine phosphorylation (Welham and Schrader, 1992). To 
confirm that this concentration also induces maximal PKB phosphorylation dose 
response analyses were performed. For all these experiments, stimulations were carried 
out for the length of time shown above to induce maximal PKB phosphorylation in the 
particular cell line examined.
3.7 Dose Response Analysis in FD6 Cells
In FD-6 cells both IL-3 (Figure 3.7A) and IL-4 (Figure 3.7B) activated PKB in a dose 
responsive manner, which mimicked the total cellular tyrosine phosphorylation induced 
by each cytokine. Maximal PKBSer473 phosphorylation was observed at 20ng/ml using 
recombinant IL-3 and 20pg/ml using synthetic IL-4. These concentrations were used in 
subsequent experiments.
3.8 Dose Response Analysis in MC9 Cells
In SCF-stimulated MC9 cells maximal Ser473 phosphorylation occurred between 5 and 
50ng/ml, while maximal tyrosine phosphorylation was seen at 50ng/ml SCF (Figure 
3.8A). In MC9 cells stimulated with synthetic IL-4 maximal Ser473 and tyrosine 
phosphorylation was observed at 20pg/ml (Figure 3.8B). When cells were stimulated 
with IL-3 maximal phosphorylation was observed at 10-20ng/ml (Figure 3.9). In 
subsequent experiments MC9 cells were stimulated with lOng/ml IL-3, 50ng/ml SCF 
and 20pg/ml IL-4.
3.9 Dose Response Analysis in BaF/3 Cells
In BaF/3 cells IL-3 activated PKB in a dose-responsive manner (Figure 3.10). 
Maximal tyrosine and Ser473 phosphorylation were observed at 10-20ng/ml IL-3 and 
lOng/ml was used in subsequent experiments.
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Figure 3.7
Dose-Response analyses in FD-6 Cells
B
IL-3





0 0.5 1 5 10 20 pg/ml
■gyi







FD-6 cells were starved of serum and factor for lhr prior to stimulation with the 
appropriated dose of cytokine for 5 min (IL-3), 10 min (IL-4). Cells were lysed and 
whole cell extracts (8xl05 cell equivalents) separated by SDS-PAGE and 
transferred to nitrocellulose. These were immunoblotted with a-phospho-tyrosine 
(a-PY, upper panels) or a-phospho-Ser473 PKB (a-pPKB, middle panels). The 
PKB blots were stripped and reprobed with a-PKB (lower panels). These 
experiments are representative of (A) 4 and (B) 4 independent experiments.
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Figure 3.8
Dose-Response Analysis of MC9 Cells to IL-4 and SCF
B
SCF IL-4
Blot: 0 1 5 10 50 ng/ml 0 0.5 1 5 10 20 50 pg/ml
a-PY




MC9 cells were starved of serum and factor for lhr prior to stimulation with the 
appropriated dose of cytokine for 5 min. Cells were lysed and whole cell extracts 
(8xl05 cell equivalents) separated by SDS-PAGE and transferred to 
nitrocellulose. These were immunoblotted with a-phospho-tyrosine (a-PY, upper 
panels) or a-phospho-Ser473 PKB (a-pPKB, middle panels). The PKB blots were 
stripped and reprobed with a-PKB (lower panels). The experiment shown in (A) 











MC9 cells were starved of serum and factor for lhr prior to stimulation with the 
appropriated dose of IL-3 for 5 min. Cells were lysed and whole cell extracts 
(8xl05 cell equivalents) separated by SDS-PAGE and transferred to 
nitrocellulose. These were immunoblotted with a-phospho-tyrosine (a-PY, upper 
panel) or a-phospho-Ser473 PKB (a-pPKB, middle panel). The PKB blots were 
stripped and reprobed with aPKB (lower panel). This experiment is
representative of 2 independent experiments.
87
Figure 3.10
Dose response analysis of BaF/3 Cells to IL-3
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BaF/3 cells were starved of serum and factor for lhr prior to stimulation with the 
appropriated dose of cytokine for 5 min. Cells were lysed and whole cell extracts 
(8xl05 cell equivalents) separated by SDS-PAGE and transferred to 
nitrocellulose. These were immunoblotted with a-phospho-tyrosine (a-PY, upper 
panel) or a-phospho-Ser473 PKB (a-pPKB, middle panel). The PKB blots were 
stripped and reprobed with a-PKB (lower panel). This experiment was 
performed once.
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3.10 Effect of PI3K Inhibition on PKB activation
Activation of PKB has been shown to be mediated through PI3K in a number of 
systems (Dudek et al., 1997; Kauffman-Zeh et al., 1997; Kennedy et al., 1997; Khwaja 
et al., 1997; Songyang et al., 1997). Hence it was of interest to determine what effect 
inhibition of PI3K would have on PKB activation in these haemopoietic cells. The 
time-points and concentration of factor used in these experiments were those that 
induced maximal PKB activity, as determined in the previous experiments (Figures 3.1- 
3.10). Cells were treated with the pharmacological PI3K inhibitor LY294002 prior to 
cytokine stimulation and the phosphorylation of histone2B and PKBSer473 examined. 
LY294002 is a reversible inhibitor, which competes for binding to the active ATP 
binding site in the p i 10 catalytic subunit of PI3K (Vlahos et al., 1994).
3.11 Effect of PI3K Inhibition on PKB activation in FD-6 Cells
In FD-6 cells, pre-treatment with lOpM LY294002 completely abrogated the 
PKBSer473 phosphorylation induced by IL-3 and IL-4 (Figure 3.11 A, middle panel). It 
greatly reduced the phosphorylation induced by treatment with GM-CSF and reduced 
that induced by insulin. In FD-5 cells (a different sub-clone to FD-6 cells) the insulin- 
induced activation of PKB was completely inhibited by pre-treatment with 30pM 
LY294002 (Figure 3.12, middle panel). When PKB activation was measured directly 
using in vitro kinase assays similar results were obtained (Figure 3.1 IB). This indicates 
that in FD-6 cells IL-3, IL-4, insulin and GM-CSF all activate PKB through a PI3K 
mediated pathway.
3.12 Effect of PI3K Inhibition on PKB activation MC9 Cells
Treatment of MC9 cells with the PI3K inhibitor LY294002 for 30 minutes prior to 
stimulation with IL-3, IL-4, SCF, GM-CSF or insulin completely abrogated the 
phosphorylation of Ser473 induced by these cytokines (Figure 3.13A, middle panel). 
Similar results were observed when the effects of LY294002 pre-treatment on PKB 
activity was measured directly using in vitro kinase assays. Pre-treatment with 
LY294002 completely inhibited the IL-3-, IL-4- and insulin-induced activation of PKB 
(Figure 3.13B). Treatment of MC9 cells with LY294002 before stimulation with SCF 
and GM-CSF also resulted in a dramatic reduction of PKB activity, but did not reduce 
the activity to basal levels. These results show that in MC9 cells IL-3, IL-4, insulin, 
SCF and GM-CSF all activate PKB through a PI3K mediated pathway. LY294002 pre­
treatment did not completely abrogate the activation of PKB in response to SCF and
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GM-CSF. This could be because the PKB activation induced by these factors is too 
strong to be inhibited by IOjiM LY294002 (as seen with insulin stimulation of FD-5 and 
FD-6 cells in Figures 3.11 and 3.12) or that other pathways are involved in the 
activation of PKB by these factors in MC9 cells.
3.13 Effect of PI3K Inhibition on PKB activation BaF/3 Cells
Pre-treatment of BaF/3 cells with lOpM LY294002 for 30 minutes completely 
abolished both the IL-3 and IL-4 induced phosphorylation of PKB on Ser473 (Figure 
3.14A, middle panel). In vitro kinase assays showed that LY294002 treatment 
abrogated the IL-4 induced activation of PKB and reduced that induced by IL-3 (Figure 
3.14B). This shows that both IL-3 and IL-4 activate PKB via a PI3K mediated pathway 
in BaF/3 cells. Pre-treatment with LY294002 did not effect the tyrosine 
phosphorylation induced by stimulation with either cytokine.
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Figure 3.11
Effect of LY294002 on PKB Activation in FD-6 Cells
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FD-6 cells were starved of serum and factor for 30 min followed by a 30 min 
incubation with lOpM LY294002 or carrier (DMSO) alone. Cells were stimulated 
with growth factor (20ng/ml IL-3 for 5 min; 20pg/ml IL-4 for 10 min; 5pg/ml GM- 
CSF for 5 min; 5pg/ml insulin for 2min). (A) Whole cell lysates were separated on 
duplicate gels by SDS-PAGE, transferred to nitrocellulose, and probed with a- 
phosphotyrosine (a-PY, upper panel) and a-phosphoSer473 (a-pPKB, middle 
panel). Blots were stripped and reprobed with a-PKB (lower panel). (B) Cells 
were lysed (107 cell equivalents) and immunoprecipitated with a-PKB. In vitro 
kinase assays were performed using histone2B (H2B) as the substrate and the 
products separated by SDS-PAGE and transferred to nitrocellulose. The 
membranes were cut in half, the upper immunoblotted with a-PKB (upper panel) 
and the lower subjected to autoradiography (lower panel). This experiment is 
representative of (A) 4 and (B) 3 independent experiments. The experiments shown 
in (A) and (B) are not performed on cell extracts from the same stimulation.
91
Figure 3.12










FD-5 cells were starved of factor and serum for 30 minutes followed by a 30 minute 
incubation with the indicated concentration of LY294002 (pM) or carrier (DMSO) 
alone. Cells were stimulated with 5pg/ml of insulin for 2 minutes and whole cell 
extracts were separated on on duplicate gels by SDS-PAGE and transferred to 
nitrocellulose. Blots were immuno-blotted with a-phosphotyrosine (a-PY, upper 
panel) and a-phosphoSer473 (a-pPKB, middle panel). Blots were stripped and 
reprobed with a-PKB (lower panel). This experiment is representative of 2 
independent experiments. The experiments shown in (A) and (B) are not performed 
on cell extracts from the same stimulation.
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Figure 3.13
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MC9 cells were starved of serum and factor for 30 min followed by a 30 min 
incubation with lOpM LY294002 or carrier (DMSO) alone. Cells were stimulated 
with growth factor (20ng/ml IL-3 for 5 min; 20pg/ml IL-4 for 10 min; 50ng/ml SCF 
for 5 min; 5pg/ml GM-CSF for 5 min; 5pg/ml insulin for 2 min). (A) Whole cell 
lysates were separated on duplicate gels by SDS-PAGE and transferred to 
nitrocellulose, and probed with a-phosphotyrosine (a-PY, upper panel) and a- 
phosphoSer473 (a-pPKB, middle panel). Blots were stripped and reprobed with a- 
PKB (lower panel). (B) Cells were lysed (107 cell equivalents) and 
immunoprecipitated with a-PKB. In vitro kinase assays were performed using 
histone2B (H2B) as the substrate and the products separated by SDS-PAGE and 
transferred to nitrocellulose. The membranes were cut in half, the upper 
immunoblotted with a-PKB (upper panel) and the lower subjected to 
autoradiography (lower panel). This experiment is representative of (A) 3 and (B) 2 
independent experiments. The experiments shown in (A) and (B) are not performed 
on cell extracts from the same stimulation.
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BaF/3 cells were starved of serum and factor for 30 min followed by a 30 min 
incubation with lOpM LY294002 or carrier (DMSO) alone. Cells were stimulated 
with growth factor (20ng/ml IL-3 for 5 min; 20pg/ml IL-4 for 10 min). (A) Whole 
cell lysates were separated on duplicate gels by SDS-PAGE and transferred to 
nitrocellulose, and probed with a-phosphotyrosine (a-PY, upper panel) and a- 
phosphoSer473 (a-pPKB, middle panel). Blots were stripped and reprobed with a- 
PKB (lower panel). (B) Cells were lysed (107 cell equivalents) and 
immunoprecipitated with a-PKB. In vitro kinase assays were performed using 
histone2B (H2B) as the substrate and the products separated by SDS-PAGE and 
transferred to nitrocellulose. The membranes were cut in half, the upper 
immunoblotted with a-PKB (upper panel) and the lower subjected to 
autoradiography (lower panel). This experiment is representative of (A) 2 and (B) 3 
independent experiments. The experiments shown in (A) and (B) are not performed 
on cell extracts from the same stimulation.
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3.14 Comparison of the levels of PKB phosphorylation
Both PI3K and PKB have been implicated in the growth and survival of haemopoietic 
cells. The experiments above show that all the growth factors examined are able to 
induce the activation of PKB through PI3K in the responsive haemopoietic cell lines 
used. However, not all the growth factors examined are able to promote the long-term 
survival and proliferation of these cells. Therefore, the relative levels of PKB activation 
induced by each factor were compared to determine whether a correlation exists 
between the level of PKB activation and the functional responses of survival and 
proliferation. In addition to examining the effect of PI3K inhibition on PKB activity 
Figures 3.11-3.14 were used to compare the relative levels of PKB activity induced by 
each growth factor. Cells were stimulated for the length of time and dose known to 
induce maximum PKB activation/phosphorylation and both Ser473 phosphorylation and 
PKB activity examined. In MC/9 cells IL-3, IL-4, GM-CSF and insulin all activated 
PKB to a similar level while SCF induced a much greater level of activation (Figure 
3.12). In FD-6 cells the insulin-induced activation was far greater than that induced by 
the other cytokines and IL-4 induced very little activation (Figure 3.11). Both IL-3 and 
IL-4 induced the activation of PKB in BaF/3 cells, again IL-4 to a very low level 
(Figure 3.14).
After autoradiography of the in vitro kinase assays, the histone2B bands were excised, 
counted in a scintillation counter and the counts used to determine the fold-increase in 
PKB activity following factor treatment. These are summarized in Table 3.1. The fold- 
activation of PKB by each cytokine varied with each experiment but the relative level of 
activation induced by each growth factor remained constant. For example, the insulin- 
induced activation of PKB in FD-6 cells was consistently much greater than the 
activation induced by IL-3, IL-4 and GM-CSF. The trends observed here are similar to 
those seen when the levels of Ser473 phosphorylation are compared.
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Table 3.1












FD-6 2.5-8 2 ND 2.5-5 3-10
n = 6 n = 7 n = 2 n = 3
MC9 1.5-2 1.5-2 2.5-4 1.5 1.5-2.5
n = 4 n = 5 n = 4 n = 2 n = 2
In vitro kinase assays were performed as described in Figures 3.1-3.6 and 3.11, 3.13- 
3.14. After autoradiography the histone2B bands were excised from the blot, their 
radioactivity counted on a scintillation counter and the maximum fold-activation of 
PKB by each cytokine was determined. The values above show the range of fold- 
activation induced by each growth factor. ND = not determined.
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3.15 Cytokine induced phosphorylation of BAD
Having established that IL-3, IL-4, SCF, insulin and GM-CSF activate PKB and that 
the level and kinetics of activation varies with each cytokine and cell line, it was of 
interest to look at the effects of these differences on substrates of PKB. At the time of 
this work Bad, a pro-apoptotic member of the Bcl-2 family, was reported to be 
phosphorylated on two sites, Ser112 and Ser136, but subsequently a third phosphorylation 
site, Ser155, has been identified (Zhou et al., 2000; Lizcano et al., 2000). The Ser136 site 
is phosphorylated by PKB in response to IL-3 stimulation and it had been proposed that 
this accounts for the survival signal generated by IL-3 and PKB (del Peso et al., 1997; 
Zha etal., 1996).
3.16 Hyper-Phosphorylation of Bad in MC9 Cells
Phosphorylation of Bad causes a shift in its migration through SDS-PAGE and this can 
be used to determine the phosphorylation status of Bad (Zha et al., 1996). Bad was 
immunoprecipitated from cell extracts prior to SDS-PAGE through 12.5% low bis 
(118:1) gels and immunoblotted with anti-Bad. As previously reported (Scheid and 
Duronio, 1998) in MC/9 cells IL-4 and insulin induced no change in the migration of 
Bad indicating that they are unable to induce the hyper-phosphorylation of Bad (Figure
3.15 A). IL-3, SCF and GM-CSF, however, induced the complete conversion of Bad to 
its slower migrating, hyper-phosphorylated form. In unstimulated MC9 cells both the 
slower and faster migrating forms of Bad were always detected reflecting a high basal 
level of phosphorylation, the reasons for which are not clear.
3.17 Hyper-Phosphorylation of Bad in FD-6 Cells
In FD-6 cells (Figure 3.15B, upper panel) IL-3 induced a complete conversion of Bad 
to its slower migrating, hyper-phosphorylated form and IL-4 was able to induce a partial 
but consistently observed conversion. Interestingly, insulin, while being the strongest 
inducer of PKB activation in FD-6 cells, induced a very low level of Bad hyper­
phosphorylation. Pre-treatment with LY294002 decreased the mobility shift in all cases 
highlighting the requirement for PI3K.
PKB is thought to phosphorylate Bad on Ser136, therefore, the phosphorylation of this 
site was examined using antibodies specific for phospho-Ser . Phospho-Ser 
antibodies from both NEB and UBI were tried, however, neither appeared to be specific 
to Bad (data not shown). Therefore, to further clarify the phosphorylation of Bad 
particularly in response to IL-4 and insulin this blot was stripped and reprobed with an
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119antibody reputed to be specific for phospho-Ser (Figure 3.15B lower panel). This
119result shows that IL-4 and insulin induce a low level of Ser phosphorylation in FD-6 
cells and confirms the shift in Bad migration observed when cells are stimulated with 
these factors.
3.18 Hyper-Phosphorylation of Bad in BaF/3 Cells
In BaF/3 cells (Figure 3.15C, upper panel) IL-4 was unable to convert Bad to its 
slower migrating, phosphorylated form, insulin stimulation induced little if any change 
in migration, while IL-3 was a potent inducer of Bad phosphorylation. As seen in the 
FD-6 cell line pre-treatment with LY294002 decreased the mobility shift again 
highlighting the requirement for PI3K. This blot was stripped and reprobed with
119phospho-Ser (Figure 3.15C, lower panel). Consistent with the mobility shift data, IL- 
3 induced significant Ser112 phosphorylation and insulin induced a low level of Ser112 
phosphorylation in BaF/3 cells. No Ser112 phosphorylation was observed in IL-4 
stimulated BaF/3 cells.
Taken together, these results do not show a correlation between the level of PKB 
activation and the ability to induce Bad hyperphosphorylation as judged by a shift in 
mobility. Insulin is a potent activator of PKB in FD-6 cells yet barely induces the 
hyper-phosphorylation of Bad. Conversely, IL-4 is a relatively poor activator of PKB in 
this cell line yet is able to induce Bad phosphorylation. In MC/9 cells both insulin and 
IL-4 are able to activate PKB to levels similar to those of IL-3 and GM-CSF, yet while 
the latter two growth factors can induce Bad phosphorylation insulin and IL-4 cannot. 
Yet in BaF/3 cells there appears to be a correlation between PKB activation and Bad 
hyper-phosphorylation. IL-3 which is a relatively potent PKB activator, can induce Bad 
hyper-phosphorylation, while IL-4, which induces relatively little PKB activation is 
unable to phosphorylate Bad.
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Figure 3.15
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(A) MC-9 cells were starved of factor and serum for 1 hour, or (B) FD-6, and (C) BaF/3 
cells were starved of factor and serum for 30 minutes followed by a 30 minute 
incubation with lOpM LY294002 or carrier (DMSO) alone. Cells (2x107) were 
stimulated at the dose and time previously shown to induce maximal PKB activation 
(see legend to Figures 3.11, 3.13 and 3.14) and immunoprecipitated with a-Bad, 
separated by SDS-PAGE and transfered to nitrocellulose. Blots were immunoblotted 
with a-Bad (upper panels), and (B) and (C) stripped and reprobed with a-phosphoSer112 
(lower panels). These experiments are representative of (A) 3, (B) 5, and (C) 2 
independent experiments.
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3.19 Cytokine induced Survival and Proliferation
The previous results indicate that cytokine-induced activation of PKB does not 
necessarily result in the hyper-phosphorylation of Bad. As both of these events had 
previously been thought to be important for cellular survival (Datta et al., 1997), it was 
of interest to investigate which cytokines could support the survival and proliferation of 
BaF/3 and FD-6 cell lines. These factor-dependent cell lines are useful models for 
studying cell survival and proliferation because they will cease to proliferate and 
undergo apoptosis in the absence of a survival signal.
3.20 Survival and proliferation of FD-6 Cells
XTT dye reduction assays were used to measure the proliferation/survival of FD-6 
cells in response to IL-3, IL-4 and insulin. These assays measure the bio-reduction of 
XTT to its soluble, coloured formazan product, giving an indication of cellular 
metabolic activity and hence proliferation and survival of cells. In 72 hour XTT dose 
response assays both IL-3 and IL-4 supported the proliferation of FD-6 cells (Figure 
3.16A), however, these cells did not proliferate in response to insulin concentrations of 
O.lpg/ml to lpg/ml.
To investigate the role that insulin and IL-4 can play in the survival of FD-6 cells 
viability assays were performed. FD-6 cells were grown in IL-4, insulin or serum alone 
and the percentage of viable cells were determined by dye exclusion assays. Live cells 
were distinguished from dead ones by their exclusion of trypan blue and the percentage 
of each determined. Cells grown in IL-4 maintained a viability of approximately 85% 
(Figure 3.16B) over 72 hours. Insulin appeared to give some protection from apoptosis 
in the short term, the viability of insulin treated cells was approximately 10% greater 
than that of cells in serum alone at 24 and 48 hours but by 72 hours no difference was 
seen. Therefore insulin, despite being a potent activator of PKB in FD-6 cells, is unable 
to provide a signal for these cells to survive and proliferate.
3.21 Survival of BaF/3 Cells
Viability assays were performed to investigate the ability of IL-3, IL-4 and insulin to 
promote the survival of BaF/3 cells. Cells grown in IL-3 maintained a viability of 
greater than 90% over 48 hours (Figure 3.17). IL-4, despite inducing a very low level 
of PKB activation and not promoting the dual phosphorylation of Bad, appeared to 
afford some protection from apoptosis. However, insulin was unable to sustain viability 
above the levels of serum alone.
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Figure 3.16
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(A) FD-6 cells were washed free of factor and set up with growth factor (at a 
starting concentration of IL-3, 2ng/ml; IL-4 lOng/ml: insulin lpg/ml) or serum 
alone with serial 1:2 dilutions across a 96 well plate as described in materials and 
methods. After 72 hours the assays were developed and the mean values with 
standard error are plotted. (B) FD-6 cells were washed free of factor and set up 
with growth factor at a concentration of IL-3, 2ng/ml; IL-4 lOng/ml: insulin 
lpg/ml or serum alone. The percentage of viable cells was determined by the 




Viability of BaF/3 Cells in Response to Cytokines
100
serum alone
0 12 24 36 48
BaF/3 cells were washed free of IL-3 and serum and seeded at 105/ml in 2ng/ml 
IL-3, lOng/ml IL-4, lpg/ml insulin or 10% v/v serum only. The percentage of 
viable cells was determined at the specified times by their exclusion of trypan 
blue. Values are the average of 4 counts and are plotted with standard error. 
This experiment is representative of 3 independent experiments.
102
Table 3.2 
Summary of Cytokine Responses





Baf/3 IL-3 Yes Yes Yes Yes
IL-4 Yes No Limited No
FD-6 IL-3 Yes Yes Yes Yes
IL-4 Yes Yes Yes Yes
Insulin Yes Yes No No
MC-9 IL-3 Yes Yes Yes Yes
IL-4 Yes No ND ND
SCF Yes Yes ND ND
Insulin Yes No ND ND
GM-CSF Yes Yes ND ND
The effects of cytokine simulation of each cell line on PKB activation, Bad 
phosphorylation and the correlation of these events with survival and proliferation are 
summarised. This table highlights the finding that a definite and consistent correlation 




PI3K and its downstream effector PKB have been implicated in the generation of 
survival and proliferative signals in a number of cell types and in response to a variety 
of stimuli (Dudek et al., 1997; Kauffman-Zeh et al., 1997; Kennedy et al., 1997; 
Khwaja et al., 1997; Songyang et al., 1997). However, the question of whether PKB 
activation is absolutely required or necessary for the generation of a 
survival/proliferative signal had not been investigated. This issue was addressed by 
investigating cytokine-induced activation of PKB and whether this is sufficient for the 
continued growth and survival of cells. The results presented here show that an 
absolute correlation between PKB activation, cell survival and proliferation does not 
exist.
Cytokines are known to act as growth and survival factors for haemopoeitic cells 
(Metcalf, 1989). All the cytokines examined activated PKB in a PI3K-dependent 
manner, as this activation was sensitive to inhibition by LY294002 (Figures 3.11-3.14). 
However, not all the cytokines were able to induce a mobility shift in Bad due to hyper­
phosphorylation, and not all cytokines were sufficient to provide a survival and/or 
proliferative signal to the cells. In FD-6 cells, insulin was a potent activator of PKB, 
increasing the activity by up to 10-fold (Table 3.1). However, insulin was limited in its 
ability to promote the survival of these cells. In 72hr XTT assays insulin was unable to 
promote growth or survival of FD-6 cells (Figure 3.16A), and in viability assays, while 
insulin perhaps gave partial protection from apoptosis at 24 and 48hrs, by 72hrs it 
afforded no more protection than serum alone (Figure 3.16B). Contrasting with insulin, 
IL-4, which induced only 2-fold activation of PKB in this cell type (Table 3.1), was able 
to maintain the viability of FD-6 cells at 85% (Figure 3.16B) and induced their 
proliferation as measured in XTT assays (Figure 3.16A). This demonstrates that 
activation of PKB does not automatically lead to the generation of a survival signal.
One downstream effector of the PKB survival pathway is the pro-apoptotic member of 
the Bcl-2 family, Bad. Phosphorylation of Bad prevents its interaction with the anti- 
apoptotic family members Bcl-2 and B c1-X l allowing them to inhibit apoptosis. A 
number of serine phosphorylation sites have been identified on Bad and further 
investigations have identified the kinases that phsophorylate these sites: Ser112 is 
phosphorylated by MAPKAP-Kl (RSK) via the MAP kinase pathway (Bonni et al., 
1999), Ser136 is phosphorylated by PKB (Zha et al., 1996) and Ser155 by PKA (Lizcano
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et al., 2000). The separation of Bad on SDS-PAGE gels results in a doublet, the lower 
band consisting of both hypo- and un-phosphorylated protein and the upper of hyper- 
phosphorylated Bad (Zha et al., 1996). However, it is unclear how many sites on Bad 
need to be phosphorylated in order to see a band shift. This shift in migration was used 
to examine the phosphorylation status of BacJ in response to cytokine stimulation. In all 
cell types examined, IL-4 was able to activate PKB, yet this did not necessarily result in 
the hyper-phosphorylation of Bad. It had been previously reported that IL-4 was unable 
to promote the hyper-phosphorylation of Bad in MC-9 cells (Scheid and Duronio, 1998) 
and similar results were observed here in both MC9 (Figure 3.15A) and BaF/3 (Figure 
3.15C) cells. However, this may not be a universal phenomenon as cell-type differences 
were discovered. In FD-6 cells a consistent, but low level of Bad hyper­
phosphorylation was observed in response to IL-4 stimulation and phosphorylation of 
Ser112 could be detected (Figure 3.15B). Given that IL-4 is unable to induce the hyper­
phosphorylation of Bad in MC9 and BaF/3 cells this is a surprising result. IL-4 is able 
to promote the long-term survival and proliferation of FD-6 cells and while it does 
afford limited protection from death in BaF/3 cells (Figure 3.17) it is not sufficient to 
promote the long-term growth and survival of either BaF/3 or MC9 cells. One 
interpretation of this result is a requirement for Bad hyper-phosphorylation to drive the 
long-term survival and proliferation of cells. This hypothesis is supported by the 
finding that in BaF/3 cells, which are dependent on IL-3 for their continued growth and 
survival, IL-3 but not IL-4 or insulin was able to induce the hyper-phosphorylation of 
Bad (Figure 3.15C). However, insulin also promotes a low but consistently observed 
level of Bad phosphorylation in FD-6 cells (Figure 3.15B), yet it is unable to promote 
the growth or survival of these cells (Figure 3.16).
Bad is phosphorylated by PKB on Ser136 (Datta et al., 1997) but attempts to directly 
investigate the phosphorylation at this site using phospho-specific antibodies were 
unsuccessful. However, the cytokine-induced phosphorylation of Bad on Ser112 was 
examined in FD-6 and BaF/3 cells (Figure 3.15B and C). The kinase that 
phosphorylates Bad on Ser112 has recently been identified as MAPKAP-K1. Given that 
the immediate upstream regulators of MAPKAP-Kl, Erkl and 2, are not activated by 
IL-4 in the FD-6 parental cell line FDMAC11/4.5 (Welham et al., 1994b) it is surprising 
that we observed phosphorylation of Ser112 in response to IL-4 stimulation. However, a 
recent study found that the NEB phospho-Ser112 antibody also binds, albeit to a lesser 
extent, to phosphorylated Ser136 and Ser155 residues (Lizcano et al., 2000). Therefore
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phosphorylation of these residues may account for the “Ser112” phosphorylation 
observed in response to IL-4 stimulation of FD-6 cells.
In BaF/3 cells IL-3 was able to convert Bad to its hyper-phosphorylated form. This 
effect was partially inhibited by pre-treatment with LY294002 indicating that it is 
mediated at least in part through PI3K. In BaF/3 cells PI3K inhibition has been shown 
to inhibit both PKB (this study) and the MAPKAP-K1 regulators the Erk 1 and 2 
(Craddock et al., manuscript submitted). Thus, despite inhibition of two of the known 
Bad kinases, the IL-3 mediated hyper-phosphorylation is only partially blocked. It is 
unclear how many residues on Bad need to be phosphorylated in order to induce the 
shift in migration but as serine phosphorylated Bad migrates in the lower band along 
with un-phosphorylated protein (Zha et al., 1996) it would appear that more than one 
residue must be phosphorylated. This suggests that either other physiological kinases 
responsible for phosphorylation at Ser112 and Ser136 exist or there are additional serine 
phosphorylation sites on Bad. Recent work has suggested that Ser170 is also a site of 
phosphorylation on Bad (V. Duronio, personal communication) and phosphorylation of 
this site could contribute to the shift in migration observed in the absence of PI3K 
activity.
Insulin was the most potent activator of PKB in FD-6 cells (Figures 3.11-3.14) and it 
has also been shown to activate Erkl and Erk2 to its sister cell line FD-5 (Welham et 
al., 1995). In contrast, IL-4 induced a relatively weak activation of PKB in FD-6 cells 
and is unable to activate Erkl and Erk2 in the parental cell line FDMAC4.5/11 
(Welham et al., 1994b). Given this, it is surprising that insulin was not more effective 
than IL-4 at inducing the hyper-phosphorylation and especially the Ser112 
phosphorylation of Bad in FD-6 cells (Figure 3.15B). The strength of PKB activation 
observed and the fact that the activating MAPKAP-K1 kinases, Erkl and Erk2, are 
activated in response to insulin suggest that the activation of these kinases alone is not 
sufficient to promote the hyper-phosphorylation of Bad. Lizcano et al. (2000) reported 
that the phospho-specific Ser112 antibody used in these experiments also recognised 
phosphorylated Ser136 and Ser155 residues but with a lower affinity. Therefore it is 
unclear whether the insulin-induced “Ser112” phosphorylation observed is due to Ser112, 
Ser136 or Ser155 phosphorylation, although, phosphorylation at any of these serine 
residues lessens the affinity of Bad for Bcl-2 and B c1-X l (Zhou et al., 2000; Zha et al., 
1996). It would be interesting to examine which of these sites are phosphorylated in
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response to insulin and IL-4 stimulation to determine which pathways are important for 
the phosphorylation of Bad in these cells.
The apoptotic functions of the Bcl-2 family are thought to be regulated in part by the 
relative concentrations of pro- and anti-apoptotic members (Oltvai and Korsmeyer, 
1994). When Bad is phosphorylated it interacts with 14-3-3 proteins (Zha et al., 1996). 
This effectively removes Bad from the Bcl-2 family pool, thereby increasing the 
concentration of anti-apoptotic family members, which promote cell survival (Section 
1.3.2). In FD-6 cells, IL-3 was the most efficient factor at phosphorylating Bad. IL-4 
and insulin to a lesser extent were also able to induce Bad phosphorylation in this cell 
line. Given that the relative levels of Bcl-2 family members are thought to be the 
important factor governing their role in apoptosis, it is surprising that IL-4 despite 
inducing far less Bad hyper-phosphorylation that IL-3, is just as efficient at promoting 
the growth and survival of FD-6 cells. In contrast, insulin is unable to promote the 
growth and survival of FD-6 cells, yet the level of Bad phosphorylation induced by 
insulin is only marginally less than that induced by IL-4. It is difficult to determine 
what level of Bad phosphorylation is physiologically relevant to the survival of the cell 
and as the relative levels of Bcl-2 proteins seem to be important the effects of growth 
factor-stimulation on the expression and “activity” of the other Bcl-2 family members 
must be considered. As such, using gel-shifts to look at the hyper-phosphorylation of 
Bad can only give an indication of the general level of Bad phosphorylation. This does 
not automatically mean that the cell is receiving a survival signal.
A number of techniques could be used to investigate which site(s) on Bad are 
phosphorylated in response to cytokine stimulation and which of these are functionally 
relevant to cell survival. A phospho-peptide mapping technique could be used. Bad 
immunoprecipitates from cytokine treated and 32P labelled cells would be subjected to 
tryptic digestion and the products resolved in two dimensions by electrophoresis 
followed by ascending chromatography. This technique could be used to compare 
which phospho-peptides are produced by each cytokine. However, the identity of the 
phosphorylated residues would need to be determined by a phospho-amino acid analysis 
or a mass spectroscopic approach.
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Alternatively, a molecular approach could be taken, whereby the phosphorylation sites 
on Bad (ie. Ser112, Ser136, Ser155 and Ser170) are mutated in turn. These Bad variants 
could be transfected into cells and the cytokine-induced phosphorylation investigated 
either by looking at the incorporation of 32P, or by gel shifts. The advantage of using 
this system is that the effects of these Bad variants on cell survival could also be 
investigated.
The results presented in this chapter suggest that an absolute correlation between the 
PI3K mediated activation of PKB, Bad phosphorylation and cell survival do not exist. 
The activation of PKB did not necessarily result in Bad phosphorylation, nor did PKB 
activation and Bad phosphorylation necessarily result in the survival of the cells. These 
findings question the widely accepted dogma that the activation of PKB is necessary 
and sufficient for cell survival.
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Chapter 4
The Role of the PI3K/PKB Pathway in Proliferation
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4.1 Introduction
The results described in Chapter 3 demonstrated that all the cytokines tested activate 
PKB in responsive cell lines and that this activation is mediated through PI3K. The 
PI3K/PKB pathway has been widely implicated in the survival of many cell types 
(Dudek et al., 1997; Kennedy et al., 1997; Kauffman-Zeh et al., 1997; Songyang et al., 
1997; Datta et al., 1997). However, from the results presented in Chapter 3, it appears 
that there may be cell type specific differences in the requirement of PKB for the 
generation of a survival signal.
The fact that only a limited correlation between PKB activation, Bad phosphorylation 
and cellular survival was observed pointed to the possibility that these PI3K dependent 
events may be more important for pathways other than survival. The PI3K and PKB 
pathway has also been implicated in the regulation of cellular proliferation (Brennan et 
al., 1997; Ahmed et al., 1997; Craddock et al., 1999). Therefore the aim of this chapter 
was to examine the role that PI3K plays in the proliferation of FD-6 and BaF/3 cells and 
to determine if PKB is involved in this pathway.
To investigate the role of PI3K in proliferation, two approaches were used to inhibit 
PI3K activity. Firstly, the pharmacological PI3K inhibitor LY294002 was used to block 
PI3K activity in both FD-6 and BaF/3 cells and secondly, the role of PI3K in the IL-3- 
driven proliferation of BaF/3 cells was further examined using a stable BaF/3 cell line 
that inducibly expresses a dominant negative PI3K (Ap85) (Craddock et al., 1999). In 
order to identify the role, if any, that PKB plays in the IL-3-induced proliferation of 
BaF/3 cells, the PKB signalling pathway was reconstituted in these Ap85 cells by the 
expression of a constitutively active PKB variant (gagPKB). The tetracycline-regulated 
gene expression system was used to express both Ap85 and gagPKB because this 
system allows tight control over the expression of exogenous protein. Given the 
putative roles of PI3K and PKB in survival and proliferation, this was considered vital. 
These cell lines provide elegant models in which to study the effects of PI3K and PKB 
in IL-3 driven proliferation.
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4.2 The Effects of PI3K inhibition on cytokine induced proliferation
BaF/3 cells are dependent on IL-3 and FD-6 cells on either IL-3 or IL-4 for their 
continued growth and survival. In the previous chapter it was demonstrated that these 
factors activate PKB through PI3K in BaF/3 and FD-6 cells. PI3K and PKB have been 
implicated in both proliferation and survival in a number of cell types (Brennan et al., 
1997; Ahmed et al., 1997). However, the activation of PKB by specific cytokines in 
BaF/3 and FD-6 cells did not correlate with the long-term survival of these cell lines in 
all cases. To determine whether the PI3K/PKB pathway is involved in proliferation, the 
effect of PI3K inhibition on the proliferation of BaF/3 and FD-6 cells was examined. 
To measure proliferation, XTT dye-reduction assays were used. These assays measure 
the bio-reduction of XTT to its soluble coloured formazan product and are in effect a 
measure of the metabolic activity of the cell. The results obtained from XTT assays 
were previously found to closely mimic those obtained when DNA synthesis was 
examined by measuring H-thymidine incorporation (Craddock et al., 1999). Therefore, 
XTT assays can be used to measure the growth and proliferation of a population of 
cells.
4.3 Effect of LY294002 on the Proliferation of FD-6 Cells
PI3K was inhibited in FD-6 cells by concentrations of LY294002 and XTT assays 
were used to measure the IL-3 and IL-4-driven proliferation. Both the IL-3- (Figure
4.1 A) and IL-4- (Figure 4. IB) induced proliferation were inhibited in a dose-dependent 
manner by LY294002. IL-4 induced proliferation was more sensitive to PI3K inhibition 
than that of IL-3; LY294002 concentrations of less than 3pM did not significantly effect 
proliferation in response to IL-3, while IL-4-driven proliferation was inhibited by 
concentrations of LY294002 as low a lpM. These data demonstrate that PI3K is 
important for the IL-3- and IL-4-induced proliferation of FD-6 cells.
4.4 Effect of LY294002 on the Proliferation of BaF/3 Cells
The effect of PI3K inhibition by LY294002 on the IL-3-induced proliferation of BaF/3 
cells was measured using XTT assays. Figure 4.2 shows that the IL-3-induced 
proliferation of BaF/3 cells was inhibited in a dose-dependent manner by LY294002. 
This indicates that PI3K is needed for the IL-3-driven proliferation of BaF/3 cells.
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BaF/3 cells were washed free of factor and set up in triplicate with growth 
factor (at a starting concentration of 2ng/ml IL-3 (A) or lOng/ml IL-4 (B) 
with serial 1:2 dilutions across a 96 well plate), or serum alone as described 
in material and methods. The appropriate dose of LY294002 was added 
and after 72 hours the assays were developed. The mean values (n=3) with 
standard deviation are plotted.
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Figure 4.2
Effect of LY294002 on Proliferation of BaF/3 Cells
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BaF/3 cells were washed free of factor and set up in triplicate with IL-3 (at 
a starting concentration of 2ng/ml with serial 1:2 dilutions across a 96 well 
plate), or serum alone as described in material and methods. The 
appropriate dose of LY294002 was added and after 72 hours the assays 
were developed. The mean values (n=3) with standard deviation are 
plotted.
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4.5 Effect of PI3K inhibition on Apoptosis in BaF/3 Cells
XTT assays measure the net metabolic activity of a population of cells. A high reading 
can be obtained either from a population of cells that are metabolically active, a large 
population of cells or a combination of the two. Therefore, while XTT assays primarily 
measure the proliferation of a population of cells they can also be influenced by the rate 
of apoptosis in the given population. To confirm that the decrease in metabolic activity 
observed after PI3K inhibition by LY294002 is due to a decrease in proliferation rather 
than an increase in apoptosis, the effects of PI3K inhibition on apoptosis were 
examined. FACS analysis of cells stained with propidium iodide and annexin V was 
used to compare the number of cells undergoing apoptosis in the presence and absence 
of LY294002. Figure 4.3 compares the dot plots of BaF/3 cells at 24, 48 and 72 hours 
after PI3K inhibition by LY294002 (+ LY) with control cells (-LY). Cells undergoing 
apoptosis are stained by annexinV only and these are present in the lower right 
quadrant. PI3K inhibition with LY294002 did not increase the numbers of cell 
undergoing apoptosis. These results are consistent with the view that the decrease in 
metabolic activity observed in the presence of LY294002 is due to a decrease in 
proliferation and not an increase in apoptosis.
4.6 Dominant-Negative PI3K (Ap85)
In the above experiments PI3K activity was inhibited using LY294002, which is potent 
against most classes of PI3K. To investigate more specifically the role of class Ia PI3K 
in PKB activation and proliferation, BaF/3 cells that express a dominant negative class 
Ia  PI3K (Ap85) were used (Craddock et al., 1999). Class Ia  PI3Ks consist of a 
regulatory p85 subunit and catalytic p i 10 subunit (see Section 1.5.4). Ap85 lacks 
amino acid residues 479-513, which is the region of p85 that interacts with the pi 10a 
catalytic subunit. This prevents the interaction of Ap85 with p i 10. Ap85 acts as a 
dominant negative by competing with endogenous p85 subunits for binding through its 
SH2 domains to phosphorylated YXXM motifs on effector/receptor molecules. As 
Ap85 does not bind pllO , p i 10 is excluded from this activating complex and this 
prevents it from undergoing the conformational change, which results in the activation 
of its catalytic activity.
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Figure 4.3
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BaF/3 cells were set up at 104/ml either in the presence (+LY) or absencce (-LY) of 
lOpM LY294004. At the specified times, cells were washed and stained with 
annexinV and propidium iodide. Cells were analysed by flow cytometry and 10 
000 events were recorded.
4.7 The Tetracycline-Regulated Expression System
As the PI3K/PKB pathway has been implicated in the growth and survival of many 
cell types it was thought that the expression of dominant negative forms of these kinases 
could be lethal to the cell. Therefore, tight control over the expression of these proteins 
was considered vital. The tetracycline-regulated expression system allows the levels of 
expressed protein to be regulated by the addition or removal tetracycline (Gossen and 
Bujard, 1992). It is a two-vector system based on the repression rather than induction of 
expression. Systems that are based on repression remove the concern that any effects 
that are observed may be non-specific and caused by the addition of the drug that is 
used to induce gene expression (for example dexamethasone).
The two vectors used in the tetracycline-regulated gene expression system are the 
regulator plasmid (pUHD15-lpuro) and the response plasmid (pUHD10-3neo or hygro). 
The regulator plasmid encodes the tetracycline-sensitive transactivator, tTA. tTA is 
under the control of the CMV promoter/enhancer, and followed by the SV40 polyA 
signal. It contains a puromycin resistance marker for the selection of transfected cells 
(Mui et al., 1996). The response plasmid has a tTA-dependent promoter upstream of 
the multiple cloning site (MCS) where the gene of interest is inserted. Two forms of 
this plasmid were used in this study, one with a neomycin selective marker and one with 
a hygromycin selective marker. The two selection markers make it possible to create 
cell lines expressing two different mutant proteins. In this instance, it was used to 
express both Ap85 and gagPKB concurrently.
In this system, the presence of tetracycline represses the activity of the tetracycline- 
sensitive transactivator (tTA) and prevents it binding to the tTA-dependent promoter. 
This prevents the gene of interest on the response plasmid from being expressed. 
Removal of tetracycline allows tTA to bind the promoter in the response plasmid and 
drive expression of the cDNA of interest (Figure 4.4).
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Figure 4.4




















A tetracycline sensitive transactivator, tTA, is encoded by the regulator plasmid 
pUHD15-lpuro. In the presence of tetracycline, the tTA is inactive and so is prevented 
from binding to the tTA-dependent promoter of the response plasmid, pUHDlO- 
3neo/hygro, and the gene of interest is not expressed. Upon removal of tetracycline, 
tTA can bind to the promoter, resulting in expression of the gene.
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4.8 Effect of dominant-negative PI3K (Ap85) Expression on PKB phosphorylation
In BaF/3 cells, the IL-3-induced activation of PKB was significantly reduced by 
treatment with the PI3K inhibitor LY294002 (Figure 3.14). LY294002 is potent against 
all three classes of PI3K. Therefore, to specifically examine the role of class Ia PI3K in 
PKB activation the BaF/3(Ap85) cell line that was discussed in section 4.6 was used. In 
this cell line the dominant negative class Ia PI3K (Ap85) is inducibly expressed under 
the control of tetracycline (Craddock et al., 1999). The BaF/3(Ap85) clone, 1D8 was 
used in this work. Antibodies specific to both PKB-Thr308 and PKB-Ser473 were used to 
examine the activation of PKB. Phosphorylation of both these sites is required for the 
optimal activation of PKB (Alessi et al., 1996) and previous work showed that 
phosphorylation of Ser473 is a good indicator of the activity of PKB (Figures 3.1-3.14).
4.9 Dose response analysis of PKB Phosphorylation
In the presence of tetracycline (and therefore absence of Ap85) IL-3 induced the 
phosphorylation of PKB at both Ser473 and Thr308 in a dose responsive manner (Figure 
4.5). As with un-transfected BaF/3 cells, maximal phosphorylation was observed at 
lOng/ml IL-3. Expression of Ap85 dramatically reduced the IL-3-induced 
phosphorylation of both PKB-Ser473 and PKB-Thr308, indicating that classlA PI3Ks are 
involved in the IL-3-induced activation of PKB in BaF/3 cells. Although this 
experiment was only performed once personally, it reproduces work previously 
published by the laboratory (Craddock et al., 1999).
4.10 Kinetic analysis of PKB Phosphorylation
As expected from work on un-transformed BaF/3 cells (Figure 3.6), in the presence of 
tetracycline IL-3 phosphorylated PKB at both Ser473 and Thr308 with maximum 
phosphorylation observed at 5 minutes (Figure 4.6). Withdrawal of tetracycline and the 
subsequent expression of Ap85 significantly reduced the IL-3-induced phosphorylation 
of both sites. Although this experiment was only performed once personally, it 
reproduces work previously published by the laboratory (Craddock et al., 1999).
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Figure 4.5
Effect of Ap85 on PKB phosphorylation
Dose response analysis
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Cells were set up at 105/ml in the absence (- Tet) or presence (+ Tet) of 
tetracycline for 24hr prior to starving of IL-3 and serum for 4hrs. Cells were 
stimulated for 5 minutes with the indicated concentration of IL-3. Whole cell 
lysates (4xl05 cell equivalents) were separated be SDS PAGE on duplicate gels 
and immunblotted with (C) a-phospho-Ser473 or (B) a-phospho-Thr308. Blots 
were stripped and reprobed with (D) a-PKB, (A) a-phospho-tyrosine and (E) a- 
myc-tag. This experiment is a repeat of work published (Craddock et al. 1999).
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Figure 4.6




0 2 5 10 30 60 0 2 5 10 30 60 min
A 1 1—117 t a a - 9 7











Cells were set up at 105/ml in the absence (- Tet) or presence (+ Tet) of 
tetracycline for 24hr prior to starving of IL-3 and serum for 4hrs. Cells were 
stimulated with lOng/ml IL-3 for the indicated times. Whole cell lysates (4xl05 
cell equivalents) were separated be SDS PAGE on duplicate gels and 
immunblotted with (C) a- phospho-Ser473 or (B) a-phospho-Thr308. Blots were 
stripped and reprobed with (D) a-PKB, (A) a-phospho-tyrosine and (E) a-myc- 
tag. This experiment is a repeat of that published (Craddock et al. 1999).
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4.11 Effect of Ap85 Expression on PKB Activity
The above results (Figures 4.5 and 4.6) show that expression of the dominant negative 
PI3K, Ap85, inhibits the IL-3-induced phosphorylation of PKB at Ser4 7 3  and Thr308. 
These two sites are phosphorylated when PKB is activated and therefore the 
phosphorylation of these sites is used to estimate the activity of PKB. In vitro kinase 
assays were performed to confirm that the activity of PKB was decreased in response to 
Ap85 expression (Figure 4.7). In the presence of tetracycline (absence of Ap85) IL-3 
induced the activation of PKB but when tetracycline was removed, thus inducing the 
expression of Ap85, the IL-3-induced activation of PKB was inhibited. The removal of 
tetracycline had no effect on the activation of PKB in cells transfected with empty 
pUHD10-3 vector.
These data (Figures 4.5-4.7) confirm the results of the previous chapter (Figure 3.14) 
that demonstrate that the IL-3-induced activation of PKB in BaF/3 cells is mediated 
through PI3K. They identify class Ia PI3K as the isoform involved in this pathway.
4.12 Effect of Ap85 Expression on Proliferation
When PI3K was inhibited by LY294002 the IL-3-induced proliferation of BaF/3 cells 
was dramatically reduced (Figure 4.2). To investigate the effect of Ap85 expression on 
IL-3-induced proliferation of BaF/3 cells XTT assays were performed. Expression of 
Ap85 significantly reduced the proliferation in response to IL-3 (Figure 4.8A). The 
ED5 0  values both in the presence and absence of tetracycline remained at 0.03ng/ml 
indicating that only the maximum has changed and the shape of the curve remains the 
same. This data, together with that presented previously (Figures 4.1-4.3) illustrate the 
major role that PI3K plays in IL-3-driven proliferation.
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Figure 4.7
Effert of Ap85 Expression on PKB Activity
Ap85 Empty Vector
+ Tet - Tet + Tet - Tet
C IL-3 C IL-3 C IL-3 C IL-3
a-PKB -PKB
In vitro 
kinase assay mm m mm HH2B
Ap85 (clone 1D8) and empty vector clone were induced for 24 hours in 
the presence (+Tet) or absence (-Tet) of 2pg/ml tetracycline. Cells were 
washed free of serum and factor and starved for 1 hour prior to 
stimulation with lOng/ml IL-3 for 5 min. Cells were lysed (107 cell 
equivalents) and immunoprecipitated with a-PKB. In vitro kinase assays 
were performed using histone2B (H2B) as the substrate and the products 
separated by SDS-PAGE and transferred to nitrocellulose. The 
membranes were cut in half, the upper immunoblotted with a-PKB 
(upper panels) and the lower subjected to autoradiography (lower panels). 
This experiment is representative of 3 independent experiments.
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Figure 4.8
Effect o f Ap85 Expression on IL-3 induced Proliferation o f BaF/3 Cells
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BaF/3 cells expressing Ap85 were washed free of factor and tetracycline 
and set up in triplicate in the presence (+) or absence (-) of tetracycline with 
IL-3 (at a starting concentration of 2ng/ml with serial 1:2 dilutions across a 
96 well plate), or serum alone as described in materials and methods. After 
72 hours the assays were developed. The mean values (n=3) with standard 
deviation are plotted. This experiment is representative of 3 independent 
experiments.
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4.13 Expression of gagPKB in Ap85 expressing cells
PI3K can be thought of as a convergent point through which a number of signals from 
diverse origins pass on their way to a number of destinations. One such pathway travels 
through PKB but a number of other pathways and proteins are regulated by PI3K. To 
determine which effects of PI3K are mediated by PKB, a constitutively active mutant 
gagPKB (Burgering and Coffer, 1995) was expressed under the control of tetracycline 
in the Ap85 cell line. The cloning strategy employed is discussed in Section 5.3, but 
briefly, gagPKB was amplified by PCR from the plasmid pSG5(gagPKB) (see Table 
2.3) and ligated into pBSNmyc2 to create the in-frame fusion of the myc tag epitope. 
The myc-tagged gagPKB cDNA was cloned into the vector pUHD10-3hygro and 
transfected into the Ap85 cell line. Transformed cells were selected in hygromycin and 
72 resistant clones were screened for the inducible expression of gagPKB. Briefly, 
clones were induced over-night in the presence or absence of tetracycline, and total cell 
extracts immuno-blotted with anti-myc-tag and anti-PKB. An example of a screening 
blot is shown in Figure 4.9. Three clones, 1D12, 2C4 and 2D4, which were over­
expressing gagPKB and tightly regulated by tetracycline were chosen for further 
analysis (Figure 4.10).
4.14 Effect of Ap85 and gagPKB expression on PKB phosphorylation
When Ap85 is expressed in BaF/3 cells the IL-3-induced proliferation and the IL-3- 
induced phosphorylation of endogenous PKB are dramatically decreased (Figures 4.5,
4.6 and 4.7). The main objective for creating the Ap85/gagPKB cell line was to re­
introduce a signalling PKB to determine what effects of PI3K are mediated through 
PKB. However, before this could be examined, we first needed to ensure that gagPKB 
was active and to examine the effects of gagPKB expression on endogenous PKB. To 
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This is an example of a screening blot. Clones were induced for 24 hours in the 
presence (+) or absence (-) of 2pg/ml tetracycline at a density of lx l05/ml. Whole 
cell lysates were separated by SDS PAGE and immunoblotted with 9E10 antibody 
(a-myc, upper panel) which recognises the N-terminal myc tag. This gel was 
stripped and reprobed with a-PKB (lower panel).
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Figure 4.10












Clones (1D12, 2C4 and 2D4) were grown for 24 hours in the presence (+) or 
absence (-) of 2pg/ml tetracycline at a density of lx l05/ml. Whole cell lysates were 
separated by SDS PAGE and immunoblotted with 9E10 antibody (a-myc, upper 
panels) which recognises myc tag. These were stripped and reprobed with a-PKB 
(lower panels).
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4.15 Dose-response analysis of PKB Phosphorylation
In the presence of tetracycline, IL-3 induced the phosphorylation of PKB at both Ser473 
and Thr308 in a dose-responsive manner with maximal phosphorylation at lOng/ml IL-3. 
This correlates with the maximal phosphorylation observed in untransfected BaF/3 cells 
(Figure 3.10). The removal of tetracycline and subsequent expression of Ap85 and
<JA O
gagPKB led to a decrease in the phosphorylation of endogenous PKB at both Thr and 
Ser473 (Figure 4.11). However, when the level of phosphorylation in the presence of 
both gagPKB and Ap85 are compared to the level seen when Ap85 only is expressed, 
there is a significant increase in phosphorylation of endogenous PKB (Figure 4.5 and 
4.10). A high level of basal gagPKB phosphorylation at Ser473 was observed and this 
phosphorylation was increased by stimulation with IL-3.
4.16 Kinetic analysis of PKB Phosphorylation
When the expression of Ap85 and gagPKB was repressed by the presence of 
tetracycline IL-3 stimulated the phosphorylation of Ser473 and Thr308, with maximal 
phosphorylation observed at 5-10 minutes (Figure 4.12). In the absence of tetracycline 
when Ap85 and gagPKB were expressed, the IL-3-induced phosphorylation of 
endogenous PKB was reduced. However, as seen in the dose-response analysis (Figure 
4.8), levels of PKB phosphorylation are increased when compared to those seen when 
Ap85 only is expressed (Figures 4.6 and 4.11). The level of basal gagPKB Thr308 
phosphorylation is lower than that seen in the dose response analysis, the reason for this 
is unclear. However, gagPKB phosphorylation at both Ser473 and Thr308 is increased by 
treatment with IL-3.
Phosphorylation at Thr308 and Ser473 are required for maximum activation of PKB. In 
addition to this, results in the previous chapter found a strong correlation between 
phosphorylation at Ser473 and PKB activity. This evidence provides support to the 
theory that gagPKB is constitutively active and acts in a dominant positive manner. 
Additionally, in vitro kinase assays indicate that gagPKB that is expressed alone in 
BaF/3 cells has a low basal level of activity (Figure 5.3). The expression of gagPKB 
also restores the phosphorylation, and presumably, the activity of endogenous PKB. 
Therefore, the Ap85/gagPKB cell line provides us with a system whereby PI3K 
pathways have been inhibited but PKB mediated pathways have been reinstated. This 
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Cells were set up at 105/ml in the absence (- Tet) or presence (+ Tet) of 
tetracycline for 24hr prior to starving of IL-3 and serum for 4hrs. Cells were 
stimulated for 5 minutes with the indicated concentration of IL-3. Whole cell 
lysates (4xl05 cell equivalents) were separated by SDS PAGE on duplicate gels 
and immunblotted with a-phospho-Ser473 (C) or a-phospho-Thr308 (B). Blots 
were stripped and reprobed with a-PKB (C), a-phospho-tyrosine (A) and a- 
myc-tag (E). This experiment is representative of 3 independent experiments.
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Figure 4.12





















Cells were set up at 105/ml in the absence (- Tet) or presence (+ Tet) of 
tetracycline for 24hr prior to starving of IL-3 and serum for 4hrs. Cells were 
stimulated with lOng/ml IL-3 for the indicated times. Whole cell lysates (4xl05 
cell equivalents) were separated be SDS PAGE on duplicate gels and 
immunblotted with a- phospho-Ser473 (C) or a-phospho-Thr308 (B). Blots were 
stripped and reprobed with a-PKB (D), a-phospho-tyrosine (A) and a-myc-tag 
(E). This experiment is a representative of 3 independent experiments.
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4.17 Effect of Ap85 and gagPKB expression on proliferation
The major effect of PI3K inhibition in BaF/3 cells was a reduction in IL-3-induced 
proliferation (Figures 4.2 and 4.7). Given that PKB is activated through PI3K and that 
PKB is reported to play a role in proliferation in IL-2 signalling (Brennan et al., 1997; 
Ahmed et al., 1997) it was interesting to see if expression of gagPKB was sufficient to 
overcome the inhibitory effect of Ap85 expression on proliferation (Figure 4.8). XTT 
dye-reduction assays showed that gagPKB expression was unable to restore the IL-3- 
induced proliferation of BaF/3 Ap85 (1D8) cells to the levels observed in the absence of 
Ap85 (Figure 4.13). ED5o values in the presence and absence of tetracycline were
0.2ng/ml and 0.4ng/ml IL-3 respectively.
These data demonstrate that PKB is not required for the PI3K-mediated proliferation 
of BaF/3 cells, indicating that either another pathway downstream of PI3K is involved 
or that the gagPKB construct used is unable to reconstitute the PKB signal which is 
inhibited in Ap85 cells.
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Figure 4.13
Effect of Ap85 and gagPKB Expression on IL-3-Induced
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BaF/3/Ap85 cells expressing gagPKB, (A) clone 1D12 and (B) clone 2C4, were 
washed free of factor and tetracycline and set up in triplicate in the presence (+) or 
absence (-) of tetracycline with IL-3 (at a starting concentration of 2ng/ml with 
serial 1:2 dilutions across a 96 well plate), or serum alone as described in materials 
and methods. After 72 hours the assays were developed. The mean values (n=3) 
with standard deviation are plotted. Insert: At the same time that the XTT assays 
were set up, cells were grown +/- tetracycline for 72 hours. Cells extracts were 
separated by SDS-PAGE and immunoblotted with a-PKB to see protein expression. 
This experiment is representative of 3 independent experiments.
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4.18 Discussion
The experiments presented in this chapter used the tetracycline-regulated inducible 
gene expression system to express a dominant negative PI3K and a constitutively active 
PKB mutant in BaF/3 cells. The major effect of PI3K inhibition observed in these cells 
was an inhibition of the IL-3-mediated proliferation (Figure 4.1,4.2 and 4.7). Attempts 
to reverse the negative effect of PI3K inhibition on proliferation by reconstituting the 
PKB signal in these cells proved unsuccessful (Figure 4.13). This suggests that either 
PKB is not involved in the PI3K mediated proliferative pathway or the PKB mutant 
used is unable to successfully reconstitute the PKB signalling pathway.
The PKB mutant used in this study is based on the oncogenic v-Akt, which is made up 
of a gag fusion (consisting of p i2, p i 5 and a truncated p30), a 21 amino acid region of 
cellular PKB untranslated sequence and cellular PKB (Bellacosa et al., 1991). v-Akt is 
myristylated at its N-terminal glycine and this is thought to target it to the cellular 
membrane, where presumably it is constitutively phosphorylated and active (Ahmed et 
al., 1993). Indeed, v-Akt has a cellular distribution of 40% plasma membranes 30% 
nuclear and 30% cytosolic, while PKB is 90% cytosolic (Ahmed et al., 1993). The 
gagPKB used in this and other studies (Burgering and Coffer, 1995) was constructed by 
fusing a MoMuLV cDNA fragment encoding the gag proteins to the N-terminus of 
PKB. It is presumed that this fusion protein is processed to give a myristylated N- 
terminal glycine residue that targets it to the plasma membrane. However, the gagPKB 
construct used in this study has a myc tag attached to its N-terminus to aid in the 
detection of the mutated protein. Therefore, the myc-gagPKB does not have an N- 
terminal glycine residue, which is required for myristolation. Cellular distribution 
studies of the myc-tagged gagPKB show that only 5% is located at the membrane in 
unstimulated cells (C. Beck and M.J. Welham, unpublished data). However, in 
unstimulated BaF/3 cells when co-expressed with Ap85, gagPKB is phosphorylated on 
both Ser473 and Thr308 (Figures 4.11 and 4.12). Phosphorylation at both of these sites is 
required for maximal activation of PKB and work in the previous chapter (Figures 3.1- 
3.15) showed that the phosphorylation of Ser473 correlates with the activity of PKB. 
This suggests that despite not being targeted to the membrane at high levels, gagPKB is 
active in unstimulated Ap85 expressing cells. These data suggest that either membrane 
association is not important for the phosphorylation of gagPKB in the absence of PI3K 
activity or gagPKB associates transiently with the membrane resulting in its 
phosphorylation.
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In the viral life cycle gag proteins are involved in directing the budding process as well 
as being structural components of the virion. Gag mutants that are not myristylated are 
defective at both processes and this is thought to be due to decreased membrane 
association (Shultze and Rein, 1989). However, some gag proteins are not myristylated 
(ERDIE, Wills, 1990) and myristic acid on its own does not provide enough binding 
energy to anchor proteins to the lipid bilayer (Mclaughlin and Aderem, 1995). While 
the membrane association of gag mutants that are defective at mysitolation is decreased 
it is not completely abolished (Huang and Jolicoeur, 1994). It is thought that amino 
acid residues close to N-terminus also play a role in anchoring gag proteins to 
membrane (Verderame et al., 1996; Zhou et al., 1994). Therefore, it is possible that the 
gag fusion enables gagPKB to associate with membranes in a transient manner resulting 
in its phosphorylation at Ser4 7 3  and Thr3 0 8  even in the absence of myristolation. 
Alternatively, membrane association may be less important for the phosphorylation of 
PKB in the absence of PI3K activity. PDK-1 is constitutively active and exists in the 
cytosol in unstimulated cells (Alessi et al., 1997; Pullen et al., 1998; Anderson et al., 
1998; Casamayor et al., 1999). Increased levels of PIP3  are believed to target PDK-1 to 
the membrane where it interacts and phosphorylates PKB on Thr308. In the absence of 
PIP3 , and when gagPKB is over-expressed, membrane targeting may not be required for 
the interaction of PKB and PDK-1 and the subsequent phosphorylation.
The activity of the gagPKB mutant could be confirmed by a number of methods. 
Firstly, the effect of its expression on the activity/phosphorylation of downstream 
targets of PKB could be examined. For instance, the activation of GSK3a and p, or the 
phosphorylation of Bad on Ser1 3 6  could be examined. Another method would be to look 
at the ability of the gagPKB construct to transform cell lines. v-Akt was identified as an 
oncogene, and therefore one would expect that an active gagPKB mutant should also act 
as an oncogene. This could be tested by transfecting 3T3 fibroblast cells with the 
gagPKB construct to see how many cells are transformed, as judged by morphological 
changes. Alternatively, retroviral transformation could be used in which case we would 
expect a high proportion of cells to be transformed.
Expression of Ap85 in BaF/3 cells resulted in a marked reduction in the IL-3-induced 
phosphorylation and activation of PKB (Figures 4.5-4.7). When gagPKB is also 
expressed in these cells the Ap85-induced inhibition of endogenous PKB 
phosphorylation is partially reversed, particularly in respect to Ser4 7 3  (Figures 4.10 and 
4.11). Datta et al. (1995) and Franke et al. (1997) reported that PKB can form
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oligomers through the interaction of their PH domains. This could explain the increased 
phosphorylation of endogenous PKB that we observed when gagPKB was expressed in 
BaF/3/Ap85 cells. The formation of a gagPKB -endogenous PKB oligomer in these cells 
would allow the endogenous PKB to associate with the membrane in the absence of 
PIP3. This would allow the phosphorylation and activation of endogenous PKB by the 
same mechanism that activates membrane targeted PKB mutants.
A major effect of PI3K inhibition observed in BaF/3 cells was the inhibition of IL-3- 
induced proliferation (Figures 4.2 and 4.5). To examine the role of PKB in this 
PI3K/proliferative pathway a constitutively active PKB mutant was transfected into 
BaF/3/Ap85 cells (Figures 4.6 and 4.7). This gagPKB mutant was shown to be 
phsophorylated on Ser473 and Thr308 even in the absence of IL-3 (Figures 4.11 and 4.12). 
Phosphorylation at both these sites is required for the maximal activtation of PKB and 
therefore can be used as an indication of PKB activity. In addition, gagPKB was shown 
to have a low basal level of activity when transfected alone into BaF/3 cells (Figure 
5.3). These data suggest that gagPKB is constitutively active in this BaF/3/Ap85 cell 
line. However, the re-introduction of an active PKB (gagPKB) into this PI3K 
compromised cell line did not reverse the proliferative defect (Figure 4.13). This 
suggests that either PKB is not involved in the IL-3-induced proliferation of BaF/3 
cells, or that gagPKB is unable to functionally couple to the downstream effectors of 
this pathway.
A number of PKB substrates exist primarily in the cytosol or nucleus and this raises 
the concern that membrane bound PKB, while being constitutively active, may be 
unable to couple to physiologically relevant substrates at other locations. The gagPKB 
mutant used in this work is not always at membrane. Therefore, it should be free to 
interact with substrates at locations other than the membrane. However, the possibility 
that the myc-gag fusion causes conformational changes that prevent the association of 
this mutant with its substrates cannot be ruled out.
If we accept that the gagPKB mutant is able to restore signalling from PKB, then the 
results in Figure 4.13 indicate that PKB is not involved in the IL-3-induced, PI3K 
mediated proliferation of BaF/3 cells. Therefore, other PI3K mediated pathways must 
be involved. Two additional pathways that have been implicated in proliferation and 
are regulated by PI3K are the MAPK pathway (Cross et al., 1994; Ferby et al., 1994) 
and the p70S6 kinase pathway (Weng et al., 1995). Recent work in this laboratory has 
found that the activation of the MAP kinases, Erkl and Erk2, is inhibited by the
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expression of Ap85 and that the Mek inhibitor PD98059 reduced the IL-3-induced 
proliferation of BaF/3 cells (Craddock et al., in press). This suggests that the PI3K and 
Mek mediated activation of Erkl and Erk2 may be involved in the IL-3-driven 
proliferation of BaF/3 cells. However, the combination of PD98059 and Ap85 
expression further reduced the IL-3-driven proliferation, which suggests that other PI3K 
mediated pathways are also involved. There is some evidence to suggest that PI3K may 
be modulating the levels and function of cell cycle regulators. In BaF/3 cells, treatment 
with LY294002 resulted in a decrease in phosphorylation of the pocket proteins p i07, 
p i30 and pRB, in addition to a decrease in overall cyclinD3 levels (B. Fox and M.J. 
Welham, unpublished data).
The PKB/PI3K pathway has been widely implicated in the control of apoptosis 
(reviewed in Coffer and Woodgett, 1998; Datta et al., 1999, Vanhaesebroeck and 
Alessi, 2000). However, the inhibition of PI3K by LY294002 and the subsequent 
inhibition of PKB did not significantly affect the number of BaF/3 cells undergoing 
apoptosis (Figure 4.3). This result correlates with previous work where Ap85 
expression in BaF/3 cells resulted in only a 3% increase in apoptosis (Craddock et al., 
1999). One downstream effector of PKB in the apoptotic pathway is the Bcl-2 family 
member Bad. PKB is reported to phosphorylate Bad on Ser136, which decreases its 
interaction with Bcl-2, with the net effect of decreasing apoptosis (Datta et al., 1997). 
Bad is also serine phosphorylated at other sites, and its hyper-phosphorylation results in 
a shift in its migration on SDS PAGE. The results presented in Figure 3.15C showed 
that pre-treatment of BaF/3 cells with LY294002 completely inhibited the shift in Bad 
migration indicating that it is not hyper-phosphorylated, nor is it phosphorylated at
i n  t 9 #
Ser . Migration shifts only give an indication of the overall level of phosphorylation 
as both phosphorylated and unphosphorylated Bad migrate in the lower band (Zha et al., 
1996). However, in the presence of LY294002, PKB activation (Figure 3.14) and Bad 
hyper-phosphorylation (Figure 3.15C) were inhibited, yet apoptosis was not increased 
(Figure 4.3). This suggests that in IL-3-dependent BaF/3 cells the PI3K/PKB/Bad 
pathway is not necessary to provide a survival signal.
The effect of gagPKB expression on Bad phosphorylation in the BaF/3Ap85 cells was 
not examined. Scheid et al. (1999) have reported that the PKB phosphorylation site on 
Bad, Ser136, was not phosphorylated in response to GM-CSF in MC9 cells. This 
suggests that this site is not physiologically relevant to GM-CSF signalling. As IL-3 
and GM-CSF share the pc receptor subunit and many signalling pathways, it would be
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interesting to investigate the phosphorylation status of Bad in the Ap85/gagPKB cells. 
As LY294002 treatment or Ap85 expression was sufficient to inhibit the hyper­
phosphorylation of Bad, it would be interesting to investigate the effects of gagPKB 
expression, when PI3K is inhibited, on the phosphorylation of Bad.
The Ap85/gagPKB cell line generated in this work provides an ideal cell model, in 
which to specifically investigate the PI3K dependent pathways that are mediated 
through PKB. Many studies in the past have looked at the correlation between PKB 
inhibition by PI3K inhibitors or dominant negative PI3K variants, and downstream 
effects. However, this approach does not distinguish between PKB mediated events and 
those that are mediated by other targets of PI3K. Therefore it would be interesting to 
look at the effects of PI3K inhibition coupled with a constitutively active PKB variant 
on PKB substrates, for example GSK3 and the forkhead proteins.
The results presented in this chapter used both pharmacological inhibitors and a 
dominant negative PI3K to demonstrate that PI3K plays an important role in the IL-3 
mediated proliferation of BaF/3 cells. The role of the downstream effector of PI3K, 
PKB in IL-3-driven proliferation was also examined. By expressing a constitutively 
active PKB variant, which is not dependent on PI3K for its activity, in Ap85 cells, we 
were able to reconstitute PKB signalling pathways and demonstrate that PKB is not 
sufficient to overcome the loss of PI3K and restore normal proliferation.
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Chapter 5
The Effects of PKB Variants Expression on IL-3 Signalling
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5.1 Introduction
The overall aim of this project was to investigate the role of PKB in cytokine 
signalling in haemopoietic cells. The early stages of this work (see chapter 3) found 
that all the cytokines tested were able to induce the activation of PKB in the cytokine 
dependent cell lines examined (BaF/3, FD-6 and MC9). The activation of PKB was 
found to be dependent on the integrity of PI3K signalling pathways as the inhibition of 
PI3K significantly reduced the cytokine-induced activation of PKB. At the time of this 
work PKB was widely reported to be involved in the control of apoptosis (see Coffer 
and Woodgett, 1998; Datta et al., 1999; Vanhaesebroeck and Alessi, 2000 for a review). 
However, when the activation of PKB was compared with the phosphorylation of Bad 
and the ability of a particular cytokine to maintain the viability of these cell lines a 
definite correlation was not found (Chapter 3). These data raised questions about the 
role that PKB plays in the prevention of apoptosis in these cell lines.
The experiments performed in Chapter 3 used the PI3K inhibitor LY294002 to inhibit 
PKB activity and did not directly examine the effects of PKB inhibition. PI3K regulates 
many pathways and it is possible that the inhibition of these other pathways masked the 
effects of PKB inhibition. As there are no specific pharmacological inhibitors of PKB 
available, PKB mutants were used to specifically investigate the role of PKB in 
cytokine signalling.
The tetracycline-regulated gene expression system (section 4.7) was used to express 
PKB variants in BaF/3 cells. This system was chosen because it allows the expression 
of mutant proteins to be tightly regulated. This was deemed important as PKB is 
reputed to be involved in apoptosis and proliferation, therefore interruption of this 
pathway could be lethal to the cells resulting in the inability to derive transfectants. A 
number of PKB mutants were chosen for this study. They were:
• gagPKB -  reputed to be a dominant positive PKB mutant, which was modelled on 
the constitutively active akt oncogene product (Burgering and Coffer, 1995).
• cxPKB -  reputed to be a dominant negative PKB mutant that is membrane bound by 
a C-terminal Ki ras caax sequence (van Weeren et al., 1998).
• kdPKB -  reputed to be a dominant negative PKB mutant that is rendered kinase 
inactive by the point mutation K-A179 in the active site (Burgering and Coffer, 
1995).
• wtPKB - wild-type PKB (Burgering and Coffer, 1995).
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5.2 The Effects of PKB Variants on IL-3 Signalling
By expressing these PKB variants in BaF/3 cells we hoped to create model cell 
systems in which PKB activity and signalling was either specifically inhibited or 
independent of IL-3 stimulation. The gagPKB mutant, which is modelled on v-Akt, was 
chosen for its dominant positive effects. This oncogenic form of PKB is rendered 
constitutively active by the translocation of a viral gag protein to its N-terminus. This 
targets the v-Akt to the cell membrane where it is maintained in a constitutively 
phosphorylated and active state. The gagPKB mutant used in these studies is 
homologous to v-Akt and has been shown to act in a dominant positive manner when 
transiently transfected in Rati cells (Burgering and Coffer, 1995).
To inhibit PKB mediated pathways two putative dominant negative variants were used. 
The first was a kdPKB that is rendered catalytically inactive by the point mutation of 
Lys179 to Ala in the active pocket of the kinase domain and was reported to have a 
dominant negative effect on endogenous PKB in a number of cell systems (Datta et al., 
1997; Kulik and Weber, 1998; Takata et al., 1999). However, in other systems it does 
not act as a dominant negative (Burgering and Coffer, 1995). Therefore, the 
effectiveness of kdPKB at inhibiting endogenous PKB activation appears to be 
dependent on the system used. Because of the apparent variability in the effects of 
kdPKB between systems a second putative dominant negative mutant (cxPKB) was also 
expressed in BaF/3 cells. This mutant was originally constructed to be a dominant 
positive PKB but when it was expressed it was found to act in a dominant negative 
manner. cxPKB is targeted to the cell membrane via a C-terminal caax sequence 
(KMSKDGKKKKKKSKTKCVIM) from YA-ras (van Weeren et al., 1998). The -aax 
motif (see underlined, a = aliphatic, x = any amino acid) is removed to give a C- 
terminal cysteine residue. This residue undergoes methylesterification, which helps to 
target it to the membrane. However, this processing alone is not sufficient for 
membrane association and the poly-basic charge of the 6 consecutive lysine residues is 
also required for efficient membrane association (Hancock et al., 1990). It was thought 
that by targeting cxPKB to the membrane this would render it constitutively 
phosphorylated and therefore activated. However, this was not the case and cxPKB was 
found to act in a dominant negative manner (van Weeren et al., 1998). The reason for 
this is not clear, but it may be that both the N- and C- termini of cxPKB can interact 
with the membrane. This may cause a conformational change that could prevent 
cxPKB’s activation by phosphorylation, interrupt the active site or prevent substrate 
access.
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The final PKB variant used in these studies was the wild-type PKB. This mutant was 
identical to cellular PKB with the exception of an N-terminal myc tag and being under 
the control of tetracycline. wtPKB was included primarily as a control, and while it was 
expected that over-expression of this protein would have effects on PKB signalling, it 
would always be dependent on IL-3 for activity.
5.3 Construction of pUHD10-3hygro Expression Vectors.
The plasmids expressing the PKB variants that were used for the construction of 
pUHD10-3hygro vectors were a kind gift from Boudewijn M. Th. Burgering 
(Laboratory for Physiological Chemistry, Utrecht University, Universiteitsweg 100, 
3584 CG Utrecht, The Netherlands) and are listed in Table 2.3. A two-step strategy was 
used for the construction of the expression vectors and is outlined in Figure 5.1. The 
gene of interest was amplified from the original pSG5 plasmid by PCR. The primers 
(which are listed in Table 2.2) contained BamHI restriction sites to create a restriction 
site at each end of the PCR fragment. The PCR fragment containing the PKB mutant 
was restriction digested with BamHI and ligated into the vector pSSBS.myc2. This 
generated an in-frame fusion of two tandem copies of the 10 amino acid myc epitope 
tag to the N-terminus of the PKB mutants. Myc tag epitopes are recognised by the 
9E10 antibody. Colonies were screened for vectors containing the PKB inserts in the 
correct orientation. myc-PKB fragments were digested with Sail, blunt-ended by 
klenow treatment and ligated into Xbal digested and klenow treated pUHD10-3hygro.
5.4 Expression of PKB Mutants in BaF/3 Cells.
Each of the PKB mutants (gagPKB, cxPKB, kdPKB and wtPKB) were transfected into 
BaF/3 cells that had been stably transfected with the regulator plasmid pUHD15-l (Mui 
et al., 1995). Transformed cells were selected in hygromycin and at least 72 resistant 
clones for each PKB mutant were screened in the presence and absence of tetracycline 
for exogenous PKB expression. Three clones for each mutation, which over-expressed 
the exogenous protein and had low levels of expression in the presence of tetracycline, 
were chosen for further analysis. These clones are shown in Figure 5.2.
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Figure 5.1
Cloning of PKB Variants into pUHD10-3
BamHI, .BamHI 42SG5xPKB
1. PCR xPKB fragment from pSG5xPKB
2. Digest with BamHI
3. Ligate into BamHI digested pSSBSmyc2
4. Check orientation of myc-xPKB fragment
5. Cut out Sail fragment
xPKlT g— Sail
1. Blunt ends generated by klenow treatment
2. Ligated into Xbal digested, 
klenow treated pUHD10-3
3. Check orientation of xPKB construct
PhCMV
/Xbal





The cloning steps involved in the construction of the pUHD10-3 expression 
vectors are outlined above. The same strategy was taken with each PKB variant 
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(A) gagPKB clones, (B) kdPKB clones, (C) cxPKB clones and (D) wtPKB clones 
were grown for 24 hours in the presence (+) or absence (-) of 2pg/ml tetracycline at 
a density of approximately lx l05/ml. Whole cell lysates were separated by SDS 
PAGE and immunoblotted with 9E10 antibody (a-myc, upper panel) which 
recognises myc tag. These were stripped and reprobed with a-PKB (lower panels).
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5.5 Activity of PKB Mutants
To examine the activity of each PKB mutant, clones were either stimulated with IL-3 
or left untreated. Exogenous PKB was immunoprecipitated with 9E10 antibody that 
recognises the N-terminal myc tag of each mutant and their ability to catalyse the 
phosphorylation of histone2B was examined by in vitro kinase assays (Figure 5.3). 
kdPKB was inactive both before and after stimulation with IL-3 indicating that, as 
expected, it is kinase inactive. The activity of both wtPKB and gagPKB was 
dramatically increased by treatment with IL-3. However, when the level of basal 
activity of the wtPKB and gagPKB are compared, the level of gagPKB activation is 
significantly higher, reflecting a high level of constitutive kinase activity that is 
increased upon IL-3 stimulation. The activation of cxPKB was constitutively high and 
independent of IL-3 stimulation, which was surprising given that van Weeren et al. 
(1998) found that the activity of cxPKB was comparable to that of unstimulated wtPKB 
in both unstimulated and insulin stimulated A14 cells. cxPKB is reputed to work in a 
dominant negative manner but the mechanism is not understood. One theory is that the 
caax domain anchors cxPKB to the membrane by its C-terminus while the PH domain 
targets the N-terminal domain to the membrane. This is thought to cause a 
conformational change in the enzyme thereby preventing its kinase activity. Before 
immunoprecipitation, cells are lysed interrupting the cell membrane structure and 
proteins are released from the membrane. It is feasible that this process allows cxPKB 
to regain its kinase activity, as it is no longer tethered to the membrane at both the C- 
and N-termini. This could explain the constitutive activation of cxPKB seen in in vitro 
kinase assays (Figure 5.3).
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Figure 5.3
Activity of PKB Variants in BaF/3 Cells
gagPKB kdPKB cxPKB wtPKB 
C 3 C 3 C 3 C 3
—H2B
The expression of PKB variants was induced for 24 hours by the removal of 
tetracycline. Cells were starved of serum and factor for 1 hour before 
stimulation for 10 minutes with lOng/ml IL-3 (3) or left unstimulated (C). 
PKB variants were immunoprecipitated with 9E10 and in vitro kinase 
assays performed using histone2B (H2B) as the substrate. These were 
separated by SDS PAGE, transferred to nitrocellulose and subjected to 
autoradiography. This experiment is representative of 3 independent 
experiments.
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5.6 The Effects of PKB Variants on PKB Phosphorylation
Having examined the activity of each of the PKB variants, it was then important to 
investigate the effects their expression was having on endogenous PKB activity. To do 
this the phosphorylation of endogenous PKB at Ser473 and Thr308 was examined, as 
results from in vitro kinase assays would be masked by the activity of the exogenous 
protein. Phosphorylation at both of these sites is required for the maximal activation of 
PKB (Alessi et al., 1996) and previous work found that the phosphorylation of Ser473 
closely mimicked the activity of PKB (Figures 3.1-3.5). Initially, the activation of 
endogenous PKB was examined in one clone for each PKB variant.
The gagPKB construct used in these experiments was modelled on the oncogenic v- 
Akt. It had been reported to be constitutively active and by analogy to v-Akt, it was 
thought that this was due to its constitutive phosphorylation. The effects of gagPKB 
expression on endogenous PKB were largely unknown, but it was not expected that it 
would have a marked effect on endogenous PKB activity. However, the expression of 
gagPKB in BaF/3/Ap85 cells was able to partially reverse the inhibitory effect of Ap85 
expression on the phosphorylation of endogenous PKB (compare Figures 4.5 and 4.6 
with Figures 4.11 and 4.12). This was a surprising result and suggests that in addition 
to being constitutively active, gagPKB may be acting as a dominant positive by 
increasing the activity of endogenous PKB.
To investigate the effects of gagPKB expression alone on PKB activation in BaF/3 
cells, the phosphorylation of both Ser473 and Thr308 were examined in clone 1C10 
(Figure 5.4). In the presence of tetracycline, when the expression of gagPKB is 
repressed, IL-3 induced the phosphorylation of endogenous PKB on both Ser473 and
308Thr in a dose responsive manner. However, the expression of gagPKB alone does 
not increase the phosphorylation of endogenous PKB as was observed when gagPKB 
was expressed in BaF/3/Ap85 cells (Figure 4.10).
The phosphorylation of gagPKB on Ser473 and Thr308 is also induced by IL-3 
stimulation. However, no basal phosphorylation of gagPKB is detected. Again this is 
in contrast to results seen when both Ap85 and gagPKB are expressed (Figure 4.10) and 
to the results of gagPKB in vitro kinase assays (Figure 5.3), which showed a 
constitutive level of activation. The reasons for this are not clear but it should be noted 
that the level of exogenous gagPKB expression in this experiment is not as high as that 
seen in Figure 4.10. Alessi and colleagues recently reported that basal Ser473 
phosphorylation is markedly increased in PDK-1 -/- ES cells (Williams et al., 2000).
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Thus, inhibition of the PI3K/PDK-1 pathway may act to increase Ser473 
phosphorylation.
Both kdPKB and cxPKB have been reported to have a dominant negative effect on 
PKB. Therefore, we would expect that expression of these mutants would inhibit the
AQ___________________ _ _
phosphorylation of both Ser and Thr on endogenous PKB. Figure 5.5 shows the 
effect of kdPKB expression on the phosphorylation of PKB in clone D12. In the 
absence of tetracycline when kdPKB is expressed the phosphorylation of both Ser473
AAO
and Thr is increased compared to in the presence of tetracycline. When these blots 
were stripped and reprobed with pan-PKB it is apparent that there is marginally more 
protein loaded in the - tetracycline lanes, however, this could not account for the 
magnitude of increase in phosphorylation observed. It is also interesting to note the 
high level of kdPKB phosphorylation at Ser473 and Thr308 in particular in the 
unstimulated control lanes, although as kdPKB is catalytically inactive (Figure 5.3) this 
has no impact on its activity. This is a surprising result, as in other systems kdPKB 
does not affect the activity of endogenous PKB. kdPKB is thought to act in a dominant 
negative fashion by competing with endogenous PKB to prevent activation of 
downstream targets. Therefore, the effects of kdPKB expression on PKB substrates 
must also be investigated.
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Figure 5.4



















gagPKB cells were set up at 105/ml in the absence (- Tet) or presence (+ Tet) of 
tetracycline for 24hr prior to starving of IL-3 and serum for 4hrs. Cells were 
stimulated for 5 minutes with the indicated concentration of IL-3. Whole cell 
lysates (4xl05 cell equivalents) were separated be SDS PAGE on duplicate gels 
and immunblotted with a- phospho-Ser473 (C) or a-phospho-Thr308 (B). Blots 
were stripped and reprobed with a-PKB (D) and a-phospho-tyrosine (A). This 
experiment is a representative of 2 independent experiments.
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Figure 5.5
Effect of kdPKB expression on PKB phosphorylation
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Cells were set up at 2xl04/ml in the absence (- Tet) or presence (+ Tet) of 
tetracycline for 24hr prior to starving of IL-3 and serum for 4hrs. Cells were 
stimulated for the indicated time with the lOng/ml IL-3. Whole cell lysates 
(4xl05 cell equivalents) were separated be SDS PAGE on duplicate gels and 
immunblotted with a- phospho-Ser473 (C) or a-phospho-Thr308 (B). Blots were 
stripped and reprobed with a-PKB (D), and a-phospho-tyrosine (A). This 
experiment is a representative of 2 experiments.
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cxPKB has also been reported to act as a dominant negative and inhibit endogenous 
PKB activity. Therefore we would expect the phosphorylation of Ser473 and Thr308 to 
decrease due to cxPKB expression. The results shown in Figure 5.6 found very little
  <JAQ
endogenous PKB phosphorylation at either Ser or Thr . This is possibly due to the 
“leakiness” of the clone. In this experiment the expression of cxPKB is not very 
inducible and a high level of cxPKB expression is present even in the presence of 
tetracycline (Figure 5.13D). Therefore, if cxPKB is acting as a dominant negative, a 
low level of endogenous PKB phosphorylation would be expected. cxPKB is 
constitutively phosphorylated at Thr308 (Figure 5.6B). This is interesting and may 
account for cxPKB constitutive activity in in vitro kinase assays where the membrane is 
disrupted. However, no phosphorylation is detected at Ser473 (Figure 5.6C). The caax 
motif is attached to the C-terminal tail region of PKB where the Ser473 phosphorylation 
site is located and therefore may inhibit the access of PDK2 to this site.
The general leakiness of the 4H3 clone made it very difficult to determine what effects 
cxPKB was having on endogenous PKB activity in this system. However, work on the 
cxPKB clones has continued within the laboratory and using the 1E8 clone it has been 
found that cxPKB expression inhibits the phosphorylation of endogenous Ser473, 
indicating that cxPKB is acting as a dominant negative (C. Beck and M.J. Welham, 
unpublished data).
The wtPKB mutant was included in these studies primarily as a control and as such it 
was not expected to significantly affect endogenous PKB activity. However, as 
gagPKB and kdPKB appeared to be increasing the phosphorylation of endogenous 
PKB, it was possible that wtPKB may also have this effect. Surprisingly, preliminary 
analysis, have indicated that the expression of wtPKB decreases the phosphorylation of 
endogenous PKB at both Ser473 and Thr308 (Figure 5.7).
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Figure 5.6
Effect o f cxPKB expression on PKB phosphorylation
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Cells were set up at 2xl04/ml in the absence (- Tet) or presence (+ Tet) of 
tetracycline for 24hr prior to starving of IL-3 and serum for 4hrs. Cells were 
stimulated for 5 minutes with the indicated concentration of IL-3. Whole cell 
lysates (4xl05 cell equivalents) were separated be SDS PAGE on duplicate gels 
and immunblotted with a- phospho-Ser473 (C) or a-phospho-Thr308 (B). Blots 
were stripped and reprobed with a-PKB (D), a-phospho-tyrosine (A). This 
experiment is a representative of 2 independent experiments.
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Figure 5.7
Effect of wtPKB expression on PKB phosphorylation
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Cells were set up at 2xl04/ml in the absence (- Tet) or presence (+ Tet) of 
tetracycline for 24hr prior to starving of IL-3 and serum for 4hrs. Cells were 
stimulated with lOng/ml IL3 for the indicated times. Whole cell lysates (4xl05 
cell equivalents) were separated be SDS PAGE on duplicate gels and 
immunblotted with a- phospho-Ser473 (C) or a-phospho-Thr308 (B). Blots were 
stripped and reprobed with a-PKB (D) and a-phospho-tyrosine (A). This 
experiment was performed once. Note that the order of samples has changed.
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5.7 Effect of PKB Variant Expression on Bad Phosphorylation
The effects that these PKB variants have on the PKB signalling pathway is also 
dependent on their interactions with downstream effectors of PKB. For example, the 
kdPKB variant is reported to have no effect on endogenous PKB activation (and indeed 
in this system it appears to increase endogenous PKB activity), yet it acts as a dominant 
negative by competing with endogenous PKB for downstream targets. Therefore, to 
investigate the effects that our PKB variants are having on substrates of PKB we looked 
firstly at the hyper-phosphorylation of Bad. Bad is a pro-apoptotic member of the Bcl-2 
family and when it is phosphorylated on serine residues its pro-apoptotic activity is 
abrogated. As previously discussed (Sections 3.15-3.18), hyper-phosphorylation of Bad 
results in a shift in its pattern of migration on SDS PAGE. In the previous experiments 
Bad was immuno-precipitated and run on 12.5% low bis gels to enhance the migration 
shift. However, in these experiments whole cells extracts were run on 20% gels and 
immuno-blotted with a different a-Bad antibody (R&D systems). The advantages to 
this method over the previous are that less sample is needed, an important consideration 
when cells must be seeded at a low concentration (105/ml) for optimal induction of 
expression, and using this method three phosphorylation states of Bad can be 
distinguished. The major disadvantage of examining Bad phosphorylation by looking at 
its shift in migration is that there is no way to distinguish which sites on PKB are being 
phosphorylated. PKB is known to phosphorylate Bad on Ser136, but antibodies specific 
to the phosphorylated site were inadequate. Therefore this method was used to give an 
overall indication of the phosphorylation of Bad.
The expression of gagPKB, despite being constitutively active, does not dramatically 
increase the basal phosphorylation of Bad (Figure 5.8). Similarly the kinetics and levels 
of Bad phosphorylation in IL-3 induced cells are not significantly affected by the 
expression of gagPKB. It is interesting that at 30 and 60 minute time-points three 
phosphorylation species of Bad are distinguishable. The expression of kdPKB also had 
no detectable effect on the hyper-phosphorylation of Bad (Figure 5.9). However, the 
disadvantage of using gel shifts to investigate the PKB-catalysed phosphorylation of 
Bad is that it is unclear firstly which residues are being phosphorylated and therefore 
which kinases are responsible, and secondly, it is not known how many residues must 
be phosphorylated in order to detect a shift in migration. Therefore, these experiments 
do not conclusively determine what effects these PKB variants are having on substrates 
of PKB. Work on this continues within the laboratory and the point is illustrated by 
results using the cxPKB clone 1E8. Expression of cxPKB has no effect on the mobility
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shift of Bad in response to IL-3 stimulation. However, cxPKB expression reduces the 
IL-3-induced phopshorylation of GSK3P (C. Beck and M.J. Welham, unpublished 
data).
5.8 Effects of PKB Variants on the IL-3-Induced Proliferation of BaF/3 Cells
The major functional effect of PI3K inhibition in BaF/3 cells is a dramatic reduction in 
the IL-3-induced proliferation (Figures 4.2 and 4.7, Craddock et al., 1999). This 
correlates with the inhibition of PKB by both the PI3K inhibitor LY294002 (Figure 
3.14) and Ap85 expression (Figures 4.5 and 4.6). PKB has previously been reported to 
be involved in proliferation in response to IL-2 stimulation (Brennan et al., 1997; 
Ahmed et al., 1997), but the expression of the constitutively active gagPKB in Ap85 
expressing BaF/3 cells was not sufficient to rescue the proliferative defect (Figure 4.13). 
This suggested that PKB was not involved in the PI3K mediated proliferation of BaF/3 
cells. However, a number of pathways in addition to PKB are mediated through PI3K 
and it is possible that inhibition of these pathways masked the effects of PKB on 
proliferation. Therefore, it was of interest to see what effects the expression of the PKB 
variants had on the IL-3-induced proliferation of BaF/3 cells. In these experiments, 
XTT assays were used to measure the metabolic activity of a population of cells and this 
reflects the level of proliferation of the cell population (Section 4.2).
Ahmed et al. (1997) found that BaF/3 cells expressing a constitutively active, 
myristylated PKB mutant were more likely to be transformed and become factor- 
independent. If the expression of gagPKB was sufficient to make BaF/3 cells factor 
independent we would expect the cells to grow in the absence of IL-3 and the curve 
would shift to the left when gagPKB was expressed (-Tet). However, the removal of 
tetracycline did not induce a shift in the growth curve of gagPKB clones, with ED5 0  
remaining at 0.6ng/ml (A) and 0.4ng/ml (B) in the presence and absence of tetracycline 
(Figure 5.10). Additionally, cells set up in media alone were dead after 72 hours in the 
presence or absence of tetracycline, indicating that the expression of gagPKB was not 
sufficient to transform BaF/3 cells. These data are supported by previous work where 
gagPKB was unable to restore the Ap85-inhibited proliferation in this cell line and did 
not make them factor independent (Figure 4.13).
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Figure 5.8
Effect of gagPKB expression on Bad phosphorylation
 + Tet_____________________-Tet__________
0 2 5 10 30 60 0 2 5 10 30 60min
Cells (clone 1C 10) were set up at 105/ml in the presence (+ Tet) or absence (- Tet) 
of tetracycline for 24 hrs prior to starving of IL-3 and serum for 4 hrs. Cells were 
stimulated with lOng/ml IL-3 for the indicated times. Whole cell lysates (4xl05 cell 
equivalents) were separated on 20% SDS PAGE gels and immunoblotted with a- 
Bad (R&D).. This experiment was performed once.
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Figure 5.9
Effect of kdPKB expression on Bad phosphorylation
+ Tet - Tet
0 2 5 10 30 60 0 2 5 10 30 60min
Cells (clone D12) were set up at 105/ml in the presence (+ Tet) or absence (- Tet) of 
tetracycline for 24 hrs prior to starving of IL-3 and serum for 4 hrs. Cells were 
stimulated with lOng/ml IL-3 for the indicated times. Whole cell lysates (4xl05 cell 
equivalents) were separated on 20% SDS PAGE gels and immunoblotted with a- 
Bad (R&D). This experiment was performed once.
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Figure 5.10










0.001 0.01 0.1 1 
IL-3 ng/ml
- tet





O 0 8  ■
0
1  0.4
0.001 0.01 0.1 1 10
IL-3 ng/ml
BaF/3 cells expressing gagPKB, (A) clone 1C10 and (B) clone 1F9, were washed free 
of factor and tetracycline and set up in the presence (+) or absence (-) of tetracycline 
with IL-3 (at a starting concentration of 2ng/ml with serial 1:2 dilutions across a 96 well 
plate), or serum alone as described in materials and methods. After 72 hours the assays 
were developed. The mean values (n=3) with standard deviation are plotted. Insert: At 
the same time that the XTT assays were set up, cells were grown +/- tetracycline for 72 
hours. Cell extracts were separated by SDS PAGE and immunoblotted with a-PKB to 
see protein expression. This experiment is representative of 3 independent experiments 
and similar results were found with one other clone.
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It is unclear from previous experiments whether kdPKB is acting as a dominant 
negative or not in these cells. Nevertheless, the effects of kdPKB expression were 
investigated in the IL-3-driven proliferation of BaF/3 cells. The IL-3 driven 
proliferation of BaF/3 cells was not affecfed by the expression of kdPKB (Figure 5.11). 
The ID5 0  values were slightly higher than seen in the gagPKB clones but were not 
significantly altered by the withdrawal of tetracycline.
cxPKB, despite the leakiness of the 4H3 clone, appears to be inhibiting the IL-3 
induced phosphorylation of PKB (C. Beck and M.J. Welham, unpublished). Therefore, 
if PKB is involved in the proliferation of BaF/3 cells, the expression of cxPKB clones 
would inhibit the IL-3-induced proliferation. However, the removal of tetracycline had 
no significant effect on the IL-3-induced proliferation of cxPKB clones (Figure 5.12). 
When the inducibility of cxPKB expression was checked a high level of expression was 
observed in the presence of tetracycline (Figure 5.12, insert). Therefore, it is difficult to 
determine from this result what the effects of cxPKB expression on proliferation are. 
However, XTT assays performed with the 1E8 clone, which is tightly regulated by 
tetracycline, indicate that cxPKB expression does not affect the IL-3-induced 
proliferation of BaF/3 cells (C. Beck and M.J. Welham, unpublished data)
The wtPKB mutant is identical to cellular PKB with the exception of the myc tag. 
Therefore, we would expect that expressing wtPKB would enhance any functional 
effects of PKB. As such, if PKB is involved in the IL-3-induced proliferation of BaF/3 
cells, we would expect wtPKB to enhance this proliferation. However, the expression 
of wtPKB did not enhance the IL-3-induced proliferation (Figure 5.13).
The data from these XTT assays show that the expression of a constitutively active 
PKB mutant (gagPKB) was not able to negate the dependence of BaF/3 cells for IL-3 
for proliferation nor was the expression of a dominant negative PKB (cxPKB) able to 
inhibit the IL-3- induced proliferation. Additionally, the kdPKB and wtPKB variants, 
which increase the activation of endogenous PKB, did not affect the IL-3-induced 
proliferation. Taken together, these data suggest that PKB is not involved in the IL-3- 
driven proliferation of these cells.
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Figure 5.11
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BaF/3 cells expressing kdPKB, (A) clone D12 and (B) clone A9, were washed free of 
factor and tetracycline and set up in the presence (+) or absence (-) of tetracycline with 
IL-3 (at a starting concentration of 2ng/ml with serial 1:2 dilutions across a 96 well 
plate), or serum alone as described in materials and methods. After 72 hours the assays 
were developed. The mean values (n=3) with standard deviation are plotted. Insert: At 
the same time that the XTT assays were set up, cells were grown +/- tetracycline for 72 
hours. Cell extracts were separated by SDS PAGE and immunoblotted with a-PKB to 
see protein expression. This experiment is representative of 3 independent experiments 
and similar results were found with 3 different clones.
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Figure 5.12
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BaF/3 cells expressing cxPKB, (A) clone 4H3 and (B) clone 2F5 were washed free of 
factor and tetracycline and set up in triplicate in the presence (+) or absence (-) of 
tetracycline with IL-3 (at a starting concentration of 2ng/ml with serial 1:2 dilutions 
across a 96 well plate), or serum alone as described in materials and methods. After 72 
hours the assays were developed. The mean values (n=3) with standard deviation are 
plotted. Insert At the same time that the XTT assays were set up, cells were grown +/- 
tetracycline for 72 hours. Cell extracts were separated by SDS PAGE and 
immunoblotted with a-PKB to see protein expression. This experiment is representative 
of 3 independent experiments and was performed with 3 different clones.
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Figure 5.13
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BaF/3 cells expressing wtPKB, (A) clone 3G10 and (B) clone 3G4,were washed free of 
factor and tetracycline and set up in triplicate in the presence (+) or absence (-) of 
tetracycline with IL-3 (at a starting concentration of 2ng/ml with serial 1:2 dilutions 
across a 96 well plate), or serum alone as described in materials and methods. After 72 
hours the assays were developed. The mean values (n=3) with standard deviation are 
plotted. Insert: At the same time that the XTT assays were set up, cells were grown +/- 
tetracycline for 72 hours. Cell extracts were separated by SDS PAGE and 
immunoblotted with a-PKB to see protein expression. This experiment is representative 
of 3 independent experiments and similar results were obtained with 3 different clones.
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5.9 Effects of PKB Variants on the Viability of BaF/3 Cells
Over recent years PKB has been implicated in the survival of an increasing number of 
cell types in response to an expansive array of stimuli (Reviewed in Coffer and 
Woodgett, 1998, Datta et al., 1999, Vanhaesebroeck and Alessi, 2000). However, the 
results presented in Chapters 3 and 4 question the generally accepted dogma that the 
activation of PKB is both sufficient and necessary for cell survival. In order to 
investigate this more thoroughly, we looked at the viability of the PKB clones in the 
presence and absence of tetracycline. Cells were grown over a period of 3 days in 
limiting concentrations of IL-3, or in the absence of IL-3, and the percentage of viable 
cells were determined at specific time intervals.
The expression of the constitutively active PKB variant, gagPKB, did not afford any 
extra protection from death to those cells grown in limiting amounts of IL-3 (Figure 
5.14). The survival of cells grown at lOOpg/ml IL-3 appears to decrease in the absence 
of tetracycline at 72 hours. However, at this time point the cells are beginning to die as 
a result of overcrowding and this should be kept in mind when interpreting this result. 
Similarly, the expression of the kdPKB mutant did not provide these cells with any 
increased or decreased protection from death (Figure 5.15).
If PKB could provide a survival signal to BaF/3 cells, we would expect that expression 
of the dominant negative cxPKB would increase cell death at low IL-3 concentrations. 
However, the expression of cxPKB did not increase death when cells were grown in 
50pg/ml IL-3 or in the absence of IL-3 Figure 5.16). A small decrease in cell death 
(10%) was observed in cxPKB expressing cells grown in lpg/ml IL-3. However, the 
significance of this result is not clear, as it was not observed when the experiment was 
repeated nor in the 1E8 or 2G6 clones (C. Beck and M.J. Welham, unpublished).
These results demonstrate that expression of gagPKB in BaF/3 cells is unable to 
protect cells from death in the absence of IL-3. This suggests that PKB alone is not 
sufficient to provide a growth signal. Additionally, kdPKB and cxPKB did not increase 
cell death, which poses the question of whether PKB is involved in the survival of all 
cell types in response to all cytokines.
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Figure 5.14
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BaF/3 cells expressing gagPKB were set up in the presence (+ Tet) or absence (- Tet) 
of tetracycline. After 24 hours the two populations of cells were washed free of 
factor and grown in the varying concentrations of IL-3. The percentage of live cells 
at the indicated times were determined by trypan blue exclusion assays. The mean 
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BaF/3 cells expressing kdPKB were set up in the presence (+ Tet) or absence (- Tet) 
of tetracycline. After 24 hours the two populations of cells were washed free of 
factor and grown in the varying concentrations of IL-3. The percentage of live cells 
at the indicated times were determined by trypan blue exclusion assays. The mean 
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BaF/3 cells expressing cxPKB were set up in the presence (+ Tet) or absence (- Tet) 
of tetracycline. After 24 hours the two populations of cells were washed free of 
factor and grown in the varying concentrations of IL-3. The percentage of live cells 
at the indicated times were determined by trypan blue exclusion assays. The mean 
values (n=2) are plotted with standard deviation. This experiment was performed 
twice.
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5.10 Effect of PKB Variants on Apoptosis
The viability assays shown previously (Figures 5.14-5.16) examined the effect of PKB 
variants on the survival of BaF/3 cells. The expression of a constitutively active PKB 
(gagPKB) did not protect the cells from death induced by IL-3 withdrawal, nor did the 
expression of a dominant negative PKB (cxPKB) increase cell death. BaF/3 cells are 
dependent on IL-3 for their continued growth and survival and will by die by apoptosis 
upon IL-3 withdrawal. Therefore, the role of PKB in the survival of BaF/3 cells was 
further examined by looking at the rate of apoptosis of the PKB variants. Apoptosis 
was measured by FACS analysis of cells stained with propidium iodide and annexinV.
Ahmed et al. (1997) reported that the expression of myristylated PKB in BaF/3 cells 
was sufficient to transform these cells, preventing their death upon IL-3 withdrawal. 
However, the constitutively active gagPKB mutant was unable to promote survival in 
the absence of IL-3 (Figure 5.14). To investigate this in more depth, we looked at the 
apoptosis of the gagPKB clone 1C 10 in the absence of IL-3 and in conditions of limited 
IL-3.
First the rate of apoptosis in the presence and absence of tetracycline was examined in 
BaF/3 cells that had been transfected with “empty” pUHD10-5 vector and the regulatory 
pUHD15-l vector. The dot plots shown in Figure 5.17 follow the apoptosis of these 
cells over twelve hours after IL-3 withdrawal. The lower right quadrant contains cells 
that are stained with annexinV alone, which is used to identify those cells undergoing 
apoptosis as opposed to necrotic cell death. This Figure illustrates the progression of 
unstained live cells (lower left quandrants) to those cells that are in the early stages of 
apoptotic cell death (lower right quandrants) and finally to their death (upper 
quadrants). The progression of apoptosis induced by IL-3 withdrawal of gagPKB cells 
is shown in Figure 5.18. The number of cells undergoing apoptosis at each time point 
does not vary significantly in the absence or presence of tetracycline, indicating that 
gagPKB expression is not protecting the cells from apoptosis in the absence of IL-3. 
The apoptotic profile observed with the gagPKB clone is similar to that seen in BaF/3 
cells transfected with an “empty” vector (Figure 5.17). The apoptosis of gagPKB cells 
was also investigated for up to 24 hours after IL-3 deprivation and at low concentration 
of IL-3 (lpg/ml and 1 Opg/ml). However, the expression of gagPKB did not afford any 
protection from apoptosis in these experiments.
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Figure 5.17
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tetracycline, prior to being washed free of IL-3 and seeded at 104/ml. After the 
indicated time cells were washed and stained with AnnexinV and propidium iodide. 
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gagPKB clone 1C 10 was induced for 24 hours in the presence or absence of 
tetracycline, prior to being washed free of IL-3 and seeded at 104 /ml. After the 
indicated time cells were washed and stained with AnnexinV and propidium iodide. 
Cells were analysed by flow cytometry and 10 000 events were recorded.
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To compare the effects of the expression of these PKB variants on apoptosis, a 12 hour 
time-point was chosen. Figure 5.18 compares the change in the number of cells 
undergoing apoptosis in the presence of tetracycline (no expression) to in the absence of 
tetracycline (expression of PKB variant). Therefore, negative values denote an decrease 
in the number of cells undergoing apoptosis upon expression of the PKB variant. 
gagPKB did not protect BaF/3 cells from apoptosis even in low concentration of IL-3. 
cxPKB, perhaps increased the number of apoptotic cells by a small amount but it must 
be remembered that this was only one experiment. kdPKB gave widely varying results 
between experiments and it is difficult to determine what its effects on apoptosis are. 
However, the results obtained with the expression of the kdPKB variant do illustrate the 
shortcomings of such a comparison. In this experiment we are measuring the difference 
in apoptotic cell number in cells grown in limited IL-3 in the presence or absence of 
tetracycline. The expression of exogenous PKB is induced by the withdrawal of 
tetracycline for 24 hours before the cells are washed and seeded with low IL-3. 
Therefore, we are comparing the number of apoptotic cells in two distinct cell 
populations, which may have differed in apoptotic cell number at the beginning of the 
experiment.
These concerns aside, the results presented above suggest that the expression of these 
PKB variants does not result in either a massive increase or decrease in apoptosis. 
Taken together, with the results presented in previous chapters, they suggest that PKB is 
not ultimately required for the survival of all cell types and question whether indeed it is 
involved in the survival of all cells.
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Figure 5.19
Change in Apoptotic Cell Number Induced by PKB Variant Expression







Cells were set up at 105/ml in the absence or presence of tetracycline for 24 hours prior 
to being cultured in the indicated concentration of IL-3. 12-14 hours later, cells were 
washed, stained with AnnexinV and propidium iodide and the number of apoptotic 
cells determined by FACS analysis. The values indicated here, give the increase or 
decrease in the number of cells undergoing apoptosis when the PKB variant was 
expressed. Thus, positive values indicate an increase in apoptosis upon PKB variant 
expression, and negative value indicate a decrease in the number of cells undergoing 
apoptosis when the PKB variant is expressed. The results shown are +/- standard 




The serine threonine kinase PKB has been implicated in the growth and survival of 
many cell systems and in response to a number of stimuli (Reviewed in Coffer and 
Woodgett,. 1998; Datta et al., 1999; Vanhaesebroeck and Alessi, 2000). This led to the 
general belief, that the activation of PKB was both sufficient and necessary for the 
generation of a survival signal. However, an absolute correlation between PKB 
activation, Bad phosphorylation and cell survival and proliferation was not found 
(Chapters 3 and 4), which raised the question of how important and necessary PKB 
activation is for these events. In these experiments, PI3K inactivation was used to 
inhibit the activity of PKB, but the effects of direct PKB inhibition were not examined. 
To enable the effects of PKB on IL-3 signalling to be examined directly, PKB variants 
were expressed in BaF/3 cells. These created cell models in which PKB activity was 
either inhibited or less dependent of IL-3 stimulation.
Two PKB variants that were reported to inhibit PKB signalling were transfected into 
BaF/3 cells. The first, kdPKB is catalytically inactive, however expression of this 
mutant in BaF/3 cells resulted in an increase in the phosphorylation of endogenous PKB 
in response to IL-3 stimulation. Phosphorylation at Ser4 7 3  correlates with the activity of 
PKB (Figures 3.1-3.5) and this was used to investigate the activity of endogenous PKB, 
as opposed to exogenous PKB activity. This was a surprising result especially given 
that the expression of kdPKB in other systems did not result in an increase in 
endogenous PKB activity (Kotani et al., 1999; Takata et al., 1999) or co-expressed 
wtPKB activity (van Weeren et al., 1998). In vitro kinase assays of kdPKB expressing 
clones pre-cleared with 9E10 antibody could be performed to confirm that the activity 
of endogenous PKB activity is increased by kdPKB expression. kdPKB is believed to 
act as a dominant negative in some systems by competing with endogenous PKB for its 
downstream effectors (Dudek et al., 1997; Datta et al., 1997; del Peso et al., 1997; 
Kulik and Weber, 1998). However, its expression in BaF/3 cells did not interfere with 
the hyper-phosphorylation of Bad induced by IL-3 stimulation (Figure 5.9). This is in 
contrast to 3T3 cells where kdPKB expression inhibited the shift in migration that is 
indicative of Bad hyper-phosphorylation (Datta et ah, 1997). However, van Weeren et 
al. (1998) also report that the dominant negative effects of this PKB mutant are variable.
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The second putative dominant negative PKB used in these studies was the cxPKB. In 
vitro kinase assays of this mutant had a constitutive level of activity, which was not 
increase by stimulation with IL-3. Van Weeren et al. (1998) also examined the activity 
of cxPKB. They found that the level of cxPKB activity in both unstimulated and insulin 
stimulated A14 cells was comparable to that of unstimulated wtPKB. However, 
considerably less cxPKB than wtPKB was expressed in their cells making it difficult to 
determine whether cxPKB also has a low level of constitutive activity in this cell line. 
When the phosphorylation at Ser4 7 3  and Thr3 0 8  of cxPKB was examined, it was 
constitutively phosphorylated on Thr3 0 8  (Figure 5.6). As phosphorylation at this site 
contributes to activation (Alessi et al., 1996) this could account for the basal level of 
cxPKB activity observed. The effect of cxPKB expression on the activation of 
endogenous PKB was more difficult to determine due to the constitutive expression of 
the 4H3 clone. Results in the 1E8 clone suggest that the expression of cxPKB decreases 
the phosphorylation of endogenous PKB (C. Beck and M J . Welham, unpublished) and 
low levels of endogenous phosphorylation were observed in 4H3 clone, which could be 
a result of the dominant negative effects of cxPKB (Figure 5.3). However, given the 
low constitutive activity of cxPKB (whether or not this is an artifact of the assay 
system) the effects of cxPKB expression on downstream targets of PKB need to be 
examined. Further work within the laboratory has found that the expression of cxPKB 
resulted in a small reduction of GSK3P phosphorylation, but did not inhibit the IL-3- 
induced hyper-phosphorylation of Bad or affect Bad Ser1 1 2  phosphorylation (C. Beck 
and M.J. Welham, unpublished data).
Other dominant negative PKB variants have since been reported. Of particular interest 
is the AAA mutant, which contains 3 point mutations of Lys1 7 9 Ala, Thr308Ala and 
Ser4 7 3 Ala. This PKB variant as well as being catalytically inactive inhibits the activity 
of co-transfected wtPKB (Wang et al., 1999), which suggests that it may be more 
efficient in its dominant negative effects. It would be interesting to examine its effects 
in BaF/3 cells.
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The constitutively active PKB variant gagPKB was chosen to provide an active PKB 
signal that is independent of IL-3 activity. This variant was found to have a low 
constitutive activity, which was increased upon IL-3 stimulation. Others have also 
found the activity of the gagPKB mutant to increase upon stimulation (Burgering and 
Coffer, 1995). Given the high levels of basal phosphorylation of gagPKB in Ap85 
expressing cells (Figure 4.11 and 4.12), it was surprising that a similar high level of 
basal phosphorylation was not observed in gagPKB cells (Figure 5.4). While, the low 
level of gagPKB expression in this experiment may be a reason for the disparity in 
phosphorylation levels observed, it is interesting that in PDK-1 -/- ES cells a similar 
high level of Ser4 7 3  phosphorylation was also present in unstimulated cells (Williams et 
al., 2000). As this effect was abolished by wortmannin treatment, it was explained by 
the high basal level of PI3K activity that was observed in these cells. However, it could 
also so be due to a decreased dephosphorylation of Ser473. When PKB was targeted to 
the membrane it was activated by phosphoryalation at Ser4 7 3  and Thr308. When PI3K 
was inactivated by wortmannin, LY294002 or Ap85, PKB was presumably not targeted 
to the membrane and PKB was not phosphoryated at either site (Williams et al., 2000; 
Figures 3.11-3.14, 4.5 and 4.6). However, when PKB was targeted to the membrane in 
the absence of PI3K activity (Figures 4.11 and 4.12) the increase in phosphorylation 
was much greater than that seen in presence of PI3K activity (Figure 5.4). This effect 
was more pronounced when looking at Ser4 7 3  phosphorylation. A possible explanation 
for this is that the phospho-lipid products of PI3K, PIP3 , also target PDK1 to the 
membrane. Therefore, a membrane targeted PDK-1 may be required for the 
dephosphorylation of PKB at Ser473. Thus, in the PDK-1 -/- cells where there is no 
PDK-1, phopshorylation of PKB at Ser4 7 3  is enhanced. Therefore, PDK-1 recruitment 
to the membrane by PIP3  may activate a phosphatase activity, which is active on Ser473. 
This could act as a negative feed back loop by which the positive regulatory signals of 
PKB are switched off (Figure 5.20).
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Figure 5.20








Putative feedback loop involved in the regulation of PKB. PKB is activated 
by a combination of membrane targeting through the PH domain (□  ) and 
phosphorylation on Sei473 and Thr308. Thr308 is phosphorylated by PDK1 
through a mechanism which is dependent on the presence of the phospholipid 
products of PI3K. When PKB is membrane targeted in the absence of 
phospholipids or PDK1 phosphorylation at Ser473 is increased suggesting the 
PDK1 or phospholipid regulated dephosphorylation of PKB at Ser473. 
Ceramide and osmotic stress activate a phosphatase activity which may 
catalyse the dephosphorylation of PKB at Ser473.
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Recent work has identified a pathway that leads to the dephosphorylation of PKB on 
Ser473 (Schubert et al., 2000; Zinda et al., 2001; Hajduch et al., 2001) and Thr308 (Zinda 
et al., 2001; Hajduch et al., 2001). A number of groups had reported that PKB activity 
is regulated in part by the membrane sphingolipid, ceramide and that this regulation is 
independent of PI3K-catalysed phospholipid production (Zhou et al., 1998; Schubert et 
al., 2000; Zinda et al., 2001; Hajduch et al., 2001). Ceramide production results in the 
activation of various proteins including the protein phosphatase CAPP (ceramide 
activated protein phosphatase) (Dobrowsky and Hannun, 1992; Peterson and Schreiber, 
1999). The ceramide-induced inhibition of PKB phosphorylation is sensitive to the 
phosphatase inhibitors okadaic acid and calyculin, which has lead to the speculation that 
CAPP may catalyse the dephosphorylation of PKB (Schubert et al., 2000; Zinda et al., 
2001; Hajduch et al., 2001). Schubert et al. (2000) who were investigating GM-CSF- 
stimulated TF1 cells, found that only phosphorylation at Ser473 was affected by 
ceramide treatment. Surprisingly, when these cells were treated with the phosphatase 
inhibitors okadaic acid and calyculin, phosphorylation of PKB at Thr308 was completely 
abolished. This suggests that a dephosphoryation event is involved in the PDK-1 - 
catalysed phosphorylation of Thr308, which is surprising given the constitutive activity 
of PDK-1. These findings demonstrate that the regulation of PDK-1 is more 
complicated than at first thought and point towards the involvement of a phosphatase. 
Given these findings it would be interesting to investigate the role of phosphatases in 
the phosphorylation of Thr308 by PDK-1 and the possible role of PDK-1 in the 
dephosphorylation of Ser473 by a phosphatase, perhaps CAPP.
It has been reported that osmotic stress can stimulate the production of PI(3,4,5)P3 
without inducing the activation of PKB and indeed osmotic stress was shown to inhibit 
the IGF-1-induced activation of PKB (Van der Kaay et al., 1999). This suggests that 
either osmotic stress inhibits the phosphorylation of PKB or induces its 
dephosphorylation. Pre-treatment with calyculin blocked the inhibitory effect of 
osmotic stress on the activation of PKB (Van der Kaay et al., 1999). This suggests that 
osmotic stress inhibits PKB activity through the regulation of a phosphatase. However, 
treatment with calyculin alone activated PKB to the same extent as IGF-1, which 
supports the theory that a phosphatase activity is required for the activation of PKB. 
Therefore it is possible that osmotic stress regulates PKB activity through inhibiting its 
activation, which may be mediated in part by a phosphatase.
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Ahmed et al. (1997) investigated the role of PKB in the survival and proliferation of 
BaF/3 cells in response to IL-2. They expressed a wild type IL-2RP and a deletion 
mutant ASIL-2Rp in BaF/3 cells and found that PKB was activated in response to IL-2 
in the IL-2RP expressing cells but not in the AS expressing cells. Previous work had 
demonstrated that BaF/3 cells expressing the IL-2Rp could be grown in the long-term in 
IL-2 while those expressing the AS-IL-2Rp mutant could not (Miyazaki et al., 1995). 
To investigate this correlation of PKB and the survival of BaF/3 cells in IL-2 signalling 
they expressed two forms of constitutively active PKB in AS-IL-2RP expressing BaF/3 
cells. Both myristylated PKB and the constitutively active PH domain mutant E40K 
slowed the rate of apoptosis induced by IL-3 and IL-2 withdrawal. Additionally, cells 
that survived gave rise to growth factor-independent cell lines. These results are in 
contrast to those that we observed when gagPKB was expressed in BaF/3 cells (Figure 
5.10). Ahmed and colleagues looked at the effect of PKB variants on the survival of 
BaF/3 cells that were transfected with IL-2Rp mutants, and while this receptor mutant 
does not enable these cells to grow in response to IL-2 in the absence of active PKB, it 
may couple with active PKB to drive proliferation and survival. Alternatively, it is 
interesting that the protection that myristylated PKB afforded from apoptosis was 
greater to that afforded by the E40K mutant and this correlated with a greater level of 
basal PKB activity in myristylated PKB cell lines than in the E40K cell lines. As 
gagPKB had only a low level of constitutive PKB activity perhaps the signal was not 
sufficient to transform these cells (Figure 5.3).
Therefore, it would be interesting express the myristylated PKB mutant under the 
control of tetracycline in our BaF/3 cells, to investigate its effects on the proliferation 
and survival. Given the success of the AAAPKB mutant (Wang et al., 1999), it would 
also be of interest to investigate the effects of its expression in our system and to 
compare these to the results obtained with the cxPKB mutant.
When interpreting the results presented in this chapter on the effect of the expression 
of PKB variants in BaF/3 cells it must be remembered that 3 isoforms of PKB exist. It 
is not known which isoforms of PKB are expressed in BaF/3 cells, as initial experiments 
using antibodies specific to each of the a , p and y isoforms were unsuccessful due to the 
quality of the antibodies available. The antibodies used in these studies were raised 
against PKBa and the PKB variants were also of the PKBa isoform. As such, the 
effects of the expression of these proteins on the activity of PKBp and PKBy have not 
been investigated. Therefore it is possible that the activity of PKBp and PKBy could
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compensate for any changes in PKBa activity thus masking any physiological or 
biochemical effects. It is important to firstly determine which isoforms are expressed in 
these cells and secondly look at the effects of the PKB variants expression on their 
activity. Since the issue of which isoforms of PKB are expressed in these cells was first 
examined new antibodies specific to each isoforms have become available and these 
may prove to be of sufficient quality. Alternatively RT-PCR could be performed to 
determine which transcripts are expressed in BaF/3 cells.
Over recent years, a number of possible targets of PKB have been identified. The 
effect of gagPKB and kdPKB expression on the PKB substrate Bad was investigated, 
but the effect of these PKB variants on other substrates was not examined. PKB is 
rapidly activated by cytokine-stimulation in these cells, yet it does not appear to be 
influencing cell survival or proliferation. By examining the effects of PKB variant 
expression on such downstream targets as GSK-3, and the forkhead proteins, insights 






The serine/threonine kinase PKB has been widely implicated as a positive regulator of 
growth and survival in a number of cell systems (for a review see Coffer and Woodgett, 
1998; Datta et al., 1999) and at the conception of this work the generally accepted view 
was that the activation of PKB was sufficient and necessary to drive long-term growth 
and survival. While PKB is able to provide a survival signal in some systems, the 
question of whether this is a universal phenomenon had not been addressed. Therefore, 
this project set out to investigate the role that PKB plays in the cytokine-mediated 
growth and survival of haemopoietic cells. Haemopoietic cells are dependent on 
specific cytokines for their continued growth and survival and upon cytokine 
withdrawal they die by apoptosis. Thus, they provide ideal cell models in which to 
investigate the effects of PKB on proliferation and survival.
The first objective of this work was to determine if PKB was activated in response to 
the cytokine-stimulation of responsive cells. All the cytokines examined were able to 
activate PKB by a PI3K-mediated pathway. However, this did not correlate with 
cytokine-induced proliferation and survival of these cells in all cases. This suggests that 
PKB activation alone is not always sufficient to provide a growth and survival signal to 
cells. At the time of this work, the Bcl-2 family member Bad had recently been 
identified as a substrate of PKB (Datta et al., 1997; del Peso et al., 1997). Therefore, 
the effects of the cytokine-induced PKB activation on Bad phosphorylation were also 
examined. However, the patterns of Bad hyper-phosphorylation did not always 
correlate with the cytokine-induced PKB activation or the survival of cells. In addition, 
cell type differences were observed. This evidence suggests that Bad was not vital for 
the cytokine-mediated survival of these cells.
These data, while not directly investigating the effects mediated by PKB, suggested 
that PKB activation was not absolutely required for the survival of these haemopoietic 
cells. This hypothesis gains further support from work with PKB variants in BaF/3 
cells. Preliminary results indicate that the expression of the dominant negative PKB 
variant cxPKB does not affect the IL-3-induced proliferation or survival of BaF/3 cells. 
Conversely, the expression of the constitutively active PKB variant gagPKB does not 
protect cells from apoptosis induced by IL-3 withdrawal, nor does it lessen the 
requirement of IL-3 for continued proliferation.
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Over recent years, other groups have also begun to question the absolute requirement 
of PKB for the growth and survival of cells. Scheid et al. (1999) found that in MC9 
cells stimulated with GM-CSF or IL-3 Bad was phosphorylated on Ser112 by a MEK 
dependent pathway and two other residues, but not on the PKB dependent Ser site. 
This suggests that PKB may not always be required for the hyper-phosphorylation of 
Bad, and preliminary results looking at the migration patterns of Bad in BaF/3 cells 
indicate that Bad migration patterns are not affected by the expression of dominant 
negative or constitutively active PKB variants (Figures 5.8 and 5.9, C. Beck and M.J. 
Welham unpublished data). In addition, Bad hyper-phosphorylation did not correlate 
with PKB activity in all cases. Collectively these data question the necessity of PKB 
activation for Bad hyper-phosphorylation.
Other groups have found that PKB activation is not necessary for the growth factor- 
induced cell survival. Uchida et al. (2000) found that PKB activation in the absence of 
PI3K activity was insufficient to promote the insulin-mediated survival of 32D cells 
transfected with the insulin receptor and IRS proteins. The lack of importance of PKB 
in cytokine-mediated survival is not limited to haemopoietic cells. EGF can protect 
LNCaP prostate cancer cells, in which PTEN is inactivated, from apoptosis even in the 
presence of LY294002 and subsequent inactivation of PI3K and PKB (Carson et al. 
1999).
Collectively, these results have challenged the dogma that PKB is sufficient and 
necessary for cell survival and has tempered the current understanding of the role that 
PKB plays in growth and survival. It now appears that PKB is important for the 
survival and proliferation of some cells in response to some stimuli but in other systems 
other pathways are more important.
In this work PI3K and PKB were not found to be important for the IL-3-mediated 
survival of BaF/3 cells. This raises the question of what is required to drive 
proliferation and survival of these cells in response to IL-3. IL-3 binding to its receptor 
results in the activation of a number of pathways in addition to PI3K, including the 
Jak2/STAT5 and Ras/MAPK pathways. In studies where the hpc is expressed in BaF/3 
cells, two distinct regions of the receptor that are involved in transducing growth and 
survival signals into the cell have been identified (Quelle et al., 1994). One is 
dependent on the membrane proximal region of the receptor (up to residue 544) and the 
second is dependent on the membrane distal region.
179
The membrane proximal region of (3C is required for its interation with Jak2 and the 
subsequent activation of STAT5 (Quelle et al., 1994). The activation of this pathway 
may be responsible for the growth and survival signal generated by this region, as stable 
BaF/3 transfectants expressing a constitutively active STAT5, 1*6, could be maintained 
for long periods in the absence of IL-3 (Nosaka et al., 1999). This suggests that the 
activation of STAT5 is sufficient to drive the growth and proliferation of BaF/3 cells. 
Active STAT5 up-regulates the expression of a number of proteins, including the anti- 
apoptotic Bcl-2 family member B c 1 -x l  and this correlates with an increased survival of 
BaF/3 cells.
Interestingly, Santos et al. (2000) have recently reported that STAT5 and PI3K 
cooperate with each other in order to promote the survival and proliferation of BaF/3 
cells. The expression of a dominant negative STAT5 (STAT5AD749) in BaF/3 cells 
increased cell death upon IL-3 withdrawal and this effect was enhanced when PI3K 
activity was inhibited by the addition of LY294002. It is interesting to note that PKB 
phosphorylation in these STAT5AA749 cells was significantly upregulated and 
prolonged upon stimulation with IL-3. The results in this thesis suggest that the 
PI3K/PKB can be dispensable for the IL-3 mediated survival of BaF/3 cells but perhaps 
this pathway can act in conjunction with STAT5A to help promote cell survival. It is 
possible that when a cell is compromised in another way, it is important to have a 
functional PKB to aid survival.
The distal region of pc can also provide a survival signal to BaF/3 cells as when this 
region is truncated, cells undergo apoptosis in the presence of cytokines (Kinoshita et 
al., 1995). The activation of PI3K by IL-3 requires the phosphorylation of Tyr577 and 
Tyr612 in the distal region of pc (Dijkers et al., 1999). However, PI3K activation alone 
cannot account for the survival signal that stems from the distal region of pc as 
inhibition of PI3K alone does not significantly increase the apoptosis of BaF/3 cells 
(Craddock et al., 1999; Santos et al., 2000). The Ras/MAPK pathway is also dependent 
on this region of the receptor for activation (Kinoshita et al., 1995; Wang et al., 1992; 
Jiang et al., 2000) and the expression of a constitutively active Ras mutant in the 
truncated pc BaF/3 cells was sufficient to complement the defective signalling and in 
concert with cytokine supported the long-term growth and survival (Kinoshita et al., 
1995).
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Recently Shinjyo et al. (2000) reported that IL-3-withdrawal induced the up-regulation 
of the BH3-only pro-apoptotic Bcl-2 family member Bim. Enforced expression of Bim 
to the levels seen in response to IL-3 withdrawal resulted in apoptosis even in the 
presence of IL-3 (Shinjyo et al. 2000). Expression of the dominant negative Ras, Ras 
(S17N), or inhibition of PI3K with wortmannin did not upregulate Bim levels. 
However, the inhibition of both Ras and PI3K resulted in the up-regulation of Bim and 
this correlated with a marked decrease in viability. (Shinjyo et al., 2000). Again these 
results suggest that PI3K can act in conjunction with other signalling pathways to 
promote the survival of BaF/3 cells. PKB, however, does not appear to be involved in 
this pathway as expression of a dominant negative PKB, AAAPKB, in conjunction with 
the Ras mutant did not affect cell viability (Shinjyo et al., 2000).
Collectively, these data suggest that the Jak2/STAT5, Ras/MAPK and PI3K pathways 
work together to promote the long-term proliferation and survival of BaF/3 cells (Figure 
6.1). It is interesting that in isolation their effects on apoptosis are limited but they may 
co-ordinate with each other and collectively promote the survival of these cells. This is 
a point that needs further investigation and the tetracyline-regulated inducible 
expression system used in these studies would provide an ideal system in which to 
investigate this. The transfection of STAT5 and Ras mutants into the Ap85 cells could 
be used to investigate the effects of the inhibition and constitutive activation of either 












Possible signalling pathways involved in the IL-3-induced survival of BaF/3 cells. 
IL-3 binding to its receptor on the cell membrane results in the activation of the 
Jak/STAT, Ras/Erk and PI3K signalling pathways. While the PI3K pathway in 
isolation does not appear to be involved in cell survival it has been reported to act 
in concert with both the Jak/STAT and Ras/Erk pathways to promote survival of 
BaF/3 cells. It is possible that these pathways regulate survival in part by 
controlling the levels and activity of Bcl2 family members Bad, Bim and BclXI . 
Red arrows indicate either changes in expression or “activity” of these proteins.
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The data presented in this thesis and that discussed above argue against a role for PKB 
in the prevention of apoptosis and proliferation in these cells. However, PKB is 
activated in response to IL-3 in BaF/3 cells and additionally it was activated by all the 
cytokines in all cell types examined. This raises a number of questions: why is PKB 
activated in these cells, what processes is it involved with and what is it 
phosphorylating?
A number of potential substrates of PKB have been identifies in recent years and in 
this work the phosphorylation of Bad by PKB was examined. However, the evidence 
presented here, while not conclusive, does not favour a role for PKB in the IL-3- 
mediated phosphorylation of BaF/3 cells. PKB has also been reported to phosphorylate 
GSK3a and (3 on Ser2179 respectively (Cross et al., 1994), and the expression of cxPKB 
in BaF/3 cells reduced the IL-3-mediated phosphorylation of Ser9 on GSK3P (C. Beck 
and M.J. Welham, unpublished data). The forkhead family member, FKHRL-1, has 
also been reported to be phosphorylated in response to IL-3 stimulation in BaF/3 cells 
(Mathieu et al., 2001). Phosphorylation on Ser253 is constitutive, while phosphorylation 
of Thr32 is dependent on a PI3K mediated pathway and this may well be mediated by 
PKB (Mathieu et al., 2001).
Further insights into the role(s) that PKB plays in these and other cells could be 
obtained by the identification of new downstream targets of PKB. To this end gene 
array technology could be used to identify novel transcripts whose expression is 
regulated by PKB.
The long awaited PKB knockouts should also provide clues into the functions of PKB. 
After the submission of this thesis, work was published describing a PKBp knock out 
mouse, which implicates PKBp in the maintenance of normal glucose homeostasis (Cho 
et al., 2002). Insulin-dependant blood glucose uptake into hormone responsive tissues 
was impaired leading to increase blood glucose levels and an increase production of 
insulin to compensate. This suggests that PKBp is important for insulin responses. The 
production of knock out for PKBa and y should give insights into where these isoforms 
are most important and what processes they control.
The results presented in this thesis have challenged our understanding of how cells 
regulate their proliferation and survival. At the conception of this work, it was generally 
considered that the activation of PKB was sufficient and necessary for the survival of 
cells. However, this work, and the work of others (Scheid et al., 1999; Carson et al., 
1999; Shinjyo et al., 2000; Uchida et al., 2000), have questioned whether cells are
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absolutely dependent on PKB for their continued growth and survival. Indeed the results 
presented here indicate that PKB is dispensable for cellular survival in some cases.
The question that now needs to be addressed is whether PKB can act in concert with 
other pathways to promote survival. Is PKB important for cell survival and proliferation 
when other pathways are compromised? Given their importance to the cell, it seems 
logical to have more than one pathway by which growth and survival can be regulated.
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